<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Interventions for the treatment of oral cavity and oropharyngeal cancers: surgical treatment - Worthington, HV - 2023 | Cochrane Library</title> <meta content="Interventions for the treatment of oral cavity and oropharyngeal cancers: surgical treatment - Worthington, HV - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006205.pub5/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Interventions for the treatment of oral cavity and oropharyngeal cancers: surgical treatment - Worthington, HV - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006205.pub5/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD006205.pub5" name="dc.identifier" scheme="DOI"/> <meta content="Interventions for the treatment of oral cavity and oropharyngeal cancers: surgical treatment" name="citation_title"/> <meta content="Helen V Worthington" name="citation_author"/> <meta content="Division of Dentistry, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester" name="citation_author_institution"/> <meta content="helen.worthington@manchester.ac.uk" name="citation_author_email"/> <meta content="Vishal M Bulsara" name="citation_author"/> <meta content="Anne-Marie Glenny" name="citation_author"/> <meta content="The University of Manchester" name="citation_author_institution"/> <meta content="Janet E Clarkson" name="citation_author"/> <meta content="Division of Dentistry, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester" name="citation_author_institution"/> <meta content="David I Conway" name="citation_author"/> <meta content="University of Glasgow" name="citation_author_institution"/> <meta content="Michaelina Macluskey" name="citation_author"/> <meta content="University of Dundee" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD006205.pub5" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/08/31" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006205.pub5/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006205.pub5/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006205.pub5/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Immunotherapy; Mouth; Neck; *Neoplasm Recurrence, Local; *Oropharyngeal Neoplasms [surgery]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006205.pub5&amp;doi=10.1002/14651858.CD006205.pub5&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006205.pub5&amp;doi=10.1002/14651858.CD006205.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006205.pub5&amp;doi=10.1002/14651858.CD006205.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006205.pub5&amp;doi=10.1002/14651858.CD006205.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006205.pub5&amp;doi=10.1002/14651858.CD006205.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006205.pub5&amp;doi=10.1002/14651858.CD006205.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006205.pub5&amp;doi=10.1002/14651858.CD006205.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006205.pub5&amp;doi=10.1002/14651858.CD006205.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006205.pub5&amp;doi=10.1002/14651858.CD006205.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006205.pub5&amp;doi=10.1002/14651858.CD006205.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006205.pub5&amp;doi=10.1002/14651858.CD006205.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006205.pub5&amp;doi=10.1002/14651858.CD006205.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006205.pub5&amp;doi=10.1002/14651858.CD006205.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006205.pub5&amp;doi=10.1002/14651858.CD006205.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006205.pub5&amp;doi=10.1002/14651858.CD006205.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006205.pub5&amp;doi=10.1002/14651858.CD006205.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006205.pub5&amp;doi=10.1002/14651858.CD006205.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006205.pub5&amp;doi=10.1002/14651858.CD006205.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006205.pub5&amp;doi=10.1002/14651858.CD006205.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006205.pub5&amp;doi=10.1002/14651858.CD006205.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006205.pub5&amp;doi=10.1002/14651858.CD006205.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006205.pub5&amp;doi=10.1002/14651858.CD006205.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006205.pub5&amp;doi=10.1002/14651858.CD006205.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="FKeXZrqu";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD006205\x2epub5\x26doi\x3d10\x2e1002\x2f14651858\x2eCD006205\x2epub5\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006205\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006205\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","hi","zh_HANT","pt","th","ms","fa","id","fr","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD006205.pub5",title:"Interventions for the treatment of oral cavity and oropharyngeal cancers: surgical treatment",firstPublishedDate:"Aug 31, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Oral Health Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=FKeXZrqu&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006205.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006205.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD006205.pub5/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD006205.pub5/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006205.pub5%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD006205.PUB5" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;hi&quot;,&quot;title&quot;:&quot;सारांश&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hi&quot;,&quot;title&quot;:&quot;सरल भाषा संक्षेप&quot;},{&quot;language&quot;:&quot;id&quot;,&quot;title&quot;:&quot;Saripati tinjauan sistematik&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD006205.pub5/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD006205.PUB5" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD006205.pub5/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD006205.pub5/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2194 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD006205.pub5" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006205.pub5/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006205.pub5/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006205.pub5/full#CD006205-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006205.pub5/full#CD006205-sec-0160"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006205.pub5/full#CD006205-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006205.pub5/full#CD006205-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006205.pub5/full#CD006205-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006205.pub5/full#CD006205-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006205.pub5/full#CD006205-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006205.pub5/full#CD006205-sec-0154"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006205.pub5/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006205.pub5/appendices#CD006205-sec-0165"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006205.pub5/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006205.pub5/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/supinfo/CD006205-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/supinfo/CD006205-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006205.pub5/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006205.pub5/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006205.pub5/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006205.pub5/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006205.pub5/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD006205.pub5/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Interventions for the treatment of oral cavity and oropharyngeal cancers: surgical treatment </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006205.pub5/information#CD006205-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Helen V Worthington</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006205.pub5/information#CD006205-cr-0005">Vishal M Bulsara</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006205.pub5/information#CD006205-cr-0006">Anne-Marie Glenny</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006205.pub5/information#CD006205-cr-0007">Janet E Clarkson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006205.pub5/information#CD006205-cr-0008">David I Conway</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006205.pub5/information#CD006205-cr-0009">Michaelina Macluskey</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/information/en#CD006205-sec-0175">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 31 August 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD006205.pub5">https://doi.org/10.1002/14651858.CD006205.pub5</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD006205-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006205-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006205-abs-0018">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006205-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD006205-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/hi#CD006205-abs-0004">हिंदी</a> </li> <li class="section-language"> <a class="" href="full/pt#CD006205-abs-0007">Português</a> </li> <li class="section-language"> <a class="" href="full/th#CD006205-abs-0009">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD006205-abs-0001" lang="en"> <section id="CD006205-sec-0001"> <h3 class="title" id="CD006205-sec-0001">Background</h3> <p>Surgery is a common treatment option in oral cavity cancer (and less frequently in oropharyngeal cancer) to remove the primary tumour and sometimes neck lymph nodes. People with early‐stage disease may undergo surgery alone or surgery plus radiotherapy, chemotherapy, immunotherapy/biotherapy, or a combination of these. Timing and extent of surgery varies. This is the third update of a review originally published in 2007. </p> </section> <section id="CD006205-sec-0002"> <h3 class="title" id="CD006205-sec-0002">Objectives</h3> <p>To evaluate the relative benefits and harms of different surgical treatment modalities for oral cavity and oropharyngeal cancers. </p> </section> <section id="CD006205-sec-0003"> <h3 class="title" id="CD006205-sec-0003">Search methods</h3> <p>We used standard, extensive Cochrane search methods. The latest search date was 9 February 2022. </p> </section> <section id="CD006205-sec-0004"> <h3 class="title" id="CD006205-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) that compared two or more surgical treatment modalities, or surgery versus other treatment modalities, for primary tumours of the oral cavity or oropharynx. </p> </section> <section id="CD006205-sec-0005"> <h3 class="title" id="CD006205-sec-0005">Data collection and analysis</h3> <p>Our primary outcomes were overall survival, disease‐free survival, locoregional recurrence, and recurrence; and our secondary outcomes were adverse effects of treatment, quality of life, direct and indirect costs to patients and health services, and participant satisfaction. We used standard Cochrane methods. We reported survival data as hazard ratios (HRs). For overall survival, we reported the HR of mortality, and for disease‐free survival, we reported the combined HR of new disease, progression, and mortality; therefore, HRs below 1 indicated improvement in these outcomes. We used GRADE to assess certainty of evidence for each outcome. </p> </section> <section id="CD006205-sec-0006"> <h3 class="title" id="CD006205-sec-0006">Main results</h3> <p>We identified four new trials, bringing the total number of included trials to 15 (2820 participants randomised, 2583 participants analysed). For objective outcomes, we assessed four trials at high risk of bias, three at low risk, and eight at unclear risk. The trials evaluated nine comparisons; none compared different surgical approaches for excision of the primary tumour. </p> <p>Five trials evaluated elective neck dissection (ND) versus therapeutic (delayed) ND in people with oral cavity cancer and clinically negative neck nodes. Elective ND compared with therapeutic ND probably improves overall survival (HR 0.64, 95% confidence interval (CI) 0.50 to 0.83; I<sup>2</sup> = 0%; 4 trials, 883 participants; moderate certainty) and disease‐free survival (HR 0.56, 95% CI 0.45 to 0.70; I<sup>2</sup> = 12%; 5 trials, 954 participants; moderate certainty), and probably reduces locoregional recurrence (HR 0.58, 95% CI 0.43 to 0.78; I<sup>2</sup> = 0%; 4 trials, 458 participants; moderate certainty) and recurrence (RR 0.58, 95% CI 0.48 to 0.70; I<sup>2</sup> = 0%; 3 trials, 633 participants; moderate certainty). Elective ND is probably associated with more adverse events (risk ratio (RR) 1.31, 95% CI 1.11 to 1.54; I<sup>2</sup> = 0%; 2 trials, 746 participants; moderate certainty). </p> <p>Two trials evaluated elective radical ND versus elective selective ND in people with oral cavity cancer, but we were unable to pool the data as the trials used different surgical procedures. Neither study found evidence of a difference in overall survival (pooled measure not estimable; very low certainty). We are unsure if there is a difference in effect on disease‐free survival (HR 0.57, 95% CI 0.29 to 1.11; 1 trial, 104 participants; very low certainty) or recurrence (RR 1.21, 95% CI 0.63 to 2.33; 1 trial, 143 participants; very low certainty). There may be no difference between the interventions in terms of adverse events (1 trial, 148 participants; low certainty). </p> <p>Two trials evaluated superselective ND versus selective ND, but we were unable to use the data. </p> <p>One trial evaluated supraomohyoid ND versus modified radical ND in 332 participants. We were unable to use any of the primary outcome data. The evidence on adverse events was very uncertain, with more complications, pain, and poorer shoulder function in the modified radical ND group. </p> <p>One trial evaluated sentinel node biopsy versus elective ND in 279 participants. There may be little or no difference between the interventions in overall survival (HR 1.00, 95% CI 0.90 to 1.11; low certainty), disease‐free survival (HR 0.98, 95% CI 0.90 to 1.07; low certainty), or locoregional recurrence (HR 1.04, 95% CI 0.91 to 1.19; low certainty). The trial provided no usable data for recurrence, and reported no adverse events (very low certainty). </p> <p>One trial evaluated positron emission tomography‐computed tomography (PET‐CT) following chemoradiotherapy (with ND only if no or incomplete response) versus planned ND (before or after chemoradiotherapy) in 564 participants. There is probably no difference between the interventions in overall survival (HR 0.92, 95% CI 0.65 to 1.31; moderate certainty) or locoregional recurrence (HR 1.00, 95% CI 0.94 to 1.06; moderate certainty). </p> <p>One trial evaluated surgery plus radiotherapy versus radiotherapy alone and provided very low‐certainty evidence of better overall survival in the surgery plus radiotherapy group (HR 0.24, 95% CI 0.10 to 0.59; 35 participants). The data were unreliable because the trial stopped early and had multiple protocol violations. In terms of adverse events, subcutaneous fibrosis was more frequent in the surgery plus radiotherapy group, but there were no differences in other adverse events (very low certainty). </p> <p>One trial evaluated surgery versus radiotherapy alone for oropharyngeal cancer in 68 participants. There may be little or no difference between the interventions for overall survival (HR 0.83, 95% CI 0.09 to 7.46; low certainty) or disease‐free survival (HR 1.07, 95% CI 0.27 to 4.22; low certainty). For adverse events, there were too many outcomes to draw reliable conclusions. </p> <p>One trial evaluated surgery plus adjuvant radiotherapy versus chemotherapy. We were unable to use the data for any of the outcomes reported (very low certainty). </p> </section> <section id="CD006205-sec-0007"> <h3 class="title" id="CD006205-sec-0007">Authors' conclusions</h3> <p>We found moderate‐certainty evidence based on five trials that elective neck dissection of clinically negative neck nodes at the time of removal of the primary oral cavity tumour is superior to therapeutic neck dissection, with increased survival and disease‐free survival, and reduced locoregional recurrence. </p> <p>There was moderate‐certainty evidence from one trial of no difference between positron emission tomography (PET‐CT) following chemoradiotherapy versus planned neck dissection in terms of overall survival or locoregional recurrence. </p> <p>The evidence for each of the other seven comparisons came from only one or two studies and was assessed as low or very low‐certainty. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD006205-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006205-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD006205-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD006205-abs-0019">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006205-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD006205-abs-0016">Français</a> </li> <li class="section-language"> <a class="" href="full/hi#CD006205-abs-0005">हिंदी</a> </li> <li class="section-language"> <a class="" href="full/id#CD006205-abs-0014">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="full/ms#CD006205-abs-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD006205-abs-0017">Polski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD006205-abs-0008">Português</a> </li> <li class="section-language"> <a class="" href="full/th#CD006205-abs-0010">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD006205-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD006205-abs-0002" lang="en"> <h3>Surgical treatments for oral cavity (mouth) and oropharyngeal (throat) cancers</h3> <p><b>Key messages</b> </p> <p>• In people with mouth cancer, elective removal of neck lymph nodes at the same time as primary tumour removal, compared with the removal of neck lymph nodes only when they become cancerous, probably increases survival and reduces recurrence, but may increase the risk of unwanted effects.<br/>• Future studies of surgical treatment of mouth and throat cancers should report findings according to primary tumour location and measure quality of life and illness or disability associated with treatment. </p> <p><b>What is the background to the review?</b> </p> <p>Oral cavity (mouth) and oropharyngeal (throat) cancers are becoming more common and are very difficult to cure. Treatment can involve surgery, chemotherapy, radiotherapy, or a combination of these. For people with mouth cancer, the removal of the lymph nodes (small glands that filter cancer cells and other foreign substances) is sometimes part of the treatment; this is known as neck dissection. Surgeons sometimes remove lymph nodes that appear cancer free while removing the original tumour (elective neck dissection). Other surgeons adopt a 'watch and wait' approach, removing lymph nodes when they become cancerous. The type of dissection can be radical neck dissection, where all the lymph nodes are removed, or selective neck dissection, where only diseased nodes are removed. One way to determine whether the lymph node is diseased is to perform a lymph node biopsy. </p> <p><b>What did we want to find out?</b> </p> <p>We wanted to know which surgical treatments are most likely to result in people with mouth and throat cancers living longer (overall survival), living longer without symptoms (disease‐free survival), and not having the cancer come back at the same site (locoregional recurrence) or spread to other sites (recurrence). We also wanted to know if the different treatments have unwanted effects. </p> <p><b>What did we do?</b> </p> <p>We searched for studies that randomly allocated people with mouth or throat cancer to different types of surgical treatment. We summarised the characteristics and findings of relevant studies and assessed our confidence in the results. </p> <p><b>What did we find?</b> </p> <p>We included 15 studies (four new studies in this update) that evaluated nine comparisons of different treatments. No studies compared different approaches to cutting out the original (primary) tumour. The studies involved 2820 participants. </p> <p><b>Main results</b> </p> <p>Five studies evaluated removal of the primary tumour, comparing elective neck dissection with the 'watch and wait approach' in people with mouth cancer. The results show that elective neck dissection probably leads to longer overall and disease‐free survival and less locoregional recurrence, but more unwanted effects. </p> <p>Two studies compared radical neck dissection versus selective neck dissection in people with mouth cancer. It is unclear which treatment provides better outcomes. </p> <p>Two trials evaluated a more limited neck dissection (superselective) versus selective neck dissection; we were unable to use the data reported. </p> <p>One study compared a more selective neck dissection (supraomohyoid) and a modified radical neck dissection. We were unable to use the data reported. The modified radical neck dissection group had more complications, more pain, and poorer shoulder function, but we are very uncertain about the results. </p> <p>In one study, all the people in one group had a lymph node biopsy and only had neck lymph nodes removed if the biopsy was positive, while all people in the other group had neck lymph nodes removed without a biopsy. There may be no difference between these two approaches in terms of overall survival, disease‐free survival, and locoregional recurrence. No unwanted effects were reported. </p> <p>One study evaluated using a special scan (positron emission tomography‐computed tomography (PET‐CT)) after combined chemotherapy and radiotherapy to guide decisions about neck dissection, versus a planned neck dissection before or after chemoradiotherapy. There is probably no difference between these approaches in terms of overall survival or locoregional recurrence. There may be no difference in unwanted effects, but we are very uncertain about the results. </p> <p>One trial suggested that surgery plus radiotherapy may result in better overall survival than radiotherapy alone, but we are very uncertain about the results. Surgery may result in more thickened scar tissue. There may be no difference with regard to other unwanted effects. </p> <p>One study compared surgery versus radiotherapy in people with throat cancer. There may be no difference in overall survival, disease‐free survival, or unwanted effects, but we are very uncertain about the results. </p> <p>One study compared surgery followed by radiotherapy versus chemotherapy. People receiving surgery and radiotherapy may live longer without symptoms, but we are very uncertain about the results. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>We are moderately confident that elective neck dissection at the same time as removal of the main tumour improves survival and reduces recurrence. Not all studies provided information about everything that we were interested in. </p> <p>We are moderately confident that PET‐CT does not improve survival or reduce recurrence. There are too few studies to be certain about the results. </p> <p>We have little confidence in results from other comparisons due to too few studies and limited information within them. </p> <p><b>How up to date is this evidence?</b> </p> <p>The evidence is current to 9 February 2022.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD006205-sec-0160" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD006205-sec-0160"></div> <h3 class="title" id="CD006205-sec-0161">Implications for practice</h3> <section id="CD006205-sec-0161"> <p>We found moderate‐certainty evidence based on five trials that elective neck dissection of clinically negative neck nodes at the time of removal of the primary oral cavity tumour is superior to therapeutic neck dissection, with increased survival and disease‐free survival, and reduced locoregional recurrence. </p> <p>There was moderate‐certainty evidence from one trial of no difference between positron emission tomography–computed tomography (PET‐CT) following chemoradiotherapy versus planned neck dissection for overall survival or locoregional recurrence. </p> <p>The evidence for each of the other seven comparisons came from only one or two studies and was assessed as low‐ or very low‐certainty. </p> </section> <h3 class="title" id="CD006205-sec-0162">Implications for research</h3> <section id="CD006205-sec-0162"> <p>This review identified the following areas for improvement in future research into the surgical treatment of oral or oropharyngeal tumours. </p> <p> <ul id="CD006205-list-0011"> <li> <p>Trial authors should follow the CONSORT guidelines when reporting on their trials. Ideally, trials should report hazard ratios with 95% confidence intervals for survival data, or present data that allow for the calculation of this estimate of effect. </p> </li> <li> <p>Health‐related quality of life, adverse events, health economics, and resource use are important outcome measures that should be integral to all trials of oral cavity and oropharyngeal cancers. </p> </li> <li> <p>There should be standardised and consistent reporting of adverse events and morbidity associated with treatment, with results reported per participant. </p> </li> <li> <p>Future trials of oral cavity and oropharyngeal cancers should report data based on the location of the primary tumour. </p> </li> </ul> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD006205-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD006205-sec-0008"></div> <div class="table" id="CD006205-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Elective neck dissection versus therapeutic (delayed) neck dissection</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Elective neck dissection versus therapeutic (delayed) neck dissection</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> adults with oral cancer </p> <p><b>Setting:</b> inpatient </p> <p><b>Intervention:</b> elective ND </p> <p><b>Comparison:</b> therapeutic (delayed) ND </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk (therapeutic ND)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk (elective ND)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> </p> <p>Follow‐up: 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>350<sup>a</sup> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>241 per 1000</p> <p>(194 to 301)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.64</b> </p> <p>(0.50 to 0.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>883</p> <p>(4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>We calculated mortality in place of overall survival.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>250<sup>b</sup> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>168 per 1000 (134 to 212)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>New disease, progression, and mortality</b> </p> <p>Follow‐up: 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>550<sup>a</sup> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>361 per 1000</p> <p>(302 to 428)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.56</b> </p> <p>(0.45 to 0.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>954</p> <p>(5 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>We calculated new disease, progression, and mortality in place of disease‐free survival.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>450<sup>b</sup> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>285 per 1000</p> <p>(236 to 342)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Locoregional recurrence</b> </p> <p>Follow‐up: 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300<sup>b</sup> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>187 per 1000</p> <p>(142 to 243)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.58</b> </p> <p>(0.43 to 0.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>458</p> <p>(4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Recurrence</b> </p> <p>Follow‐up: 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>600<sup>a</sup> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>348 per 1000</p> <p>(288 to 420)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.58</b> (0.48 to 0.70) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>633</p> <p>(3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events associated with treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.31</b> </p> <p>(1.11 to 1.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>746</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk not calculated as event rate (in the therapeutic groups) in 1 study was 3.6% compared with 60.5% in the other study. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>ND:</b> neck dissection; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Based on data from <a href="./references#CD006205-bbs2-0003" title="D'CruzA . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment&quot; [personal communication]. Email to: H Worthington 6 February 2023. D'CruzAK , VaishR , KapreN , DandekarM , GuptaS , HawaldarR , et al. Elective versus therapeutic neck dissection in node-negative oral cancer. New England Journal of Medicine2015;373(6):521-9. [DOI: 10.1056/NEJMoa1506007]NCT00193765. Elective vs therapeutic neck dissection in treatment of early node negative squamous carcinoma of oral cavity. www.clinicaltrials.gov/ct2/show/NCT00193765 (first received 19 September 2005). ">D'Cruz 2015</a> (lower‐middle income country).<br/><sup>b</sup> Based on data from <a href="./references#CD006205-bbs2-0007" title="HutchisonIL , RidoutF , CheungSM , ShahN , HardeeP , SurwaldC , et al. Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort. British Journal of Cancer2019;121(10):827-36. [DOI: 0.1038/s41416-019-0587-2] [PMID: 31611612]ISRCTN65018995. The role of selective neck dissection in patients with early oral squamous cell carcinoma (1-3cm primary size) and no clinical evidence of lymph node metastases in the neck (N0). www.isrctn.com/ISRCTN65018995 (first received 23 April 2010). NCT00571883. Neck surgery in treating patients with early-stage oral cancer. clinicaltrials.gov/ct2/show/NCT00571883 (first received 12 December 2007). ">Hutchison 2019</a> (high‐income country).<br/><sup>c</sup> Downgraded once due to risk of bias.<br/><sup>d</sup> Downgraded once for risk of bias as only 2/5 trials provided data on adverse events (selective reporting of subjective outcomes). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006205-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Elective radical neck dissection versus elective selective neck dissection</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Elective radical neck dissection versus elective selective neck dissection</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> adults with oral cancer </p> <p><b>Setting:</b> inpatient </p> <p><b>Intervention:</b> elective radical ND </p> <p><b>Comparison:</b> elective selective ND </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk (elective selective ND)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk (elective radical ND)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>252<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 trials reported HR for mortality but used different surgical procedures, so we could not pool data. Neither trial indicated any difference in mortality between the 2 interventions. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>New disease, progression, and mortality</b> </p> <p>Follow‐up: 5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300<sup>b</sup> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>184 per 1000<br/>(142 to 243) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.57</b> </p> <p>(0.29 to 1.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>These data were calculated from the reported HR for disease‐free survival.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Locoregional recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Recurrence</b> </p> <p>Follow‐up: 5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>250<sup>d</sup> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>303 per 1000<br/>(158 to 583) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.21</b> </p> <p>(0.63 to 2.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events associated with treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p>1 trial reported the following adverse events: flap necrosis, wound infection, fistula, vascular rupture, haematoma, seroma, and chyle fistula. There were no complications in 45 participants (59%) in the modified radical neck dissection group and no complications in 54 participants (75%) in the elective neck dissection group. There were 2 postoperative deaths in the modified radical neck dissection group and 1 postoperative death in the elective neck dissection group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>ND:</b> neck dissection; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded twice for very serious inconsistency and once for unclear/high risk of bias.<br/><sup>b</sup> Based on data from <a href="./references#CD006205-bbs2-0003" title="D'CruzA . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment&quot; [personal communication]. Email to: H Worthington 6 February 2023. D'CruzAK , VaishR , KapreN , DandekarM , GuptaS , HawaldarR , et al. Elective versus therapeutic neck dissection in node-negative oral cancer. New England Journal of Medicine2015;373(6):521-9. [DOI: 10.1056/NEJMoa1506007]NCT00193765. Elective vs therapeutic neck dissection in treatment of early node negative squamous carcinoma of oral cavity. www.clinicaltrials.gov/ct2/show/NCT00193765 (first received 19 September 2005). ">D'Cruz 2015</a> and <a href="./references#CD006205-bbs2-0007" title="HutchisonIL , RidoutF , CheungSM , ShahN , HardeeP , SurwaldC , et al. Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort. British Journal of Cancer2019;121(10):827-36. [DOI: 0.1038/s41416-019-0587-2] [PMID: 31611612]ISRCTN65018995. The role of selective neck dissection in patients with early oral squamous cell carcinoma (1-3cm primary size) and no clinical evidence of lymph node metastases in the neck (N0). www.isrctn.com/ISRCTN65018995 (first received 23 April 2010). NCT00571883. Neck surgery in treating patients with early-stage oral cancer. clinicaltrials.gov/ct2/show/NCT00571883 (first received 12 December 2007). ">Hutchison 2019</a>.<br/><sup>c</sup> Downgraded twice for very serious imprecision and once for high risk of bias.<br/><sup>d</sup> Based on data from <a href="./references#CD006205-bbs2-0001" title="Brazilian Head and Neck Cancer Study Group. Results of a prospective trial on elective modified radical classical versus supraomohyoid neck dissection in the management of oral squamous carcinoma. American Journal of Surgery1998;176(5):422-7. ">BHNCSG 1998</a>.<br/><sup>e</sup> Downgraded twice for very serious imprecision and once for unclear risk of bias.<br/><sup>f</sup> Downgraded twice for very serious risk of bias. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006205-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Superselective neck dissection versus selective neck dissection</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> adults with oral or oropharyngeal cancer </p> <p><b>Setting:</b> inpatient </p> <p><b>Intervention:</b> superselective ND </p> <p><b>Comparison:</b> selective ND </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk (selective ND)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk (superselective ND)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>New disease, progression, and mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One study reported no clear difference between the interventions, but we were unable to use the data. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Locoregional recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data not presented in a useable way and inconsistent. 1 study reported no evidence of a difference. The other study reported lower recurrence in the superselective ND group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome not reported in a usable way in either study.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events associated with treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>No adverse events reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>ND:</b> neck dissection; <b>RCT:</b> randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded twice for very serious imprecision and once for unclear risk of bias. We were unable to use the data presented.<br/><sup>b</sup> Downgraded twice for very serious imprecision and once for high risk of bias for subjective outcomes. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006205-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Supraomohyoid neck dissection versus modified radical neck dissection</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Supraomohyoid neck dissection versus modified radical neck dissection</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> adults with oral or oropharyngeal cancer </p> <p><b>Setting:</b> inpatient </p> <p><b>Intervention:</b> supraomohyoid ND </p> <p><b>Comparison:</b> modified radical ND </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk (modified radical ND)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk (supraomohyoid ND)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>New disease, progression, and mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Locoregional recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events associated with treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Significant difference in complication rates, with lower rates for the supraomohyoid procedure. </p> <p>UW‐QOL scores for all disease‐free survivors were assessed at 1 year after treatment. Scores from 9 disease‐specific domains appeared to show that supraomohyoid ND was superior to modified radical ND in the domains of pain relief (78.8% vs 75.2%, P = 0.013) and shoulder function (81.1% vs 68.1%, P &lt; 0.001), but not in any other domain. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>332</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>ND:</b> neck dissection; <b>RCT:</b> randomised controlled trial; <b>UW‐QOL:</b> University of Washington Quality of Life Questionnaire. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded twice for very serious imprecision and once for high risk of bias for subjective outcomes. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006205-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Sentinel node biopsy versus elective neck dissection</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Sentinel node biopsy versus elective neck dissection</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> adults with oral or oropharyngeal cancer </p> <p><b>Setting:</b> inpatient </p> <p><b>Intervention:</b> sentinel node biopsy </p> <p><b>Comparison:</b> elective ND </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk (elective ND)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk (sentinel node biopsy)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total mortality</b> </p> <p>Follow‐up: 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200<sup>a</sup> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1000</p> <p>(182 to 219)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 1.00</b> </p> <p>(0.90 to 1.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>279</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We calculated total mortality in place of overall survival.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>New disease, progression, and mortality</b> </p> <p>Follow‐up: 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300<sup>a</sup> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>295 per 1000</p> <p>(275 to 317)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.98</b> </p> <p>(0.90 to 1.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>279</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We calculated new disease, progression, and mortality in place of disease‐free survival.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Locoregional recurrence</b> </p> <p>Follow‐up: 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200<sup>c</sup> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>207 per 1000</p> <p>(184 to 233)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 1.04</b> </p> <p>(0.91 to 1.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>279</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>279</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"[...] the number of patients with recurrences in both arms was almost identical."</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events associated with treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>No adverse events were reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Verylow</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>ND:</b> neck dissection; <b>RCT:</b> randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Based on data from <a href="./references#CD006205-bbs2-0003" title="D'CruzA . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment&quot; [personal communication]. Email to: H Worthington 6 February 2023. D'CruzAK , VaishR , KapreN , DandekarM , GuptaS , HawaldarR , et al. Elective versus therapeutic neck dissection in node-negative oral cancer. New England Journal of Medicine2015;373(6):521-9. [DOI: 10.1056/NEJMoa1506007]NCT00193765. Elective vs therapeutic neck dissection in treatment of early node negative squamous carcinoma of oral cavity. www.clinicaltrials.gov/ct2/show/NCT00193765 (first received 19 September 2005). ">D'Cruz 2015</a> and <a href="./references#CD006205-bbs2-0007" title="HutchisonIL , RidoutF , CheungSM , ShahN , HardeeP , SurwaldC , et al. Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort. British Journal of Cancer2019;121(10):827-36. [DOI: 0.1038/s41416-019-0587-2] [PMID: 31611612]ISRCTN65018995. The role of selective neck dissection in patients with early oral squamous cell carcinoma (1-3cm primary size) and no clinical evidence of lymph node metastases in the neck (N0). www.isrctn.com/ISRCTN65018995 (first received 23 April 2010). NCT00571883. Neck surgery in treating patients with early-stage oral cancer. clinicaltrials.gov/ct2/show/NCT00571883 (first received 12 December 2007). ">Hutchison 2019</a> for elective neck dissection.<br/><sup>b</sup> Downgraded once for imprecision and once for unclear risk of bias.<br/><sup>c</sup> Based on data from <a href="./references#CD006205-bbs2-0007" title="HutchisonIL , RidoutF , CheungSM , ShahN , HardeeP , SurwaldC , et al. Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort. British Journal of Cancer2019;121(10):827-36. [DOI: 0.1038/s41416-019-0587-2] [PMID: 31611612]ISRCTN65018995. The role of selective neck dissection in patients with early oral squamous cell carcinoma (1-3cm primary size) and no clinical evidence of lymph node metastases in the neck (N0). www.isrctn.com/ISRCTN65018995 (first received 23 April 2010). NCT00571883. Neck surgery in treating patients with early-stage oral cancer. clinicaltrials.gov/ct2/show/NCT00571883 (first received 12 December 2007). ">Hutchison 2019</a> for elective neck dissection.<br/><sup>d</sup> Downgraded twice for very serious imprecision and once for high risk of bias for subjective outcomes. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006205-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">PET‐CT following chemoradiotherapy versus planned neck dissection before or after chemoradiotherapy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>PET‐CT following chemoradiotherapy versus planned neck dissection before or after chemoradiotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> adults with oral or oropharyngeal cancer </p> <p><b>Setting:</b> inpatient </p> <p><b>Intervention:</b> PET‐CT following chemoradiotherapy </p> <p><b>Comparison:</b> planned ND before or after chemoradiotherapy </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk (planned ND)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk (PET‐CT)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total mortality</b> </p> <p>Follow‐up: 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200<sup>a</sup> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>186 per 1000<br/>(135 to 253) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.92</b> </p> <p>(0.65 to 1.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>564<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>These data were calculated from the reported HR for overall survival.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>New disease, progression, and mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome not reported in a usable way.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Locoregional recurrence</b> </p> <p>Follow‐up: 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200<sup>c</sup> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1000 (189 to 211)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 1.00</b> (0.94 to 1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>564<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome not reported in a usable way.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events associated with treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>22 surgical complications in PET‐CT group compared with 83 in planned surgery group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>ND:</b> neck dissection; <b>PET‐CT:</b> positron emission tomography–computed tomography; <b>RCT:</b> randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Based on data from <a href="./references#CD006205-bbs2-0003" title="D'CruzA . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment&quot; [personal communication]. Email to: H Worthington 6 February 2023. D'CruzAK , VaishR , KapreN , DandekarM , GuptaS , HawaldarR , et al. Elective versus therapeutic neck dissection in node-negative oral cancer. New England Journal of Medicine2015;373(6):521-9. [DOI: 10.1056/NEJMoa1506007]NCT00193765. Elective vs therapeutic neck dissection in treatment of early node negative squamous carcinoma of oral cavity. www.clinicaltrials.gov/ct2/show/NCT00193765 (first received 19 September 2005). ">D'Cruz 2015</a> and <a href="./references#CD006205-bbs2-0007" title="HutchisonIL , RidoutF , CheungSM , ShahN , HardeeP , SurwaldC , et al. Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort. British Journal of Cancer2019;121(10):827-36. [DOI: 0.1038/s41416-019-0587-2] [PMID: 31611612]ISRCTN65018995. The role of selective neck dissection in patients with early oral squamous cell carcinoma (1-3cm primary size) and no clinical evidence of lymph node metastases in the neck (N0). www.isrctn.com/ISRCTN65018995 (first received 23 April 2010). NCT00571883. Neck surgery in treating patients with early-stage oral cancer. clinicaltrials.gov/ct2/show/NCT00571883 (first received 12 December 2007). ">Hutchison 2019</a> for elective ND.<br/><sup>b</sup> Downgraded once due to imprecision.<br/><sup>c</sup> Based on data from <a href="./references#CD006205-bbs2-0007" title="HutchisonIL , RidoutF , CheungSM , ShahN , HardeeP , SurwaldC , et al. Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort. British Journal of Cancer2019;121(10):827-36. [DOI: 0.1038/s41416-019-0587-2] [PMID: 31611612]ISRCTN65018995. The role of selective neck dissection in patients with early oral squamous cell carcinoma (1-3cm primary size) and no clinical evidence of lymph node metastases in the neck (N0). www.isrctn.com/ISRCTN65018995 (first received 23 April 2010). NCT00571883. Neck surgery in treating patients with early-stage oral cancer. clinicaltrials.gov/ct2/show/NCT00571883 (first received 12 December 2007). ">Hutchison 2019</a> for elective ND.<br/><sup>d</sup> Downgraded twice for very serious imprecision and once for high risk of bias for subjective outcomes. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006205-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Surgery plus radiotherapy versus radiotherapy alone</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Surgery plus radiotherapy versus radiotherapy alone</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> adults with oral or oropharyngeal cancer </p> <p><b>Setting:</b> inpatient </p> <p><b>Intervention:</b> surgery + radiotherapy </p> <p><b>Comparison:</b> radiotherapy alone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk (radiotherapy alone)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk (surgery + radiotherapy)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total mortality</b> </p> <p>Follow‐up: 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500<sup>a</sup> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>153 per 1000<br/>(67 to 336) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.24</b> </p> <p>(0.10 to 0.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>These data were calculated from the reported HR for overall survival.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>New disease, progression, and mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Locoregional recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events associated with treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Both groups reported the following severe acute adverse effects: subcutaneous fibrosis; telangiectasia (1–4 cm²); and moderate‐to‐severe oedema, xerostomia, trismus, and dysphagia. Subcutaneous fibrosis was more prevalent in the surgery + radiotherapy group (P = 0.042), but the prevalence of other adverse effects appeared to be similar in both groups. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low<sup>c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HR</b> : hazard ratio; <b>RCT:</b> randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Based on data presented by <a href="./references#CD006205-bbs2-0118" title="WarnakulasuriyaS . Global epidemiology of oral and oropharyngeal cancer. Oral Oncology2009;45(4-5):309-16.">Warnakulasuriya 2009</a><sup>.</sup><br/><sup>b</sup> Downgraded twice for very serious imprecision and once for high risk of bias.<br/><sup>c</sup> Downgraded twice for very serious imprecision and once for high risk of bias for subjective outcomes. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006205-tbl-0008"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Surgery versus radiotherapy alone</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Surgery versus radiotherapy alone</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> adults with oropharyngeal cancer </p> <p><b>Setting:</b> inpatient </p> <p><b>Intervention:</b> surgery </p> <p><b>Comparison:</b> radiotherapy alone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk (radiotherapy alone)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk (surgery)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total mortality</b> </p> <p>Follow‐up: 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500<sup>a</sup> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>437 per 1000<br/>(60 to 994) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.83</b> </p> <p>(0.09 to 7.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We calculated mortality in place of overall survival.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>New disease, progression, and mortality</b> </p> <p>Follow‐up: 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>600<sup>c</sup> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>625 per 1000<br/>(219 to 979) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 1.07</b> </p> <p>(0.27 to 4.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We calculated new disease, progression, and mortality in place of disease‐free survival.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Locoregional recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events associated with treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Both groups reported the following severe acute adverse effects: subcutaneous fibrosis, telangiectasia (1–4 cm²), and moderate‐to‐severe oedema, xerostomia, trismus, and dysphagia. Subcutaneous fibrosis was more prevalent in the surgery + radiotherapy group (P = 0.042), but the prevalence of other adverse effects appeared to be similar in both groups. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HR</b> : hazard ratio; <b>RCT:</b> randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Based on data presented by <a href="./references#CD006205-bbs2-0118" title="WarnakulasuriyaS . Global epidemiology of oral and oropharyngeal cancer. Oral Oncology2009;45(4-5):309-16.">Warnakulasuriya 2009</a>.<br/><sup>b</sup> Downgraded twice for very serious imprecision.<br/><sup>c</sup> For illustrative purposes only.<br/><sup>d</sup> Downgraded twice for very serious imprecision and once for high risk of bias for subjective outcomes. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006205-tbl-0009"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Surgery plus adjuvant radiotherapy versus chemotherapy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Surgery plus adjuvant radiotherapy versus chemotherapy</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> adults with oral or oropharyngeal cancer </p> <p><b>Setting:</b> inpatient </p> <p><b>Intervention:</b> surgery + adjuvant radiotherapy </p> <p><b>Comparison:</b> chemotherapy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk (chemotherapy)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk (surgery + adjuvant radiotherapy)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study reported that survival was significantly better in participants who underwent surgery and RT compared with the CRT group, but there were no useable data. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>New disease, progression, and mortality</b> </p> <p>Follow‐up: 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>—</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Locoregional recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported difference between groups not "statistically significant" (P = 0.355), but there were no useable data. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported for the oral cancer subgroup.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events associated with treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported for any participants.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>RCT:</b> randomised controlled trial. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup> Estimated from chemotherapy arm of <a href="./references#CD006205-bbs2-0008" title="IyerNG , TanDS , TanVK , WangW , HwangJ , Tan N-C, et al. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. Cancer2015;121(10):1599-607. SooKC , TanEH , WeeJ , LimD , TaiBC , Khoo ML et al. Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison. British Journal of Cancer2005;8(93):279-86. [DOI: 10.1038/sj.bjc.6602696] [PMCID: PMC2361563] [PMID: 16012523]">Iyer 2015</a>.<br/><sup>b</sup> Downgraded twice for very serious imprecision and once for high risk of bias. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD006205-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD006205-sec-0009"></div> <section id="CD006205-sec-0010"> <h3 class="title" id="CD006205-sec-0010">Description of the condition</h3> <p>Head and neck cancer (HNC) comprises laryngeal, pharyngeal (including oropharyngeal), and oral cavity cancers. Oral cavity and oropharyngeal cancer were historically grouped under the term oral cancer, but they are now considered two distinct cancers owing to differences in risk factors, diagnosis, and clinical management. HNC is the seventh most common cancer in the world, accounting for more than 660,000 new cases and 325,000 deaths annually (<a href="./references#CD006205-bbs2-0115" title="SungH , FerlayJ , SiegelRL , LaversanneM , SoerjomataramI , JemalA , et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer Journal for Clinicians2021;17(3):209-49. [DOI: 10.3322/caac.21660] [PMID: 33538338]">Sung 2021</a>). The different types of HNC generally have common risk factors and aetiology, dominated by tobacco smoking and alcohol consumption (<a href="./references#CD006205-bbs2-0059" title="BraviF , LeeYA , HashibeM , BoffettaP , ConwayDI , FerraroniM , et al. INHANCE Consortium investigators. Lessons learned from the INHANCE consortium: an overview of recent results on head and neck cancer. Oral Diseases2021;27(1):73-93. [DOI: 10.1111/odi.13502] [PMCID: PMC7752834] [PMID: 32569410]">Bravi 2021</a>; <a href="./references#CD006205-bbs2-0082" title="GormleyM , CreaneyG , SchacheA , IngarfieldK , ConwayDI . Reviewing the epidemiology of head and neck cancer: definitions, trends and risk factors. British Dental Journal2022;233(9):780-6. [DOI: 10.1038/s41415-022-5166-x] [PMCID: PMC9652141] [PMID: 36369568]">Gormley 2022</a>). Nasopharyngeal cancer is distinctly associated with Epstein Barr virus (EBV), and oropharyngeal (mid‐throat) cancer is increasingly associated with human papillomavirus (HPV): over 50% of cases in the UK and upwards of 70% in the USA are HPV‐positive (<a href="./references#CD006205-bbs2-0106" title="SchacheAG , PowellNG , CuschieriKS , RobinsonM , LearyS , MehannaH , et al. HPV-related oropharynx cancer in the United Kingdom: an evolution in the understanding of disease etiology. Cancer Research2016;76(22):6598-606. [DOI: 10.1158/0008-5472.CAN-16-0633.] [PMCID: PMC9158514] [PMID: 27569214]">Schache 2016</a>). Worldwide, the association of HPV and oropharyngeal cancer varies considerably (<a href="./references#CD006205-bbs2-0053" title="AnantharamanD , Abedi-ArdekaniB , BeachlerDC , GheitT , OlshanAF , Wisniewski K et al. Geographic heterogeneity in the prevalence of human papillomavirus in head and neck cancer. International Journal of Cancer2017;140(9):1968-75. [DOI: 10.1002/ijc.30608] [PMCID: PMC8969079] [PMID: 28108990]">Anantharaman 2017</a>; <a href="./references#CD006205-bbs2-0096" title="MehannaH , FranklinN , ComptonN , RobinsonM , PowellN , Biswas-BaldwinN , et al. Geographic variation in human papillomavirus-related oropharyngeal cancer: data from 4 multinational randomized trials. Head and Neck2016;38(1):E1863-69. [DOI: 10.1002/hed.24336.] [PMCID: PMC4869674] [PMID: 26749143]">Mehanna 2016</a>). Oropharyngeal and oral cavity cancers frequently overlap, although modern pathology and sequencing techniques help to determine tumour origin and HPV status (<a href="./references#CD006205-bbs2-0084" title="HelliwellTR , GilesTE . Pathological aspects of the assessment of head and neck cancers: United Kingdom National Multidisciplinary Guidelines. Journal of Laryngology &amp; Otology2016;130(S2):S59-S65. [DOI: 10.1017/S0022215116000451] [PCMID: PMC4873923] [PMID: 27841114]">Helliwell 2016</a>). Most cases of HNC are diagnosed at an advanced stage, with associated implications for treatment and prognosis (<a href="./references#CD006205-bbs2-0068" title="CreaneyG , McMahonAD , RossAJ , BhattiLA , PatersonC , ConwayDI . Head and neck cancer in the UK: what was the stage before COVID-19? UK cancer registries analysis (2011-2018). British Dental Journal2022;233(9):787-93. [DOI: 10.1038/s41415-022-5151-4] [PMCID: PMC9650177] [PMID: 36369569]">Creaney 2022</a>). </p> <p>HNC is treated by multidisciplinary HNC teams in centralised units (<a href="./references#CD006205-bbs2-0089" title="HughesC , HomerJ , BradleyP , NuttingC , NessA , PerssonM , et al. An evaluation of current services available for people diagnosed with head and neck cancer in the UK (2009-2010). Clinical Oncology2012;24(10):187-9.">Hughes 2012</a>; <a href="./references#CD006205-bbs2-0093" title="Lo NigroC , DenaroN , MerlottiA , MerlanoM . Head and neck cancer: improving outcomes with a multidisciplinary approach. Cancer Management and Research2017;18(9):363-71.">Lo Nigro 2017</a>). Clinical trials often recruit people with HNC as a single disease entity (<a href="./references#CD006205-bbs2-0051" title="AdelsteinDJ , RidgeJA , GillisonML , ChaturvediAK , D'SouzaG , GravittPE , et al. Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting; 2008 Nov 9-10; Washington (DC). Head &amp; Neck2009;31(11):1393-422.">Adelstein 2009</a>; <a href="./references#CD006205-bbs2-0090" title="KaandersJHAM , vanden BoschS , KleijnenJ . Comparison of patients with head and neck cancer in randomized clinical trials and clinical practice: a systematic review. JAMA Otolaryngology—Head &amp; Neck Surgery2022;148(7):670-6. [DOI: 10.1001/jamaoto.2022.0890] [PMID: 35587353]">Kaanders 2022</a>), which influences the evidence base available for systematic reviews. However, HPV‐positive oropharyngeal cancer is increasingly managed and evaluated as a distinct disease entity (<a href="./references#CD006205-bbs2-0063" title="BteichYT , HosriJE , WehbiJA , DaouLR . Current landscape of clinical trials for HPV-positive head and neck squamous cell carcinoma (HNSCC). Ecancermedicalscience2022;16(1):1447. [DOI: 10.3332/ecancer.2022.1447] [PCMID: PMC9666285] [PMID: 36405940]">Bteich 2022</a>). Another factor that limits the evidence base is the presence of single‐centre trials, which may show larger intervention effects than multicentre trials; this is particularly important in surgical trials, where outcomes depend on surgical technique and experience of the surgeon (<a href="./references#CD006205-bbs2-0055" title="BafetaA , DechartresA , TrinquartL , YavchitzA , BoutronI , RavaudP . Impact of single centre status on estimates of intervention effects in trials with continuous outcomes: meta-epidemiological study. BMJ2012;344(1):e813. [DOI: 10.1136/bmj.e813] [PMCID: PMC3279328] [PMID: 22334559]">Bafeta 2012</a>). </p> <p>In 2020, there were an estimated 377,713 incident oral cavity cancer cases and 177,757 associated deaths worldwide; the corresponding figures for oropharyngeal cancer were 98,412 incident cases and 48,143 deaths (<a href="./references#CD006205-bbs2-0078" title="FerlayJ , ErvikM , LamF , ColombetM , MeryL , PiñerosM , et al. Global cancer observatory: cancer today. International Agency for Research on Cancer, Lyon, France2020.">Ferlay 2020</a>). There are wide geographical variations in incidence and mortality rates of oral cancers, with the greatest burden in low‐ and middle‐income countries (<a href="./references#CD006205-bbs2-0120" title="WHO. Global oral health status report—towards universal health coverage for oral health by 2030. www.who.int/team/noncommunicable-diseases/global-status-report-on-oral-health-2022 (date accessed: February 2023) 18 November 2022.">WHO 2022</a>). However, these rates are increasing across the world, largely owing to oropharyngeal cancer and HPV (<a href="./references#CD006205-bbs2-0066" title="ChaturvediAK , AndersonWF , Lortet-TieulentJ , CuradoMP , FerlayJ , FranceschiS , et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. Journal of Clinical Oncology2013;31(36):4550-9.">Chaturvedi 2013</a>; <a href="./references#CD006205-bbs2-0080" title="GillisonML , ChaturvediAK , AndersonWF , FakhryC . Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma. Journal of Clinical Oncology2015;33(29):3235-42. [DOI: 10.1200/JCO.2015.61.6995. Epub 2015 Sep 8] [PMCID: PMC4979086] [PMID: 26351338]">Gillison 2015</a>; <a href="./references#CD006205-bbs2-0082" title="GormleyM , CreaneyG , SchacheA , IngarfieldK , ConwayDI . Reviewing the epidemiology of head and neck cancer: definitions, trends and risk factors. British Dental Journal2022;233(9):780-6. [DOI: 10.1038/s41415-022-5166-x] [PMCID: PMC9652141] [PMID: 36369568]">Gormley 2022</a>; <a href="./references#CD006205-bbs2-0094" title="LouieKS , MehannaH , SasieniP . Trends in head and neck cancers in England from 1995 to 2011 and projections up to 2025. Oral Oncology2015;51(4):341-8.">Louie 2015</a>; <a href="./references#CD006205-bbs2-0104" title="PurkayasthaM , McMahonAD , GibsonJ , ConwayDI . Trends of oral cavity, oropharyngeal and laryngeal cancer incidence in Scotland (1975-2012) – a socioeconomic perspective. Oral Oncology2016;61:70-5.">Purkayastha 2016</a>; <a href="./references#CD006205-bbs2-0112" title="SimardEP , TorreLA , JemalA . International trends in head and neck cancer incidence rates: differences by country, sex and anatomic site. Oral Oncology2014;50(5):387-403.">Simard 2014</a>). From a global perspective, survival following a diagnosis of oral cavity or oropharyngeal cancer remains poor, with a five‐year survival of around 50% and limited improvement since the late 1980s (<a href="./references#CD006205-bbs2-0082" title="GormleyM , CreaneyG , SchacheA , IngarfieldK , ConwayDI . Reviewing the epidemiology of head and neck cancer: definitions, trends and risk factors. British Dental Journal2022;233(9):780-6. [DOI: 10.1038/s41415-022-5166-x] [PMCID: PMC9652141] [PMID: 36369568]">Gormley 2022</a>; <a href="./references#CD006205-bbs2-0118" title="WarnakulasuriyaS . Global epidemiology of oral and oropharyngeal cancer. Oral Oncology2009;45(4-5):309-16.">Warnakulasuriya 2009</a>). However, in high‐income countries (e.g. the USA), five‐year survival for oral cavity and pharyngeal cancer is approaching 70% (<a href="./references#CD006205-bbs2-0097" title="National Cancer Institute. Surveillance, Epidemiology, and End Results Program. seer.cancer.gov/statfacts/html/oralcav.html (accessed February 2023) October 2022.">National Cancer Institute 2022</a>). </p> <p>There is overwhelming evidence that tobacco use, alcohol consumption, and betel quid chewing are the main risk factors for HNC (<a href="./references#CD006205-bbs2-0058" title="BouvardV , NethanST , SinghD , WarnakulasuriyaS , MehrotraR , ChaturvediAK , et al. IARC Perspective on Oral Cancer Prevention. New England Journal of Medicine2022;387(21):1999-2005.">Bouvard 2022</a>; <a href="./references#CD006205-bbs2-0059" title="BraviF , LeeYA , HashibeM , BoffettaP , ConwayDI , FerraroniM , et al. INHANCE Consortium investigators. Lessons learned from the INHANCE consortium: an overview of recent results on head and neck cancer. Oral Diseases2021;27(1):73-93. [DOI: 10.1111/odi.13502] [PMCID: PMC7752834] [PMID: 32569410]">Bravi 2021</a>; <a href="./references#CD006205-bbs2-0121" title="WinnDM , LeeYC , HashibeM , BoffettaP . The INHANCE consortium: toward a better understanding of the causes and mechanisms of head and neck cancer. Oral Diseases2015;21(6):685-93.">Winn 2015</a>). There is also strong evidence that low socioeconomic status (educational attainment and income) is associated with substantially increased risk not explained by tobacco and alcohol (<a href="./references#CD006205-bbs2-0067" title="ConwayDI , BrennerDR , McMahonAD , MacphersonLM , AgudoA , AhrensW , et al. Estimating and explaining the effect of education and income on head and neck cancer risk: INHANCE consortium pooled analysis of 31 case-control studies from 27 countries. International Journal of Cancer2015;136(5):1125-39.">Conway 2015</a>). There is a higher incidence of both oral and oropharyngeal cancers in men compared with women (<a href="./references#CD006205-bbs2-0078" title="FerlayJ , ErvikM , LamF , ColombetM , MeryL , PiñerosM , et al. Global cancer observatory: cancer today. International Agency for Research on Cancer, Lyon, France2020.">Ferlay 2020</a>; <a href="./references#CD006205-bbs2-0104" title="PurkayasthaM , McMahonAD , GibsonJ , ConwayDI . Trends of oral cavity, oropharyngeal and laryngeal cancer incidence in Scotland (1975-2012) – a socioeconomic perspective. Oral Oncology2016;61:70-5.">Purkayastha 2016</a>). The risk of HNC increases with age across populations, with most cases diagnosed in people aged over 50 years (<a href="./references#CD006205-bbs2-0118" title="WarnakulasuriyaS . Global epidemiology of oral and oropharyngeal cancer. Oral Oncology2009;45(4-5):309-16.">Warnakulasuriya 2009</a>). </p> <p>Oropharyngeal cancer is classified into two distinct types according to HPV status. HPV‐negative oropharyngeal cancer has the same main risk factors as other types of HNC, namely tobacco and alcohol consumption. HPV‐positive oropharyngeal cancer starts with exposure to high‐risk HPV, most often HPV 16, and can develop independently of tobacco or alcohol exposure (<a href="./references#CD006205-bbs2-0079" title="GillisonML , KochWM , CaponeRB , SpaffordM , WestraWH , WuL , et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. Journal of National Cancer Institute2000;92:709-20.">Gillison 2000</a>), although smoking may interact with HPV and increase risk (<a href="./references#CD006205-bbs2-0052" title="AnantharamanD , MullerDC , LagiouP , AhrensW , HolcátováI , MerlettiF . Combined effects of smoking and HPV16 in oropharyngeal cancer. International Journal of Epidemiology2016;45(3):752-61. [DOI: 10.1093/ije/dyw069. Epub 2016] [PMCID: PMC5841602.] [PMID: 27197530]">Anantharaman 2016</a>). Studies have associated HPV‐positive cases with a nearly 60% reduction in risk of mortality after adjusting for prognostic factors such as age, ethnicity, staging, smoking status, and treatment regimen (<a href="./references#CD006205-bbs2-0054" title="AngKK , HarrisJ , WheelerR , WeberR , RosenthalDI , Nguyen-TânPF , et al. Human papillomavirus and survival of patients with oropharyngeal cancer. New England Journal of Medicine2010;363(1):24-35. [DOI: 10.1056/NEJMoa0912217. Epub 2010] [PMCID: PMC2943767] [PMID: 20530316]">Ang 2010</a>). This may be related to certain characteristics of people with HPV‐positive oropharyngeal cancer, including fewer comorbidities, enhanced anti‐tumour immunity, and greater radiosensitivity and thus better response to radiotherapy (<a href="./references#CD006205-bbs2-0075" title="ElrefaeyS , MassaroMA , ChioccaS , ChiesaF , AnsarinM . HPV in oropharyngeal cancer: the basics to know in clinical practice. Acta Otorhinolaryngologica Italica2014;34(5):299-309. [PMCID: PMC4299160] [PMID: 25709145]">Elrefaey 2014</a>). </p> <p>Before the mid‐2000s, management of oropharyngeal cancer generally involved primary surgery with adjunctive radiotherapy or chemotherapy. More recent trials have adopted a different approach for HPV‐positive oropharyngeal cancers, focusing on de‐escalation of overall radiotherapy dose, omission/substitution of platinum chemotherapy, or both (<a href="./references#CD006205-bbs2-0099" title="O LearyB , YoungA , NuttingC . Recent advances in the oncological management of head and neck cancer and implications for oral toxicity. British Dental Journal2022;233(9):737-43. [DOI: 10.1038/s41415-022-5195-5. Epub 2022 Nov 11] [PMID: 36369554]">O Leary 2022</a>). Surgery remains the main treatment approach for oral cavity cancer; people with advanced oral cancer usually receive adjunctive radiotherapy, chemoradiotherapy, or immune therapy in addition to upfront chemoradiotherapy. </p> </section> <section id="CD006205-sec-0011"> <h3 class="title" id="CD006205-sec-0011">Description of the intervention</h3> <p>Surgery can be combined with one or more other treatments, namely radiotherapy, chemotherapy, or immunotherapy/biotherapy. The sequence of these combination therapies is considered important. Radiotherapy is typically administered postoperatively. Chemotherapy can be administered at the following time points in the therapy sequence. </p> <p> <ul id="CD006205-list-0001"> <li> <p>Before surgery (induction/neoadjuvant; e.g. to shrink a tumour prior to surgery or radiation) </p> </li> <li> <p>After surgery (adjuvant; e.g. when surgery is considered the primary therapy) and before radiotherapy </p> </li> <li> <p>At the same time as radiotherapy (concomitant/concurrent; this combination is also called chemoradiotherapy) </p> </li> <li> <p>Alternating with radiotherapy</p> </li> </ul> </p> <p>From the mid‐2000s, clinicians have used a form of radiotherapy called intensity‐modulated radiotherapy (IMRT) to treat oral and oropharyngeal cancers. IMRT uses higher radiation doses than traditional therapies and improves locoregional control; however, there is limited evidence on the associated side effects (<a href="./references#CD006205-bbs2-0060" title="BrennanPA , BradleyKL , BrandsM . Intensity-modulated radiotherapy in head and neck cancer – an update for oral and maxillofacial surgeons. British Journal of Oral and Maxillofacial Surgery2017;55:770-4.">Brennan 2017</a>; <a href="./references#CD006205-bbs2-0114" title="StuderG , ZwahlenRA , GraetzKW , DavisBJ , GlanzmannC . IMRT in oral cavity cancer. Radiation Oncology2007;2(16):1-7.">Studer 2007</a>). </p> <p>Locoregional control of the primary tumour is the main criterion of successful cancer treatment. Typically, surgeons aim to cut out mouth cancers with a margin of normal tissue measuring at least 1 cm. Even with this approach, there may be histopathological evidence of cancer cells at the margins, which has prognostic implications (<a href="./references#CD006205-bbs2-0056" title="BatsakisJG . Surgical excision margins: a pathologist's perspective. Advances in Anatomic Pathology1999;6(3):140-8.">Batsakis 1999</a>; <a href="./references#CD006205-bbs2-0116" title="SuttonDN , BrownJS , RogersSN , VaughanED , WoolgarJA . The prognostic implications of the surgical margin in oral squamous cell carcinoma. International Journal of Oral and Maxillofacial Surgery2003;32(1):30-4.">Sutton 2003</a>). Margins that are histologically free of tumour may demonstrate molecular changes; the presence of tumour clonogen repopulation at the margins may be predictive of disease progression (<a href="./references#CD006205-bbs2-0103" title="PartridgeM , LiSR , PateromichelakisS , FrancisR , PhillipsE , HuangXH , et al. Detection of minimal residual cancer to investigate why oral tumors recur despite seemingly adequate treatment. Clinical Cancer Research2000;6(7):2718-25.">Partridge 2000</a>). </p> <p>Spread of the tumour to the regional lymph nodes within the neck (cervical nodes) is an early and consistent event in the natural history of oral and oropharyngeal cancers (<a href="./references#CD006205-bbs2-0083" title="HaddadinKJ , SoutarDS , WebsterMH , RobertsonAG , OliverRJ , MacDonaldDG . Natural history and patterns of recurrence of tongue tumours. British Journal of Plastic Surgery2000;53(4):279-85.">Haddadin 2000</a>). The extent of cervical involvement is reflected in the staging of the tumour and has prognostic implications (<a href="./references#CD006205-bbs2-0111" title="ShahJP . Cervical lymph node metastases – diagnostic, therapeutic, and prognostic implications. Oncology (Williston Park, N.Y.)1990;4(10):61-9.">Shah 1990</a>). Therefore, surgical dissection of the cervical lymph nodes at risk of metastasis may be undertaken as part of the management of the primary tumour. Classic radical neck dissection involves removal of all cervical lymph nodes from levels I to V, as well as the sternocleidomastoid muscle, internal jugular vein, submandibular gland, and the spinal accessory nerve; this results in significant postoperative morbidity, particularly in relation to loss of the accessory nerve. In one study of 100 people who underwent radical neck dissection, almost half of participants experienced shoulder pain, shoulder droop, and reduced range of motion (<a href="./references#CD006205-bbs2-0076" title="EwingMR , MartinH . Disability following radical neck dissection. An assessment based on the postoperative evaluation of 100 patients. Cancer1952;5:873-83.">Ewing 1952</a>). Another study (published almost 60 years later) that compared radical neck dissection with accessory nerve‐sparing surgery found that all participants in the radical neck dissection group had severe shoulder dysfunction compared with only 7% of the nerve‐sparing surgery group (<a href="./references#CD006205-bbs2-0117" title="UmedaM , ShigetaT , TakahashiH , OguniA , KatakoaT , MinamikawaT , et al. Shoulder mobility after spinal accessory nerve-sparing modified radical neck dissection in oral cancer patients. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics2010;109:820-4.">Umeda 2010</a>). Radical neck dissection is currently reserved for advanced neck disease. </p> <p>Modifications to neck dissection procedures to preserve some or all of the associated structures have reduced morbidity (<a href="./references#CD006205-bbs2-0064" title="CarewJF , SinghB , ShahJP . Cervical lymph nodes. In: ShahJP , JohnsonNW , BatsakisJG , editors(s). Oral Cancer. London: Martin Dunitz, 2003:215-49.">Carew 2003</a>; <a href="./references#CD006205-bbs2-0105" title="RobbinsKT , ClaymanG , LevinePA , MedinaJ , SessionsR , ShahaA , et al. Neck dissection classification update: revisions proposed by the American Head and Neck Society and the American Academy of Otolaryngology-Head and Neck Surgery. Archives of Otolaryngology - Head &amp; Neck Surgery2002;128(7):751-8.">Robbins 2002</a>). Clinicians increasingly use selective neck dissection in the clinically N0 neck (no palpable nodes on clinical examination). In addition to the extent of neck disease at presentation, spread of the tumour outside the capsule of the lymph nodes (extracapsular spread) is another indicator of poor prognosis (<a href="./references#CD006205-bbs2-0122" title="WoolgarJA , RogersSN , LoweD , BrownJS , VaughanED . Cervical lymph node metastasis in oral cancer: the importance of even microscopic extracapsular spread. Oral Oncology2003;39(2):130-7.">Woolgar 2003</a>). Distant metastasis is uncommon in HNC; one study reported 13.8% in 1022 cases (<a href="./references#CD006205-bbs2-0072" title="DuprezF , BerwoutsD , De NeveW , BonteK , BoterbergT , DeronP , et al. Distant metastases in head and neck cancer. Head &amp; Neck2017;39(9):1733-43.">Duprez 2017</a>). Locoregional disease recurrence remains the dominant mode of treatment failure for people with advanced tumours (<a href="./references#CD006205-bbs2-0061" title="BrizelDM , AlbersME , FisherSR , ScherRL , RichtsmeierWJ , HarsV , et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. New England Journal of Medicine1998;338:1798-804.">Brizel 1998</a>). Historically, clinicians treating oral and oropharyngeal cancers did not focus on distant metastatic disease because locoregional recurrence was the main cause of death, and there were fewer effective chemotherapeutic agents to deal with distant metastases. With improvements in locoregional control, clinicians are increasingly targeting distant metastasis in the management of oral and oropharyngeal cancers. </p> <p>There is controversy surrounding the management of people with early stage tumours (T1, less than 2 cm; or T2, 2 cm to 4 cm) and clinically negative neck nodes (<a href="./references#CD006205-bbs2-0122" title="WoolgarJA , RogersSN , LoweD , BrownJS , VaughanED . Cervical lymph node metastasis in oral cancer: the importance of even microscopic extracapsular spread. Oral Oncology2003;39(2):130-7.">Woolgar 2003</a>). To date, imaging of the head and neck region is not sufficiently sensitive to identify nodal micrometastases: reported rates of occult metastases range from 23% to 43% (<a href="./references#CD006205-bbs2-0073" title="EbrahimiA , AshfordBG , ClarkJR . Improved survival with elective neck dissection in thick early-stage oral squamous cell carcinoma. Head &amp; Neck2012;34(5):709-16.">Ebrahimi 2012</a>). Some studies have demonstrated that performing neck dissection at the same time as primary tumour resection, compared with a 'watch and wait' approach (waiting for neck disease to present before performing neck dissection) may improve treatment outcomes (<a href="./references#CD006205-bbs2-0083" title="HaddadinKJ , SoutarDS , WebsterMH , RobertsonAG , OliverRJ , MacDonaldDG . Natural history and patterns of recurrence of tongue tumours. British Journal of Plastic Surgery2000;53(4):279-85.">Haddadin 2000</a>; <a href="./references#CD006205-bbs2-0088" title="HughesCJ , GalloO , SpiroRH , ShahJP . Management of occult neck metastases in oral cavity squamous carcinoma. American Journal of Surgery1993;166(4):380-3.">Hughes 1993</a>). One current clinical guideline recommends prophylactic neck treatment in T1 and T2 oral cancer with a clinically negative neck (<a href="./references#CD006205-bbs2-0100" title="PaleriV , UrbanoTG , MehannaH , RepanosC , LancasterJ , RoquesT , et al. Management of neck metastases in head and neck cancer: United Kingdom National Multidisciplinary Guidelines. Journal of Laryngology and Otology2016;130(Suppl S2):S161-9. [DOI: 10.1017/S002221511600058X]">Paleri 2016</a>), and one study found improved overall and disease‐free survival in people with early‐stage oral squamous‐cell carcinoma (SCC) who had elective neck dissection compared with those who had therapeutic neck dissection (<a href="./references#CD006205-bbs2-0003" title="D'CruzA . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment&quot; [personal communication]. Email to: H Worthington 6 February 2023. D'CruzAK , VaishR , KapreN , DandekarM , GuptaS , HawaldarR , et al. Elective versus therapeutic neck dissection in node-negative oral cancer. New England Journal of Medicine2015;373(6):521-9. [DOI: 10.1056/NEJMoa1506007]NCT00193765. Elective vs therapeutic neck dissection in treatment of early node negative squamous carcinoma of oral cavity. www.clinicaltrials.gov/ct2/show/NCT00193765 (first received 19 September 2005). ">D'Cruz 2015</a>). However, this approach implies over‐treatment and treatment‐associated morbidity in most people (<a href="./references#CD006205-bbs2-0071" title="DiasFL , KligermanJ , Matos De SaG , ArcuriRA , FreitasEQ , FariasT , et al. Elective neck dissection versus observation in stage I squamous carcinomas of the tongue and floor of the mouth. Otolaryngology, Head and Neck Surgery2001;125:23-9.">Dias 2001</a>). </p> <p>Some experts advocate sentinel node biopsy for small tumours with a clinically negative neck. One UK guideline recommends offering biopsy to people with early‐stage oral cancer (T1‐T2N0), as occurs in the Netherlands and Denmark (<a href="./references#CD006205-bbs2-0087" title="HoldenAM , SharmaD , SchillingC , GnanasegaranG , OdellEW , SassoonI , et al. Biopsy of the sentinel lymph node in oral squamous cell carcinoma: analysis of error in 100 consecutive cases. British Journal of Oral and Maxillofacial Surgery2018;56(7):615-20. [DOI: 10.1016/j.bjoms.2018.06.019]">Holden 2018</a>; <a href="./references#CD006205-bbs2-0098" title="National Institute for Health and Care Excellence. Cancer of the upper aerodigestive tract: assessment and management in people aged 16 and over. www.nice.org.uk/guidance/ng36 (accessed prior to 6 December 2018). [www.nice.org.uk/guidance/ng36]">NICE 2018</a>). One European study reported that sentinel node biopsy had a sensitivity of 86% and negative predictive value of 95%, and was a reliable and safe oncological technique for staging the clinically N0 neck in people with T1 and T2 oral cancer (<a href="./references#CD006205-bbs2-0107" title="SchillingC , StoeckliSJ , HaerleSK , BroglieMA , HuberGF , SorensenJA , et al. Sentinel European Node Trial (SENT): 3-year results of sentinel node biopsy in oral cancer. European Journal of Cancer2015;51:2777-84.">Schilling 2015</a>). A larger study, including a meta‐analysis of cT1/T2N0 people with tongue SCC, also showed a high sensitivity and negative predictive value for sentinel node biopsy (<a href="./references#CD006205-bbs2-0123" title="YangY , ZhougJ , WuH . Diagnostic value of sentinel node biopsy for cT1/T2N0 tongue squamous cell carcinoma: a meta-analysis. European Archives of Oto-Rhino-Laryngology2017;274:3843-52.">Yang 2017</a>). The widespread introduction of this diagnostic technique in oral SCC management will help to ensure timely treatment of people at high risk while sparing those at low risk from unnecessary surgery (<a href="./references#CD006205-bbs2-0108" title="SchillingC , ShawR , SchacheA , McMahonJ , CheginiS , KerawalaC , et al. Sentinel lymph node biopsy for oral squamous cell carcinoma. Where are we now?British Journal of Oral and Maxillofacial Surgery2017;55:757-62.">Schilling 2017</a>). </p> </section> <section id="CD006205-sec-0012"> <h3 class="title" id="CD006205-sec-0012">How the intervention might work</h3> <p>Surgery is an important part of oral cavity cancer management; it works by removing the primary tumour. It may also involve the removal of the neck lymph nodes as well as tissue surrounding the primary tumour to prevent recurrence. Locoregional control of the primary tumour is the main criterion of successful treatment. The treatment of oropharyngeal cancer has changed from primary surgery with adjunctive radiotherapy or chemoradiotherapy, to being primarily treated with radiotherapy, with surgery being used for early‐stage oropharyngeal treatment, using advanced surgical techniques. </p> </section> <section id="CD006205-sec-0013"> <h3 class="title" id="CD006205-sec-0013">Why it is important to do this review</h3> <p>Surgical treatment for oral cavity and oropharyngeal cancer was identified as a key priority when Cochrane Oral Health undertook an extensive <a href="https://oralhealth.cochrane.org/about-us/cochrane-oral-healths-priority-setting-process" target="_blank">prioritisation exercise</a> in 2014 and again in 2020. </p> <p>This is an update of a Cochrane Review first published in 2007, and previously updated in 2011 and 2018 (<a href="./references#CD006205-bbs2-0127" title="OliverR , ClarksonJE , ConwayD , GlennyAM , MacluskeyM , PavittS , et al. Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment. Cochrane Database of Systematic Reviews2007, Issue 4. Art. No: CD006205. [DOI: 10.1002/14651858.CD006205.pub2]">Oliver 2007</a>; <a href="./references#CD006205-bbs2-0124" title="BessellA , GlennyAM , FurnessS , ClarksonJE , OliverR , ConwayDI , et al. Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment. Cochrane Database of Systematic Reviews2011, Issue 9. Art. No: CD006205. [DOI: 10.1002/14651858.CD006205.pub3]">Bessell 2011</a>; <a href="./references#CD006205-bbs2-0125" title="BulsaraVM , WorthingtonHV , GlennyAM , ClarksonJE , ConwayDI , MacluskeyM . Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment. Cochrane Database of Systematic Reviews2018, Issue 12. Art. No: CD006205. [DOI: 10.1002/14651858.CD006205.pub4] [PMICD: PMC6517307] [PMID: 30582609]">Bulsara 2018</a>). All the evidence for the seven comparisons included in the 2018 version was of very low certainty. The comparison of elective neck dissection with therapeutic (delayed) neck dissection in people with oral cavity cancer and clinically negative neck nodes provided no evidence of either intervention leading to improved overall survival or disease‐free survival. For the other comparisons, single trials contributed data to effect measures. We knew important studies had been published since 2018 and could add valuable evidence to our review, especially for the comparison elective neck dissection versus therapeutic (delayed) neck dissection. </p> <p>The management of advanced oral cavity and oropharyngeal cancers is problematic and has traditionally relied on surgery and radiotherapy, both of which are associated with substantial adverse effects. Oropharyngeal cancers have relatively 'silent' symptoms, which may not be present during the early stages of the disease. This could partly explain why the disease stage at diagnosis has not altered since the 1960s despite public education (<a href="./references#CD006205-bbs2-0095" title="McGurkM , VhanC , JonesJ , O'ReganE , SherriffM . Delay in diagnosis and its effect on outcome in head and neck cancer. British Journal of Oral and Maxillofacial Surgery2005;43(4):281-4.">McGurk 2005</a>). Tumour recurrence and the development of multiple primary tumours are the major causes of treatment failure (<a href="./references#CD006205-bbs2-0069" title="DayGL , BlotWJ . Second primary tumours in patients with oral cancer. Cancer1992;70(1):14-9.">Day 1992</a>; <a href="./references#CD006205-bbs2-0103" title="PartridgeM , LiSR , PateromichelakisS , FrancisR , PhillipsE , HuangXH , et al. Detection of minimal residual cancer to investigate why oral tumors recur despite seemingly adequate treatment. Clinical Cancer Research2000;6(7):2718-25.">Partridge 2000</a>; <a href="./references#CD006205-bbs2-0122" title="WoolgarJA , RogersSN , LoweD , BrownJS , VaughanED . Cervical lymph node metastasis in oral cancer: the importance of even microscopic extracapsular spread. Oral Oncology2003;39(2):130-7.">Woolgar 2003</a>). Surgical treatment may be disfiguring and result in a substantially reduced quality of life due to difficulties with altered appearance, speech, and eating and drinking, with associated social isolation. Developments in surgical delivery aim to improve its efficacy and reduce the impact on people's quality of life. </p> <p>This review was undertaken as part of a series of reviews looking at the different treatment modalities for oral and oropharyngeal cancer: surgery (<a href="./references#CD006205-bbs2-0125" title="BulsaraVM , WorthingtonHV , GlennyAM , ClarksonJE , ConwayDI , MacluskeyM . Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment. Cochrane Database of Systematic Reviews2018, Issue 12. Art. No: CD006205. [DOI: 10.1002/14651858.CD006205.pub4] [PMICD: PMC6517307] [PMID: 30582609]">Bulsara 2018</a>), chemotherapy (<a href="./references#CD006205-bbs2-0102" title="ParmarA , MacluskeyM , Mc GoldrickN , ConwayDI , Glenny A-M, ClarksonJE , et al. Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy. Cochrane Database of Systematic Reviews2021, Issue 12. Art. No: CD006386. [DOI: 10.1002/14651858.CD006386.pub4]">Parmar 2021</a>), radiotherapy (<a href="./references#CD006205-bbs2-0081" title="GlennyAM , FurnessS , WorthingtonHV , ConwayDI , OliverR , ClarksonJE , et al. Interventions for the treatment of oral cavity and oropharyngeal cancer: radiotherapy. Cochrane Database of Systematic Reviews2010, Issue 12. Art. No: CD006387. [DOI: 10.1002/14651858.CD006387.pub2]">Glenny 2010</a>), and immunotherapy (<a href="./references#CD006205-bbs2-0065" title="ChanKK , Glenny A-M, WeldonJC , FurnessS , WorthingtonHV , WakefordH . Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy. Cochrane Database of Systematic Reviews2015, Issue 12. Art. No: CD010341. [DOI: 10.1002/14651858.CD010341.pub2]">Chan 2015</a>). In this update of our surgical review, we aimed to answer the following two broad questions. </p> <p> <ul id="CD006205-list-0002"> <li> <p>Does surgery, alone or combined with other treatment modalities, improve outcomes for people with oral cavity and oropharyngeal cancers? </p> </li> <li> <p>Which type of surgery is most effective for treating people with oral cavity and oropharyngeal cancers? </p> </li> </ul> </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD006205-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD006205-sec-0014"></div> <p>To evaluate the relative benefits and harms of different surgical treatment modalities for oral cavity and oropharyngeal cancers. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD006205-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD006205-sec-0015"></div> <section id="CD006205-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD006205-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs), including cluster‐RCTs.</p> </section> <section id="CD006205-sec-0018"> <h4 class="title">Types of participants</h4> <p>Cancer diagnoses were based on the International Classification of Diseases for Oncology (ICD‐O) codes (<a href="./references#CD006205-bbs2-0119" title="World Health Organization. International Classification of Diseases for Oncology (ICD-O). 2nd edition. Geneva: World Health Organization, 1990.">WHO 1990</a>). We included people with oral cancer (C01–C06) and oropharyngeal cancer (C09, C10). We excluded cancers of the hypopharynx (C13), nasopharynx (C11), larynx (C32), and lip (C00). </p> <p>We included RCTs of HNC where more than 50% of participants had primary tumours in the oral cavity or oropharynx, or where separate data could be extracted for participants with these cancers. </p> <p>Cancers were primary SCCs arising from the oral mucosa. We included histological variants of SCCs (e.g. adenosquamous, verrucous, basaloid, papillary). Although these variants are known to have differing natural histories to most conventional SCCs, they have a common aetiology, incidence is low, and they are generally managed in the same way. We also included carcinoma in situ. </p> <p>We excluded epithelial malignancies of the salivary glands, odontogenic tumours, sarcomas, and lymphomas, as these have a different aetiology and are managed differently. </p> </section> <section id="CD006205-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Surgical treatment of the primary tumour is typically a main therapeutic intervention. For this review, eligible surgical treatment could involve traditional scalpel‐based surgery, laser cutting or ablation, or harmonic scalpel. We included RCTs of the following comparisons. </p> <p> <ul id="CD006205-list-0003"> <li> <p>One surgical treatment modality versus another surgical treatment modality</p> </li> <li> <p>Other treatment interventions (radiotherapy, chemotherapy, immunotherapy/biotherapy, or any combination of these) with versus without surgery </p> </li> <li> <p>Surgery versus no surgery</p> </li> </ul> </p> <p>We anticipated that there would be no studies comparing surgery with placebo (although such studies would have been eligible). We did not consider salvage or palliative surgery. </p> <p>We included studies that carried out surgical treatment of the neck lymph nodes (cervical lymph nodes) before, after, or at the same time as surgical treatment of the primary tumour. We did not consider studies that investigated surgical treatment of the cervical lymph nodes without treatment of the primary tumour. We included studies concerned with cervical lymph node management in the surgical treatment of the primary tumour. </p> <p>The treatments evaluated must have been the primary treatment for the tumour, and participants should not have received any prior intervention other than diagnostic biopsy. </p> </section> <section id="CD006205-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We excluded studies that did not measure any of our primary outcomes (e.g. short‐term studies focusing on postsurgical outcomes such as wound closure). As we did not expect to find many data, we planned to report dichotomous outcomes at all available time points; this was not necessary for time‐to‐event data, as hazard ratios (HRs) summarise all time points of measurement. </p> <section id="CD006205-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD006205-list-0004"> <li> <p>Overall survival (or total mortality; we also planned to evaluate disease‐related mortality, if possible) </p> </li> <li> <p>Disease‐free survival (i.e absence of new disease, progression, and mortality)</p> </li> <li> <p>Locoregional recurrence</p> </li> <li> <p>Recurrence (including loco‐regional recurrence and distant metastasis)</p> </li> </ul> </p> </section> <section id="CD006205-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD006205-list-0005"> <li> <p>Adverse events associated with treatment</p> </li> <li> <p>Quality of life</p> </li> <li> <p>Direct and indirect costs to patients and health services</p> </li> <li> <p>Participant satisfaction</p> </li> </ul> </p> </section> </section> </section> <section id="CD006205-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>In the original version of this review, searches were conducted as part of a series of Cochrane Reviews on the treatment modalities for oral cavity and oropharyngeal cancer (<a href="./references#CD006205-bbs2-0127" title="OliverR , ClarksonJE , ConwayD , GlennyAM , MacluskeyM , PavittS , et al. Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment. Cochrane Database of Systematic Reviews2007, Issue 4. Art. No: CD006205. [DOI: 10.1002/14651858.CD006205.pub2]">Oliver 2007</a>). The reviews were divided into four themes: surgery, chemotherapy, radiotherapy, and immunotherapy/targeted therapies. A search strategy was developed that would encompass three of the four broad themes (surgery, chemotherapy, radiotherapy; see <a href="./references#CD006205-bbs2-0124" title="BessellA , GlennyAM , FurnessS , ClarksonJE , OliverR , ConwayDI , et al. Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment. Cochrane Database of Systematic Reviews2011, Issue 9. Art. No: CD006205. [DOI: 10.1002/14651858.CD006205.pub3]">Bessell 2011</a> for details of the search strategy). From 2011 onwards, we conducted a more specific search for the surgery theme. </p> <section id="CD006205-sec-0024"> <h4 class="title">Electronic searches</h4> <p>Cochrane Oral Health's Information Specialist conducted systematic searches in the following databases for RCTs and controlled clinical trials. There were no language, publication year, or publication status restrictions. </p> <p> <ul id="CD006205-list-0006"> <li> <p>Cochrane Oral Health's Trials Register (searched 9 February 2022; <a href="./appendices#CD006205-sec-0166">Appendix 1</a>) </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2022, Issue 1) in the Cochrane Library (searched 9 February 2022; <a href="./appendices#CD006205-sec-0167">Appendix 2</a>) </p> </li> <li> <p>MEDLINE Ovid (1946 to 9 February 2022; <a href="./appendices#CD006205-sec-0168">Appendix 3</a>) </p> </li> <li> <p>Embase Ovid (1980 to 9 February 2022; <a href="./appendices#CD006205-sec-0169">Appendix 4</a>) </p> </li> </ul> </p> <p>Subject strategies were modelled on the search strategy designed for MEDLINE Ovid. Where appropriate, we combined strategies with subject strategy adaptations of the highly sensitive search strategies designed by Cochrane for identifying RCTs and controlled clinical trials, as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD006205-bbs2-0092" title="LefebvreC , GlanvilleJ , BriscoeS , FeatherstoneR , LittlewoodA , MarshallC , et al. Technical Supplement to Chapter 4: Searching for and selecting studies. In: Higgins JPT, Thomas J, Chandler J, Cumpston MS, Li T, Page MJ, Welch VA (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Lefebvre 2022</a>). </p> </section> <section id="CD006205-sec-0025"> <h4 class="title">Searching other resources</h4> <p>Cochrane Oral Health's information specialist searched the following trials registries for ongoing trials. </p> <p> <ul id="CD006205-list-0007"> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://clinicaltrials.gov/" target="_blank">clinicaltrials.gov</a>; searched 9 February 2022; <a href="./appendices#CD006205-sec-0170">Appendix 5</a>) </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (WHO ICTRP; <a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch</a>; searched 9 February 2022; <a href="./appendices#CD006205-sec-0171">Appendix 6</a>) </p> </li> </ul> </p> <p>Where necessary, we contacted authors of key papers and abstracts to request further information about their trials. </p> <p>We searched the reference lists of included studies and relevant systematic reviews for further studies. </p> <p>There was no separate search for adverse events associated with interventions; we considered adverse events described in included studies only. </p> <p>We checked that no included studies had been retracted due to error or fraud.</p> </section> </section> <section id="CD006205-sec-0026"> <h3 class="title" id="CD006205-sec-0026">Data collection and analysis</h3> <section id="CD006205-sec-0027"> <h4 class="title">Selection of studies</h4> <p>At least two review authors (from HW, VB, AMG, DC, MM) independently scanned the titles and abstracts (when available) of all reports identified through the electronic searches. The search was designed to be sensitive and include controlled clinical trials; these were filtered out early in the selection process if they were not randomised. As HNC studies often include people with oral cavity or oropharyngeal cancer, we undertook a broad search to include all possible studies. We obtained the full‐text articles of studies that appeared to meet our inclusion criteria or that provided insufficient information in the title and abstract to make a decision. We excluded studies reported as conference abstracts only. Two review authors independently assessed the full reports of potentially eligible studies to establish whether they met our inclusion criteria. We resolved disagreements by discussion or by consulting a third review author if necessary. We listed studies rejected at this or subsequent stages in the <a href="./references#CD006205-sec-0182" title="">Characteristics of excluded studies</a> table, and recorded our reasons for exclusion. </p> </section> <section id="CD006205-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>At least two review authors independently extracted data from included studies. The data extraction forms were piloted on several papers and modified as required before use. We discussed any disagreements, consulting a third review author where necessary. However, group discussion was often required following data extraction due to the complexity of the data presented. Where necessary, we contacted study authors for clarification or missing information. Had any trials required translation, an experienced review author would have completed a data extraction sheet in their native language, when available. A second review author would have checked the numerical data from these non‐English language papers. </p> <p>For each trial, we recorded the following data.</p> <p> <ul id="CD006205-list-0008"> <li> <p>Year of publication, country of origin, and source of study funding</p> </li> <li> <p>Details of the participants, including demographic characteristics, inclusion and exclusion criteria, and proportion with oral cavity and oropharyngeal cancer </p> </li> <li> <p>Details of the type of intervention, timing, and duration</p> </li> <li> <p>Details of the outcomes reported, including method of assessment and time intervals</p> </li> </ul> </p> <p>We planned to include HNC trials with combined data (i.e. no outcome data available by primary tumour site) if more than 50% of participants had oral/oropharyngeal cancer. Where separate 'pure' oral/oropharyngeal cancer data were available, we extracted and analysed these 'pure' data and ignored the combined head and neck data. </p> </section> <section id="CD006205-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>At least two review authors independently conducted assessment of risk of bias of included studies using the Cochrane risk of bias tool (RoB 1; <a href="./references#CD006205-bbs2-0085" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Wiley, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). We resolved any disagreements through discussion or by consulting a third review author where necessary. We assessed six domains for each included study: sequence generation, allocation concealment, blinding (of outcome assessors), completeness of outcome data, selective outcome reporting, and other potential sources of bias. We made an overall risk of bias assessment for each study at an outcome level (objective or subjective), according to the most severe assessment of the domains. </p> <p>We assigned a 'low', 'high', or 'unclear' risk of bias judgement for each domain according to the following criteria. </p> <p> <ul id="CD006205-list-0009"> <li> <p>Sequence generation: low risk if use of a random number table, computerised system, central randomisation by statistical co‐ordinating centre, randomisation by an independent service using minimisation technique, permuted block allocation, or Zelan technique. If the paper merely stated that participants were randomised or randomly allocated with no further information, we assigned an unclear risk of bias judgement. Otherwise, we judged the study at high risk of bias. </p> </li> <li> <p>Allocation concealment: low risk if centralised allocation including access by telephone call or fax; or pharmacy‐controlled randomisation or sequentially numbered, sealed, opaque envelopes. If it was clear that the investigators had not used any of these methods, we judged the study at high risk of bias. If this information was unavailable, we judged the study at unclear risk. </p> </li> <li> <p>Blinding of outcome assessment (objective outcomes): as mortality is the primary outcome that is most frequently and reliably reported, we decided to assess all trials as being at low risk of bias for this domain. </p> </li> <li> <p>Blinding of outcome assessment (subjective outcomes): given the nature of the interventions, all subjective outcome measurements were considered to be at high risk of bias for this domain. </p> </li> <li> <p>Outcome data: outcome data were considered complete if all randomised participants were included in the analysis of the outcome(s). However, in trials of treatment for cancer, this is rarely the case. We considered trials with less than 10% attrition (less than 10% of randomised participants excluded from analyses) at low risk of bias if they provided reasons for exclusions for each group, and the numbers and reasons were similar in each group. Where postrandomisation exclusions were greater than 10%, or there were no reasons provided for exclusions for each group, or where rates and reasons were different for each group, we assigned an unclear risk of bias judgement. </p> </li> <li> <p>Selective outcome reporting: we judged trials at low risk of reporting bias if the outcomes of interest described in the methods section were systematically reported in the results section. Where reported outcomes did not include prespecified outcomes or outcomes expected in trials of treatments for oral and oropharyngeal cancer, or where trials reported additional analyses, we considered them at unclear risk of bias. </p> </li> <li> <p>Other bias: we noted examples of potential sources of bias such as baseline imbalance in potentially important prognostic factors between the treatment groups, or the use of a co‐intervention in only one group (e.g. nasogastric feeding). If there was no information about the intervention groups at baseline, we assessed studies at unclear risk of bias. If there was a major problem with the conduct of the study such as early termination, we judged it at high risk of other bias. </p> </li> </ul> </p> </section> <section id="CD006205-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>The primary outcome most frequently and reliably reported in cancer studies is total mortality, expressed as an HR along with a 95% confidence interval (CI). An HR provides an estimate of the ratio of the hazard rates for a particular event between the experimental group and a control group over the duration of the entire study. For overall survival, the event of interest is death (total mortality). It is preferable to express the outcome in terms of overall survival; however, statistically, the estimate of effect is the HR of death. Similarly, for disease‐free survival, we used the HR for the combined outcome of new disease, progression, and mortality. </p> <p>We entered these data into the meta‐analysis using the inverse variance method. If studies did not quote HRs, we calculated the log HR and the standard error (SE) from the available summary statistics or Kaplan‐Meier curves, according to the methods proposed by Parmar and colleagues (<a href="./references#CD006205-bbs2-0101" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta-analysis of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815-34.">Parmar 1998</a>), or we requested these data from study authors. </p> <p>For dichotomous outcomes, we expressed the estimates of effect of an intervention as risk ratios (RRs) together with 95% CIs. We used dichotomous data for primary outcomes only where HRs were unavailable or could not be calculated. We planned to combine data from similar follow‐up periods. </p> </section> <section id="CD006205-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>The participant was the unit of analysis. We analysed cluster‐RCTs as described in Chapter 23 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD006205-bbs2-0086" title="HigginsJPT , EldridgeS , Li T (editors). Chapter 23: Including variants on randomized trials. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook. Wiley, 2022.">Higgins 2022</a>). To include studies with more than two intervention groups in a meta‐analysis, we omitted groups that were irrelevant to the comparison, and combined multiple relevant groups to create a single pair‐wise comparison. Most of the trials included time‐to‐event data presented as HRs. For data presented for all participants at different time points, we used the latest time point. We took care to analyse the data for events that may re‐occur (e.g. adverse events) to avoid unit‐of‐analysis errors. </p> </section> <section id="CD006205-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We attempted to contact trial authors to retrieve data missing from the trial report, or to clarify areas where data or trial design and conduct were unclear. </p> <p>The primary method of analysis was using HRs, which accounts for missing data by censoring.</p> </section> <section id="CD006205-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We conducted meta‐analyses only if there were studies of similar comparisons reporting the same outcome measures. We assessed the significance of any discrepancies in the estimates of the treatment effects between trials using the Chi<sup>2</sup> test and the I<sup>2</sup> statistic. </p> </section> <section id="CD006205-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>For the four primary outcomes, had there been sufficient studies (more than 10 per comparison), we would have generated funnel plots and investigated possible publication bias through a visual inspection of funnel plot asymmetry and through the Begg and Mazumdar adjusted rank correlation test and the Egger regression asymmetry test (<a href="./references#CD006205-bbs2-0057" title="BeggCB , MazumdarM . Operating characteristics of a rank correlation test for publication bias. Biometrics1991;50(4):1088-101.">Begg 1994</a>; <a href="./references#CD006205-bbs2-0074" title="EggerM , Davey-SmithG , SchneiderM , MinderC . Bias in meta-analysis detected by a simple, graphical test. BMJ1997;315(7109):629-34.">Egger 1997</a>). </p> </section> <section id="CD006205-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We conducted meta‐analyses only if there were studies of similar comparisons reporting the same outcome measures. We combined RRs for dichotomous data and HRs for survival data using random‐effects models. If studies reported RRs over a fixed time point such as three years, we used these data to calculate the HR over that period so that we could include the outcome in a meta‐analysis of HRs. </p> </section> <section id="CD006205-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Due to the different natural history and treatment regimens for oral cavity and oropharyngeal cancers, we planned to analyse these cancer types separately, if possible, for overall survival and disease‐free survival, using a formal statistical test to compare subgroups. </p> </section> <section id="CD006205-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>Had there been sufficient data, we would have performed sensitivity analyses to examine the effects of randomisation, allocation concealment, and quality of follow‐up/completeness of data on overall survival and disease‐free survival. </p> </section> <section id="CD006205-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We developed summary of findings tables for all comparisons; each table included our four primary outcomes and adverse events associated with treatment. We assessed the certainty of the body of evidence using the GRADE approach, which considers the overall risk of bias of the included studies, directness of the evidence, consistency of the results, precision of the estimates, and risk of publication bias. We rated the certainty of the body of evidence for each outcome as high, moderate, low, or very low (<a href="https://archie.cochrane.org/sections/documents/view?document=037104012901025074&amp;published=true&amp;format=JATS#REF-GRADEpro-GDT" target="_blank">GRADEpro GDT</a>; <a href="./references#CD006205-bbs2-0109" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editors. Available from guidelinedevelopment.org/handbook. The GRADE Working Group, 2003.">Schünemann 2013</a>; <a href="./references#CD006205-bbs2-0110" title="SchünemannHJ , HigginsJPT , VistGE , GlasziouP , AklEA , SkoetzN , GuyattGH . Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook. Wiley, 2022.">Schünemann 2022</a>). We formatted the summary of findings tables for HRs as outlined by <a href="./references#CD006205-bbs2-0113" title="SkoetzN , GoldkuhleM , vanDalenEC , AklEA , TrivellaM , MustafaRA , et al. GRADE guidelines 27: how to calculate absolute effects for time-to-event outcomes in summary of findings tables and evidence profiles. Journal of Clinical Epidemiology2020;118:124-31. [DOI: 10.1016/j.jclinepi.2019.10.015] [PMID: 31711910]">Skoetz 2020</a>. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD006205-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD006205-sec-0039"></div> <section id="CD006205-sec-0040"> <h3 class="title">Description of studies</h3> <section id="CD006205-sec-0041"> <h4 class="title">Results of the search</h4> <p>We identified 3374 research papers through the electronic searching for this update, after the removal of duplicates (<a href="#CD006205-fig-0001">Figure 1</a>). In the title and abstract screen, we identified 22 potentially eligible records. After retrieving and reading the full‐text articles, we included four new trials in this review update (<a href="./references#CD006205-bbs2-0005" title="GarrelR , PerriardF , FavierV , RichardF , Pierre DauresJ , De BoutrayM . Equivalence randomized trial comparing treatment based on sentinel node biopsy versus neck dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States2020;38(Suppl 15):6501. GarrelR , PoissonnetG , Moyà PlanaA , FakhryN , DolivetG , LallemantB , et al. Equivalence randomized trial to compare treatment on the basis of sentinel node biopsy versus neck node dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology2020;38(34):4010-18. [DOI: 10.1200/JCO.20.01661]NCT02855723. Randomized, open-label economic and medical study on the lymph node management of squamous cell carcinoma of the oral cavity and oropharynx tumor Stage 1 or 2, nodes 0 (T1-T2 N0) operable (SentiMERORL). clinicaltrials.gov/ct2/show/NCT02855723 (first received 4 August 2016). ">Garrel 2020</a>; <a href="./references#CD006205-bbs2-0007" title="HutchisonIL , RidoutF , CheungSM , ShahN , HardeeP , SurwaldC , et al. Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort. British Journal of Cancer2019;121(10):827-36. [DOI: 0.1038/s41416-019-0587-2] [PMID: 31611612]ISRCTN65018995. The role of selective neck dissection in patients with early oral squamous cell carcinoma (1-3cm primary size) and no clinical evidence of lymph node metastases in the neck (N0). www.isrctn.com/ISRCTN65018995 (first received 23 April 2010). NCT00571883. Neck surgery in treating patients with early-stage oral cancer. clinicaltrials.gov/ct2/show/NCT00571883 (first received 12 December 2007). ">Hutchison 2019</a>; <a href="./references#CD006205-bbs2-0011" title="FabianA , KrugD . Radiotherapy versus transoral robotic surgery for primary treatment of oropharyngeal squamous cell carcinoma: randomisation decides. Strahlentherapie und Onkologie2019;196(2):202-4. NCT01590355. A phase II randomized trial for early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs trans-oral robotic surgery (ORATOR). clinicaltrials.gov/ct2/show/NCT01590355 (first received 2 May 2012). NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. Lancet Oncology2019;20(10):1349-59. [DOI: 10.1016/S1470-2045(19)30410-3] [PMID: 31416685]NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Randomized trial of radiotherapy versus transoral robotic surgery for oropharyngeal squamous cell carcinoma: long-term results of the ORATOR trial. Journal of Clinical Oncology2022;40(8):866-75. [DOI: 10.1200/JCO.21.01961]NicholsAC , YooJ , HammondJA , FungK , WinquistE , ReadN , et al. Early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs. trans-oral robotic surgery (ORATOR) – study protocol for a randomized phase II trial. BMC Cancer2013;13:133. [DOI: 10.1186/1471-2407-13-133]PalmaDA , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus trans-oral robotic surgery for oropharyngeal squamous cell carcinoma: results of a randomized trial. Radiotherapy and Oncology2019;139(Supp 1):S39-40. ">Nichols 2019</a>; <a href="./references#CD006205-bbs2-0012" title='NCT00847717. Trial of IIb preserving neck dissection. clinicaltrials.gov/ct2/show/NCT00847717 (first received 19 February 2009). PandeyM , KarthikeyanS , JoshiD , KumarM , ShuklaM . Results of a randomized controlled trial of level IIb preserving neck dissection in clinically node-negative squamous carcinoma of the oral cavity. World Journal of Surgical Oncology2018;16(1):219. [DOI: 10.1186/s12957-018-1518-z] [PMID: 30409212]PandeyM . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 2 February 2023. '>Pandey 2018</a>). We identified eight new ongoing trials (see <a href="./references#CD006205-sec-0183" title="">Characteristics of ongoing studies</a>), and we excluded five new trials (see <a href="./references#CD006205-sec-0182" title="">Characteristics of excluded studies</a>). We also excluded a trial that had been included in previous versions of this review, as the primary site delivered interstitial radiotherapy rather than surgery (<a href="./references#CD006205-bbs2-0037" title="VandenbrouckC , Sancho-GarnierH , ChassagneD , SaravaneD , CachinY , MicheauC . Elective versus therapeutic radical neck dissection in epidermoid carcinoma of the oral cavity: results of a randomized clinical trial. Cancer1980;46(2):386-90. ">Vandenbrouck 1980</a>). </p> <div class="figure" id="CD006205-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA diagram showing study selection process." data-id="CD006205-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_n/nCD006205-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA diagram showing study selection process.</p> </div> </div> </div> </section> <section id="CD006205-sec-0042"> <h4 class="title">Included studies</h4> <p>We included 15 RCTs in this review update. Eight were multicentre trials (<a href="./references#CD006205-bbs2-0001" title="Brazilian Head and Neck Cancer Study Group. Results of a prospective trial on elective modified radical classical versus supraomohyoid neck dissection in the management of oral squamous carcinoma. American Journal of Surgery1998;176(5):422-7. ">BHNCSG 1998</a>; <a href="./references#CD006205-bbs2-0002" title='BierJ , HowaldtHP , PitzH , 4th German-Austrian-Swiss Study Group therapy study. Prospective, randomized, clinical study of squamous cell cancer of the mouth: "Radical neck dissection versus conservative neck dissection". Fortschritte der Kiefer- und Gesichts-Chirurgie1992;37:108-10. BierJ , SchlumsD , MetelmannH , HowaldtHP , PitzH . A comparison of radical and conservative neck dissection. International Journal of Oral &amp; Maxillofacial Surgery1993;22(2):102-7. BierJ . Radical neck dissection versus conservative neck dissection for squamous cell carcinoma of the oral cavity. Recent Results in Cancer Research1994;134:57-62. '>Bier 1994</a>; <a href="./references#CD006205-bbs2-0005" title="GarrelR , PerriardF , FavierV , RichardF , Pierre DauresJ , De BoutrayM . Equivalence randomized trial comparing treatment based on sentinel node biopsy versus neck dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States2020;38(Suppl 15):6501. GarrelR , PoissonnetG , Moyà PlanaA , FakhryN , DolivetG , LallemantB , et al. Equivalence randomized trial to compare treatment on the basis of sentinel node biopsy versus neck node dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology2020;38(34):4010-18. [DOI: 10.1200/JCO.20.01661]NCT02855723. Randomized, open-label economic and medical study on the lymph node management of squamous cell carcinoma of the oral cavity and oropharynx tumor Stage 1 or 2, nodes 0 (T1-T2 N0) operable (SentiMERORL). clinicaltrials.gov/ct2/show/NCT02855723 (first received 4 August 2016). ">Garrel 2020</a>; <a href="./references#CD006205-bbs2-0007" title="HutchisonIL , RidoutF , CheungSM , ShahN , HardeeP , SurwaldC , et al. Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort. British Journal of Cancer2019;121(10):827-36. [DOI: 0.1038/s41416-019-0587-2] [PMID: 31611612]ISRCTN65018995. The role of selective neck dissection in patients with early oral squamous cell carcinoma (1-3cm primary size) and no clinical evidence of lymph node metastases in the neck (N0). www.isrctn.com/ISRCTN65018995 (first received 23 April 2010). NCT00571883. Neck surgery in treating patients with early-stage oral cancer. clinicaltrials.gov/ct2/show/NCT00571883 (first received 12 December 2007). ">Hutchison 2019</a>; <a href="./references#CD006205-bbs2-0010" title='ISRCTN13735240. A multicentre randomised phase III trial comparing positron emission tomography–computed tomography guided watch and wait policy versus planned NECK dissection for the management of locally advanced (N2/N3) nodal metastases in patients with head and neck squamous cancer. www.isrctn.com/ISRCTN13735240 (first received 21 May 2007). MehannaH , McConkeyCC , RahmanJK , Wong W-L, SmithAF , NuttingC , et al. PET-NECK a multicentre randomised phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer. Health Technology Assessment2017;21:17. [DOI: 10.3310/hta21170]MehannaH , Wong W-L, McConkeyCC , RahmanJK , RobinsonM , HartleyAG , et al. PET-CT surveillance versus neck dissection in advanced head and neck cancer. New England Journal of Medicine2016;374(15):1444-54. [DOI: 10.1056/NEJMoa1514493]MehannaH . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 31 January 2023. '>Mehanna 2017</a>; <a href="./references#CD006205-bbs2-0011" title="FabianA , KrugD . Radiotherapy versus transoral robotic surgery for primary treatment of oropharyngeal squamous cell carcinoma: randomisation decides. Strahlentherapie und Onkologie2019;196(2):202-4. NCT01590355. A phase II randomized trial for early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs trans-oral robotic surgery (ORATOR). clinicaltrials.gov/ct2/show/NCT01590355 (first received 2 May 2012). NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. Lancet Oncology2019;20(10):1349-59. [DOI: 10.1016/S1470-2045(19)30410-3] [PMID: 31416685]NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Randomized trial of radiotherapy versus transoral robotic surgery for oropharyngeal squamous cell carcinoma: long-term results of the ORATOR trial. Journal of Clinical Oncology2022;40(8):866-75. [DOI: 10.1200/JCO.21.01961]NicholsAC , YooJ , HammondJA , FungK , WinquistE , ReadN , et al. Early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs. trans-oral robotic surgery (ORATOR) – study protocol for a randomized phase II trial. BMC Cancer2013;13:133. [DOI: 10.1186/1471-2407-13-133]PalmaDA , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus trans-oral robotic surgery for oropharyngeal squamous cell carcinoma: results of a randomized trial. Radiotherapy and Oncology2019;139(Supp 1):S39-40. ">Nichols 2019</a>; <a href="./references#CD006205-bbs2-0014" title="Dr Robertson. Personal communication2006. RobertsonAG , SoutarDS , PaulJ , WebsterM , LeonardAG , MooreKP , et al. Early closure of a randomized trial: surgery and postoperative radiotherapy versus radiotherapy in the management of intra-oral tumours. Clinical Oncology (Royal College of Radiologists (Great Britain))1998;10(3):155-60. ">Robertson 1998</a>; <a href="./references#CD006205-bbs2-0015" title="YuenAP , HoCM , ChowTL , TangLC , CheungWY , NgRW , et al. Prospective randomized study of selective neck dissection versus observation for N0 neck of early tongue carcinoma. Head &amp; Neck2009;31(6):765-72. ">Yuen 2009</a>), with the number of centres ranging from three to 38. Four trials were undertaken in India (<a href="./references#CD006205-bbs2-0003" title="D'CruzA . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment&quot; [personal communication]. Email to: H Worthington 6 February 2023. D'CruzAK , VaishR , KapreN , DandekarM , GuptaS , HawaldarR , et al. Elective versus therapeutic neck dissection in node-negative oral cancer. New England Journal of Medicine2015;373(6):521-9. [DOI: 10.1056/NEJMoa1506007]NCT00193765. Elective vs therapeutic neck dissection in treatment of early node negative squamous carcinoma of oral cavity. www.clinicaltrials.gov/ct2/show/NCT00193765 (first received 19 September 2005). ">D'Cruz 2015</a>; <a href="./references#CD006205-bbs2-0004" title="FakihAR , RaoRS , BorgesAM , PatelAR . Elective versus therapeutic neck dissection in early carcinoma of the oral tongue. American Journal of Surgery1989;158(4):309-13. FakihAR , RaoRS , PatelAR . Prophylactic neck dissection in squamous cell carcinoma of oral tongue: a prospective randomized study. Seminars in Surgical Oncology1989;5(5):327-30. ">Fakih 1989</a>; <a href="./references#CD006205-bbs2-0012" title='NCT00847717. Trial of IIb preserving neck dissection. clinicaltrials.gov/ct2/show/NCT00847717 (first received 19 February 2009). PandeyM , KarthikeyanS , JoshiD , KumarM , ShuklaM . Results of a randomized controlled trial of level IIb preserving neck dissection in clinically node-negative squamous carcinoma of the oral cavity. World Journal of Surgical Oncology2018;16(1):219. [DOI: 10.1186/s12957-018-1518-z] [PMID: 30409212]PandeyM . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 2 February 2023. '>Pandey 2018</a>; <a href="./references#CD006205-bbs2-0013" title="RastogiS , SharmaA , ChoudhuryR , TripathiS , Al WayliH , AmrithrajA , et al. Is superselective neck dissection safer than supraomohyoid neck dissection for oral carcinoma patients with N0 neck in terms of shoulder morbidity and recurrence rate?Journal of Oral and Maxillofacial Surgery2018;76(3):647-55. [DOI: 10.1016/j.joms.2017.08.002]">Rastogi 2018</a>), three in the UK (<a href="./references#CD006205-bbs2-0007" title="HutchisonIL , RidoutF , CheungSM , ShahN , HardeeP , SurwaldC , et al. Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort. British Journal of Cancer2019;121(10):827-36. [DOI: 0.1038/s41416-019-0587-2] [PMID: 31611612]ISRCTN65018995. The role of selective neck dissection in patients with early oral squamous cell carcinoma (1-3cm primary size) and no clinical evidence of lymph node metastases in the neck (N0). www.isrctn.com/ISRCTN65018995 (first received 23 April 2010). NCT00571883. Neck surgery in treating patients with early-stage oral cancer. clinicaltrials.gov/ct2/show/NCT00571883 (first received 12 December 2007). ">Hutchison 2019</a>; <a href="./references#CD006205-bbs2-0010" title='ISRCTN13735240. A multicentre randomised phase III trial comparing positron emission tomography–computed tomography guided watch and wait policy versus planned NECK dissection for the management of locally advanced (N2/N3) nodal metastases in patients with head and neck squamous cancer. www.isrctn.com/ISRCTN13735240 (first received 21 May 2007). MehannaH , McConkeyCC , RahmanJK , Wong W-L, SmithAF , NuttingC , et al. PET-NECK a multicentre randomised phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer. Health Technology Assessment2017;21:17. [DOI: 10.3310/hta21170]MehannaH , Wong W-L, McConkeyCC , RahmanJK , RobinsonM , HartleyAG , et al. PET-CT surveillance versus neck dissection in advanced head and neck cancer. New England Journal of Medicine2016;374(15):1444-54. [DOI: 10.1056/NEJMoa1514493]MehannaH . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 31 January 2023. '>Mehanna 2017</a>; <a href="./references#CD006205-bbs2-0014" title="Dr Robertson. Personal communication2006. RobertsonAG , SoutarDS , PaulJ , WebsterM , LeonardAG , MooreKP , et al. Early closure of a randomized trial: surgery and postoperative radiotherapy versus radiotherapy in the management of intra-oral tumours. Clinical Oncology (Royal College of Radiologists (Great Britain))1998;10(3):155-60. ">Robertson 1998</a>), two in Brazil (<a href="./references#CD006205-bbs2-0001" title="Brazilian Head and Neck Cancer Study Group. Results of a prospective trial on elective modified radical classical versus supraomohyoid neck dissection in the management of oral squamous carcinoma. American Journal of Surgery1998;176(5):422-7. ">BHNCSG 1998</a>; <a href="./references#CD006205-bbs2-0009" title="Dr Kilgerman. Personal communcation2006. KligermanJ , LimaRA , SoaresJR , PradoL , DiasFL , FreitasEQ , et al. Supraomohyoid neck dissection in the treatment of T1/T2 squamous cell carcinoma of oral cavity. American Journal of Surgery1994;168(5):391-4. ">Kligerman 1994</a>), two in China (<a href="./references#CD006205-bbs2-0006" title="GuoCB , FengZ , ZhangJG , PengX , CaiZG , MaoC , et al. Supraomohyoid neck dissection and modified radical neck dissection for clinically node-negative oral squamous cell carcinoma: a prospective study of prognosis, complications and quality of life. Journal of Craniofacial Surgery2014;42(8):1885-90. [DOI: 10.1016/j.jcms.2014.07.007]">Guo 2014</a>; <a href="./references#CD006205-bbs2-0015" title="YuenAP , HoCM , ChowTL , TangLC , CheungWY , NgRW , et al. Prospective randomized study of selective neck dissection versus observation for N0 neck of early tongue carcinoma. Head &amp; Neck2009;31(6):765-72. ">Yuen 2009</a>), one in France (<a href="./references#CD006205-bbs2-0005" title="GarrelR , PerriardF , FavierV , RichardF , Pierre DauresJ , De BoutrayM . Equivalence randomized trial comparing treatment based on sentinel node biopsy versus neck dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States2020;38(Suppl 15):6501. GarrelR , PoissonnetG , Moyà PlanaA , FakhryN , DolivetG , LallemantB , et al. Equivalence randomized trial to compare treatment on the basis of sentinel node biopsy versus neck node dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology2020;38(34):4010-18. [DOI: 10.1200/JCO.20.01661]NCT02855723. Randomized, open-label economic and medical study on the lymph node management of squamous cell carcinoma of the oral cavity and oropharynx tumor Stage 1 or 2, nodes 0 (T1-T2 N0) operable (SentiMERORL). clinicaltrials.gov/ct2/show/NCT02855723 (first received 4 August 2016). ">Garrel 2020</a>), one in Canada and Australia (<a href="./references#CD006205-bbs2-0011" title="FabianA , KrugD . Radiotherapy versus transoral robotic surgery for primary treatment of oropharyngeal squamous cell carcinoma: randomisation decides. Strahlentherapie und Onkologie2019;196(2):202-4. NCT01590355. A phase II randomized trial for early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs trans-oral robotic surgery (ORATOR). clinicaltrials.gov/ct2/show/NCT01590355 (first received 2 May 2012). NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. Lancet Oncology2019;20(10):1349-59. [DOI: 10.1016/S1470-2045(19)30410-3] [PMID: 31416685]NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Randomized trial of radiotherapy versus transoral robotic surgery for oropharyngeal squamous cell carcinoma: long-term results of the ORATOR trial. Journal of Clinical Oncology2022;40(8):866-75. [DOI: 10.1200/JCO.21.01961]NicholsAC , YooJ , HammondJA , FungK , WinquistE , ReadN , et al. Early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs. trans-oral robotic surgery (ORATOR) – study protocol for a randomized phase II trial. BMC Cancer2013;13:133. [DOI: 10.1186/1471-2407-13-133]PalmaDA , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus trans-oral robotic surgery for oropharyngeal squamous cell carcinoma: results of a randomized trial. Radiotherapy and Oncology2019;139(Supp 1):S39-40. ">Nichols 2019</a>), one in centres across Europe (Austria, Germany, and Switzerland; <a href="./references#CD006205-bbs2-0002" title='BierJ , HowaldtHP , PitzH , 4th German-Austrian-Swiss Study Group therapy study. Prospective, randomized, clinical study of squamous cell cancer of the mouth: "Radical neck dissection versus conservative neck dissection". Fortschritte der Kiefer- und Gesichts-Chirurgie1992;37:108-10. BierJ , SchlumsD , MetelmannH , HowaldtHP , PitzH . A comparison of radical and conservative neck dissection. International Journal of Oral &amp; Maxillofacial Surgery1993;22(2):102-7. BierJ . Radical neck dissection versus conservative neck dissection for squamous cell carcinoma of the oral cavity. Recent Results in Cancer Research1994;134:57-62. '>Bier 1994</a>), and one in Singapore (<a href="./references#CD006205-bbs2-0008" title="IyerNG , TanDS , TanVK , WangW , HwangJ , Tan N-C, et al. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. Cancer2015;121(10):1599-607. SooKC , TanEH , WeeJ , LimD , TaiBC , Khoo ML et al. Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison. British Journal of Cancer2005;8(93):279-86. [DOI: 10.1038/sj.bjc.6602696] [PMCID: PMC2361563] [PMID: 16012523]">Iyer 2015</a>). We wrote to the authors of 12 of the included studies to request missing data and details about the randomisation sequence generation and allocation concealment, as appropriate. We received replies from the authors of five trials (<a href="./references#CD006205-bbs2-0003" title="D'CruzA . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment&quot; [personal communication]. Email to: H Worthington 6 February 2023. D'CruzAK , VaishR , KapreN , DandekarM , GuptaS , HawaldarR , et al. Elective versus therapeutic neck dissection in node-negative oral cancer. New England Journal of Medicine2015;373(6):521-9. [DOI: 10.1056/NEJMoa1506007]NCT00193765. Elective vs therapeutic neck dissection in treatment of early node negative squamous carcinoma of oral cavity. www.clinicaltrials.gov/ct2/show/NCT00193765 (first received 19 September 2005). ">D'Cruz 2015</a>; <a href="./references#CD006205-bbs2-0009" title="Dr Kilgerman. Personal communcation2006. KligermanJ , LimaRA , SoaresJR , PradoL , DiasFL , FreitasEQ , et al. Supraomohyoid neck dissection in the treatment of T1/T2 squamous cell carcinoma of oral cavity. American Journal of Surgery1994;168(5):391-4. ">Kligerman 1994</a>; <a href="./references#CD006205-bbs2-0010" title='ISRCTN13735240. A multicentre randomised phase III trial comparing positron emission tomography–computed tomography guided watch and wait policy versus planned NECK dissection for the management of locally advanced (N2/N3) nodal metastases in patients with head and neck squamous cancer. www.isrctn.com/ISRCTN13735240 (first received 21 May 2007). MehannaH , McConkeyCC , RahmanJK , Wong W-L, SmithAF , NuttingC , et al. PET-NECK a multicentre randomised phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer. Health Technology Assessment2017;21:17. [DOI: 10.3310/hta21170]MehannaH , Wong W-L, McConkeyCC , RahmanJK , RobinsonM , HartleyAG , et al. PET-CT surveillance versus neck dissection in advanced head and neck cancer. New England Journal of Medicine2016;374(15):1444-54. [DOI: 10.1056/NEJMoa1514493]MehannaH . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 31 January 2023. '>Mehanna 2017</a>; <a href="./references#CD006205-bbs2-0012" title='NCT00847717. Trial of IIb preserving neck dissection. clinicaltrials.gov/ct2/show/NCT00847717 (first received 19 February 2009). PandeyM , KarthikeyanS , JoshiD , KumarM , ShuklaM . Results of a randomized controlled trial of level IIb preserving neck dissection in clinically node-negative squamous carcinoma of the oral cavity. World Journal of Surgical Oncology2018;16(1):219. [DOI: 10.1186/s12957-018-1518-z] [PMID: 30409212]PandeyM . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 2 February 2023. '>Pandey 2018</a>; <a href="./references#CD006205-bbs2-0014" title="Dr Robertson. Personal communication2006. RobertsonAG , SoutarDS , PaulJ , WebsterM , LeonardAG , MooreKP , et al. Early closure of a randomized trial: surgery and postoperative radiotherapy versus radiotherapy in the management of intra-oral tumours. Clinical Oncology (Royal College of Radiologists (Great Britain))1998;10(3):155-60. ">Robertson 1998</a>); based on these replies, we made changes to the risk of bias assessments for three trials. </p> <section id="CD006205-sec-0043"> <h5 class="title">Participants</h5> <p>Participants were recruited over periods ranging from two years to 10 years, with the earliest recruitment commencing in 1985 (<a href="./references#CD006205-bbs2-0004" title="FakihAR , RaoRS , BorgesAM , PatelAR . Elective versus therapeutic neck dissection in early carcinoma of the oral tongue. American Journal of Surgery1989;158(4):309-13. FakihAR , RaoRS , PatelAR . Prophylactic neck dissection in squamous cell carcinoma of oral tongue: a prospective randomized study. Seminars in Surgical Oncology1989;5(5):327-30. ">Fakih 1989</a>). A total of 2820 participants were randomly allocated to treatments, and 2583 were included in the outcome evaluations. </p> <p>Fourteen included trials reported tumour extent using the TNM system (where T defines tumour size and any spread of cancer into nearby tissue, N defines spread of cancer to nearby lymph nodes, and M defines metastasis). Seven trials included people with T1 to T2 tumours (<a href="./references#CD006205-bbs2-0003" title="D'CruzA . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment&quot; [personal communication]. Email to: H Worthington 6 February 2023. D'CruzAK , VaishR , KapreN , DandekarM , GuptaS , HawaldarR , et al. Elective versus therapeutic neck dissection in node-negative oral cancer. New England Journal of Medicine2015;373(6):521-9. [DOI: 10.1056/NEJMoa1506007]NCT00193765. Elective vs therapeutic neck dissection in treatment of early node negative squamous carcinoma of oral cavity. www.clinicaltrials.gov/ct2/show/NCT00193765 (first received 19 September 2005). ">D'Cruz 2015</a>; <a href="./references#CD006205-bbs2-0004" title="FakihAR , RaoRS , BorgesAM , PatelAR . Elective versus therapeutic neck dissection in early carcinoma of the oral tongue. American Journal of Surgery1989;158(4):309-13. FakihAR , RaoRS , PatelAR . Prophylactic neck dissection in squamous cell carcinoma of oral tongue: a prospective randomized study. Seminars in Surgical Oncology1989;5(5):327-30. ">Fakih 1989</a>; <a href="./references#CD006205-bbs2-0005" title="GarrelR , PerriardF , FavierV , RichardF , Pierre DauresJ , De BoutrayM . Equivalence randomized trial comparing treatment based on sentinel node biopsy versus neck dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States2020;38(Suppl 15):6501. GarrelR , PoissonnetG , Moyà PlanaA , FakhryN , DolivetG , LallemantB , et al. Equivalence randomized trial to compare treatment on the basis of sentinel node biopsy versus neck node dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology2020;38(34):4010-18. [DOI: 10.1200/JCO.20.01661]NCT02855723. Randomized, open-label economic and medical study on the lymph node management of squamous cell carcinoma of the oral cavity and oropharynx tumor Stage 1 or 2, nodes 0 (T1-T2 N0) operable (SentiMERORL). clinicaltrials.gov/ct2/show/NCT02855723 (first received 4 August 2016). ">Garrel 2020</a>; <a href="./references#CD006205-bbs2-0007" title="HutchisonIL , RidoutF , CheungSM , ShahN , HardeeP , SurwaldC , et al. Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort. British Journal of Cancer2019;121(10):827-36. [DOI: 0.1038/s41416-019-0587-2] [PMID: 31611612]ISRCTN65018995. The role of selective neck dissection in patients with early oral squamous cell carcinoma (1-3cm primary size) and no clinical evidence of lymph node metastases in the neck (N0). www.isrctn.com/ISRCTN65018995 (first received 23 April 2010). NCT00571883. Neck surgery in treating patients with early-stage oral cancer. clinicaltrials.gov/ct2/show/NCT00571883 (first received 12 December 2007). ">Hutchison 2019</a>; <a href="./references#CD006205-bbs2-0009" title="Dr Kilgerman. Personal communcation2006. KligermanJ , LimaRA , SoaresJR , PradoL , DiasFL , FreitasEQ , et al. Supraomohyoid neck dissection in the treatment of T1/T2 squamous cell carcinoma of oral cavity. American Journal of Surgery1994;168(5):391-4. ">Kligerman 1994</a>; <a href="./references#CD006205-bbs2-0011" title="FabianA , KrugD . Radiotherapy versus transoral robotic surgery for primary treatment of oropharyngeal squamous cell carcinoma: randomisation decides. Strahlentherapie und Onkologie2019;196(2):202-4. NCT01590355. A phase II randomized trial for early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs trans-oral robotic surgery (ORATOR). clinicaltrials.gov/ct2/show/NCT01590355 (first received 2 May 2012). NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. Lancet Oncology2019;20(10):1349-59. [DOI: 10.1016/S1470-2045(19)30410-3] [PMID: 31416685]NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Randomized trial of radiotherapy versus transoral robotic surgery for oropharyngeal squamous cell carcinoma: long-term results of the ORATOR trial. Journal of Clinical Oncology2022;40(8):866-75. [DOI: 10.1200/JCO.21.01961]NicholsAC , YooJ , HammondJA , FungK , WinquistE , ReadN , et al. Early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs. trans-oral robotic surgery (ORATOR) – study protocol for a randomized phase II trial. BMC Cancer2013;13:133. [DOI: 10.1186/1471-2407-13-133]PalmaDA , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus trans-oral robotic surgery for oropharyngeal squamous cell carcinoma: results of a randomized trial. Radiotherapy and Oncology2019;139(Supp 1):S39-40. ">Nichols 2019</a>; <a href="./references#CD006205-bbs2-0015" title="YuenAP , HoCM , ChowTL , TangLC , CheungWY , NgRW , et al. Prospective randomized study of selective neck dissection versus observation for N0 neck of early tongue carcinoma. Head &amp; Neck2009;31(6):765-72. ">Yuen 2009</a>), two included people with T2 to T4 tumours (<a href="./references#CD006205-bbs2-0001" title="Brazilian Head and Neck Cancer Study Group. Results of a prospective trial on elective modified radical classical versus supraomohyoid neck dissection in the management of oral squamous carcinoma. American Journal of Surgery1998;176(5):422-7. ">BHNCSG 1998</a>; <a href="./references#CD006205-bbs2-0014" title="Dr Robertson. Personal communication2006. RobertsonAG , SoutarDS , PaulJ , WebsterM , LeonardAG , MooreKP , et al. Early closure of a randomized trial: surgery and postoperative radiotherapy versus radiotherapy in the management of intra-oral tumours. Clinical Oncology (Royal College of Radiologists (Great Britain))1998;10(3):155-60. ">Robertson 1998</a>), one included people with T1 to T3 tumours (<a href="./references#CD006205-bbs2-0013" title="RastogiS , SharmaA , ChoudhuryR , TripathiS , Al WayliH , AmrithrajA , et al. Is superselective neck dissection safer than supraomohyoid neck dissection for oral carcinoma patients with N0 neck in terms of shoulder morbidity and recurrence rate?Journal of Oral and Maxillofacial Surgery2018;76(3):647-55. [DOI: 10.1016/j.joms.2017.08.002]">Rastogi 2018</a>), and four included people with T1 to T4 tumours (<a href="./references#CD006205-bbs2-0006" title="GuoCB , FengZ , ZhangJG , PengX , CaiZG , MaoC , et al. Supraomohyoid neck dissection and modified radical neck dissection for clinically node-negative oral squamous cell carcinoma: a prospective study of prognosis, complications and quality of life. Journal of Craniofacial Surgery2014;42(8):1885-90. [DOI: 10.1016/j.jcms.2014.07.007]">Guo 2014</a>; <a href="./references#CD006205-bbs2-0008" title="IyerNG , TanDS , TanVK , WangW , HwangJ , Tan N-C, et al. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. Cancer2015;121(10):1599-607. SooKC , TanEH , WeeJ , LimD , TaiBC , Khoo ML et al. Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison. British Journal of Cancer2005;8(93):279-86. [DOI: 10.1038/sj.bjc.6602696] [PMCID: PMC2361563] [PMID: 16012523]">Iyer 2015</a>; <a href="./references#CD006205-bbs2-0010" title='ISRCTN13735240. A multicentre randomised phase III trial comparing positron emission tomography–computed tomography guided watch and wait policy versus planned NECK dissection for the management of locally advanced (N2/N3) nodal metastases in patients with head and neck squamous cancer. www.isrctn.com/ISRCTN13735240 (first received 21 May 2007). MehannaH , McConkeyCC , RahmanJK , Wong W-L, SmithAF , NuttingC , et al. PET-NECK a multicentre randomised phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer. Health Technology Assessment2017;21:17. [DOI: 10.3310/hta21170]MehannaH , Wong W-L, McConkeyCC , RahmanJK , RobinsonM , HartleyAG , et al. PET-CT surveillance versus neck dissection in advanced head and neck cancer. New England Journal of Medicine2016;374(15):1444-54. [DOI: 10.1056/NEJMoa1514493]MehannaH . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 31 January 2023. '>Mehanna 2017</a>; <a href="./references#CD006205-bbs2-0012" title='NCT00847717. Trial of IIb preserving neck dissection. clinicaltrials.gov/ct2/show/NCT00847717 (first received 19 February 2009). PandeyM , KarthikeyanS , JoshiD , KumarM , ShuklaM . Results of a randomized controlled trial of level IIb preserving neck dissection in clinically node-negative squamous carcinoma of the oral cavity. World Journal of Surgical Oncology2018;16(1):219. [DOI: 10.1186/s12957-018-1518-z] [PMID: 30409212]PandeyM . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 2 February 2023. '>Pandey 2018</a>). One trial did not record tumour stage at trial entry (<a href="./references#CD006205-bbs2-0002" title='BierJ , HowaldtHP , PitzH , 4th German-Austrian-Swiss Study Group therapy study. Prospective, randomized, clinical study of squamous cell cancer of the mouth: "Radical neck dissection versus conservative neck dissection". Fortschritte der Kiefer- und Gesichts-Chirurgie1992;37:108-10. BierJ , SchlumsD , MetelmannH , HowaldtHP , PitzH . A comparison of radical and conservative neck dissection. International Journal of Oral &amp; Maxillofacial Surgery1993;22(2):102-7. BierJ . Radical neck dissection versus conservative neck dissection for squamous cell carcinoma of the oral cavity. Recent Results in Cancer Research1994;134:57-62. '>Bier 1994</a>). </p> <p>Nine trials included people with clinically negative neck nodes (<a href="./references#CD006205-bbs2-0001" title="Brazilian Head and Neck Cancer Study Group. Results of a prospective trial on elective modified radical classical versus supraomohyoid neck dissection in the management of oral squamous carcinoma. American Journal of Surgery1998;176(5):422-7. ">BHNCSG 1998</a>; <a href="./references#CD006205-bbs2-0003" title="D'CruzA . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment&quot; [personal communication]. Email to: H Worthington 6 February 2023. D'CruzAK , VaishR , KapreN , DandekarM , GuptaS , HawaldarR , et al. Elective versus therapeutic neck dissection in node-negative oral cancer. New England Journal of Medicine2015;373(6):521-9. [DOI: 10.1056/NEJMoa1506007]NCT00193765. Elective vs therapeutic neck dissection in treatment of early node negative squamous carcinoma of oral cavity. www.clinicaltrials.gov/ct2/show/NCT00193765 (first received 19 September 2005). ">D'Cruz 2015</a>; <a href="./references#CD006205-bbs2-0004" title="FakihAR , RaoRS , BorgesAM , PatelAR . Elective versus therapeutic neck dissection in early carcinoma of the oral tongue. American Journal of Surgery1989;158(4):309-13. FakihAR , RaoRS , PatelAR . Prophylactic neck dissection in squamous cell carcinoma of oral tongue: a prospective randomized study. Seminars in Surgical Oncology1989;5(5):327-30. ">Fakih 1989</a>; <a href="./references#CD006205-bbs2-0005" title="GarrelR , PerriardF , FavierV , RichardF , Pierre DauresJ , De BoutrayM . Equivalence randomized trial comparing treatment based on sentinel node biopsy versus neck dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States2020;38(Suppl 15):6501. GarrelR , PoissonnetG , Moyà PlanaA , FakhryN , DolivetG , LallemantB , et al. Equivalence randomized trial to compare treatment on the basis of sentinel node biopsy versus neck node dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology2020;38(34):4010-18. [DOI: 10.1200/JCO.20.01661]NCT02855723. Randomized, open-label economic and medical study on the lymph node management of squamous cell carcinoma of the oral cavity and oropharynx tumor Stage 1 or 2, nodes 0 (T1-T2 N0) operable (SentiMERORL). clinicaltrials.gov/ct2/show/NCT02855723 (first received 4 August 2016). ">Garrel 2020</a>; <a href="./references#CD006205-bbs2-0007" title="HutchisonIL , RidoutF , CheungSM , ShahN , HardeeP , SurwaldC , et al. Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort. British Journal of Cancer2019;121(10):827-36. [DOI: 0.1038/s41416-019-0587-2] [PMID: 31611612]ISRCTN65018995. The role of selective neck dissection in patients with early oral squamous cell carcinoma (1-3cm primary size) and no clinical evidence of lymph node metastases in the neck (N0). www.isrctn.com/ISRCTN65018995 (first received 23 April 2010). NCT00571883. Neck surgery in treating patients with early-stage oral cancer. clinicaltrials.gov/ct2/show/NCT00571883 (first received 12 December 2007). ">Hutchison 2019</a>; <a href="./references#CD006205-bbs2-0009" title="Dr Kilgerman. Personal communcation2006. KligermanJ , LimaRA , SoaresJR , PradoL , DiasFL , FreitasEQ , et al. Supraomohyoid neck dissection in the treatment of T1/T2 squamous cell carcinoma of oral cavity. American Journal of Surgery1994;168(5):391-4. ">Kligerman 1994</a>; <a href="./references#CD006205-bbs2-0012" title='NCT00847717. Trial of IIb preserving neck dissection. clinicaltrials.gov/ct2/show/NCT00847717 (first received 19 February 2009). PandeyM , KarthikeyanS , JoshiD , KumarM , ShuklaM . Results of a randomized controlled trial of level IIb preserving neck dissection in clinically node-negative squamous carcinoma of the oral cavity. World Journal of Surgical Oncology2018;16(1):219. [DOI: 10.1186/s12957-018-1518-z] [PMID: 30409212]PandeyM . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 2 February 2023. '>Pandey 2018</a>; <a href="./references#CD006205-bbs2-0013" title="RastogiS , SharmaA , ChoudhuryR , TripathiS , Al WayliH , AmrithrajA , et al. Is superselective neck dissection safer than supraomohyoid neck dissection for oral carcinoma patients with N0 neck in terms of shoulder morbidity and recurrence rate?Journal of Oral and Maxillofacial Surgery2018;76(3):647-55. [DOI: 10.1016/j.joms.2017.08.002]">Rastogi 2018</a>; <a href="./references#CD006205-bbs2-0015" title="YuenAP , HoCM , ChowTL , TangLC , CheungWY , NgRW , et al. Prospective randomized study of selective neck dissection versus observation for N0 neck of early tongue carcinoma. Head &amp; Neck2009;31(6):765-72. ">Yuen 2009</a>), three trials included people with neck nodes clinically staged as N0 to N2 (<a href="./references#CD006205-bbs2-0006" title="GuoCB , FengZ , ZhangJG , PengX , CaiZG , MaoC , et al. Supraomohyoid neck dissection and modified radical neck dissection for clinically node-negative oral squamous cell carcinoma: a prospective study of prognosis, complications and quality of life. Journal of Craniofacial Surgery2014;42(8):1885-90. [DOI: 10.1016/j.jcms.2014.07.007]">Guo 2014</a>; <a href="./references#CD006205-bbs2-0011" title="FabianA , KrugD . Radiotherapy versus transoral robotic surgery for primary treatment of oropharyngeal squamous cell carcinoma: randomisation decides. Strahlentherapie und Onkologie2019;196(2):202-4. NCT01590355. A phase II randomized trial for early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs trans-oral robotic surgery (ORATOR). clinicaltrials.gov/ct2/show/NCT01590355 (first received 2 May 2012). NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. Lancet Oncology2019;20(10):1349-59. [DOI: 10.1016/S1470-2045(19)30410-3] [PMID: 31416685]NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Randomized trial of radiotherapy versus transoral robotic surgery for oropharyngeal squamous cell carcinoma: long-term results of the ORATOR trial. Journal of Clinical Oncology2022;40(8):866-75. [DOI: 10.1200/JCO.21.01961]NicholsAC , YooJ , HammondJA , FungK , WinquistE , ReadN , et al. Early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs. trans-oral robotic surgery (ORATOR) – study protocol for a randomized phase II trial. BMC Cancer2013;13:133. [DOI: 10.1186/1471-2407-13-133]PalmaDA , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus trans-oral robotic surgery for oropharyngeal squamous cell carcinoma: results of a randomized trial. Radiotherapy and Oncology2019;139(Supp 1):S39-40. ">Nichols 2019</a>; <a href="./references#CD006205-bbs2-0014" title="Dr Robertson. Personal communication2006. RobertsonAG , SoutarDS , PaulJ , WebsterM , LeonardAG , MooreKP , et al. Early closure of a randomized trial: surgery and postoperative radiotherapy versus radiotherapy in the management of intra-oral tumours. Clinical Oncology (Royal College of Radiologists (Great Britain))1998;10(3):155-60. ">Robertson 1998</a>), one trial included people with neck nodes clinically staged as N0 to N3 (<a href="./references#CD006205-bbs2-0008" title="IyerNG , TanDS , TanVK , WangW , HwangJ , Tan N-C, et al. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. Cancer2015;121(10):1599-607. SooKC , TanEH , WeeJ , LimD , TaiBC , Khoo ML et al. Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison. British Journal of Cancer2005;8(93):279-86. [DOI: 10.1038/sj.bjc.6602696] [PMCID: PMC2361563] [PMID: 16012523]">Iyer 2015</a>), one trial included people with clinically staged N2 to N3 nodes (<a href="./references#CD006205-bbs2-0010" title='ISRCTN13735240. A multicentre randomised phase III trial comparing positron emission tomography–computed tomography guided watch and wait policy versus planned NECK dissection for the management of locally advanced (N2/N3) nodal metastases in patients with head and neck squamous cancer. www.isrctn.com/ISRCTN13735240 (first received 21 May 2007). MehannaH , McConkeyCC , RahmanJK , Wong W-L, SmithAF , NuttingC , et al. PET-NECK a multicentre randomised phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer. Health Technology Assessment2017;21:17. [DOI: 10.3310/hta21170]MehannaH , Wong W-L, McConkeyCC , RahmanJK , RobinsonM , HartleyAG , et al. PET-CT surveillance versus neck dissection in advanced head and neck cancer. New England Journal of Medicine2016;374(15):1444-54. [DOI: 10.1056/NEJMoa1514493]MehannaH . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 31 January 2023. '>Mehanna 2017</a>), and one trial included clinically negative or positive neck nodes without specifying the stage (<a href="./references#CD006205-bbs2-0002" title='BierJ , HowaldtHP , PitzH , 4th German-Austrian-Swiss Study Group therapy study. Prospective, randomized, clinical study of squamous cell cancer of the mouth: "Radical neck dissection versus conservative neck dissection". Fortschritte der Kiefer- und Gesichts-Chirurgie1992;37:108-10. BierJ , SchlumsD , MetelmannH , HowaldtHP , PitzH . A comparison of radical and conservative neck dissection. International Journal of Oral &amp; Maxillofacial Surgery1993;22(2):102-7. BierJ . Radical neck dissection versus conservative neck dissection for squamous cell carcinoma of the oral cavity. Recent Results in Cancer Research1994;134:57-62. '>Bier 1994</a>). </p> <p>Of the 15 included trials, nine recruited people with oral cavity cancer only (<a href="./references#CD006205-bbs2-0001" title="Brazilian Head and Neck Cancer Study Group. Results of a prospective trial on elective modified radical classical versus supraomohyoid neck dissection in the management of oral squamous carcinoma. American Journal of Surgery1998;176(5):422-7. ">BHNCSG 1998</a>; <a href="./references#CD006205-bbs2-0002" title='BierJ , HowaldtHP , PitzH , 4th German-Austrian-Swiss Study Group therapy study. Prospective, randomized, clinical study of squamous cell cancer of the mouth: "Radical neck dissection versus conservative neck dissection". Fortschritte der Kiefer- und Gesichts-Chirurgie1992;37:108-10. BierJ , SchlumsD , MetelmannH , HowaldtHP , PitzH . A comparison of radical and conservative neck dissection. International Journal of Oral &amp; Maxillofacial Surgery1993;22(2):102-7. BierJ . Radical neck dissection versus conservative neck dissection for squamous cell carcinoma of the oral cavity. Recent Results in Cancer Research1994;134:57-62. '>Bier 1994</a>; <a href="./references#CD006205-bbs2-0003" title="D'CruzA . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment&quot; [personal communication]. Email to: H Worthington 6 February 2023. D'CruzAK , VaishR , KapreN , DandekarM , GuptaS , HawaldarR , et al. Elective versus therapeutic neck dissection in node-negative oral cancer. New England Journal of Medicine2015;373(6):521-9. [DOI: 10.1056/NEJMoa1506007]NCT00193765. Elective vs therapeutic neck dissection in treatment of early node negative squamous carcinoma of oral cavity. www.clinicaltrials.gov/ct2/show/NCT00193765 (first received 19 September 2005). ">D'Cruz 2015</a>; <a href="./references#CD006205-bbs2-0004" title="FakihAR , RaoRS , BorgesAM , PatelAR . Elective versus therapeutic neck dissection in early carcinoma of the oral tongue. American Journal of Surgery1989;158(4):309-13. FakihAR , RaoRS , PatelAR . Prophylactic neck dissection in squamous cell carcinoma of oral tongue: a prospective randomized study. Seminars in Surgical Oncology1989;5(5):327-30. ">Fakih 1989</a>; <a href="./references#CD006205-bbs2-0007" title="HutchisonIL , RidoutF , CheungSM , ShahN , HardeeP , SurwaldC , et al. Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort. British Journal of Cancer2019;121(10):827-36. [DOI: 0.1038/s41416-019-0587-2] [PMID: 31611612]ISRCTN65018995. The role of selective neck dissection in patients with early oral squamous cell carcinoma (1-3cm primary size) and no clinical evidence of lymph node metastases in the neck (N0). www.isrctn.com/ISRCTN65018995 (first received 23 April 2010). NCT00571883. Neck surgery in treating patients with early-stage oral cancer. clinicaltrials.gov/ct2/show/NCT00571883 (first received 12 December 2007). ">Hutchison 2019</a>; <a href="./references#CD006205-bbs2-0009" title="Dr Kilgerman. Personal communcation2006. KligermanJ , LimaRA , SoaresJR , PradoL , DiasFL , FreitasEQ , et al. Supraomohyoid neck dissection in the treatment of T1/T2 squamous cell carcinoma of oral cavity. American Journal of Surgery1994;168(5):391-4. ">Kligerman 1994</a>; <a href="./references#CD006205-bbs2-0012" title='NCT00847717. Trial of IIb preserving neck dissection. clinicaltrials.gov/ct2/show/NCT00847717 (first received 19 February 2009). PandeyM , KarthikeyanS , JoshiD , KumarM , ShuklaM . Results of a randomized controlled trial of level IIb preserving neck dissection in clinically node-negative squamous carcinoma of the oral cavity. World Journal of Surgical Oncology2018;16(1):219. [DOI: 10.1186/s12957-018-1518-z] [PMID: 30409212]PandeyM . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 2 February 2023. '>Pandey 2018</a>; <a href="./references#CD006205-bbs2-0013" title="RastogiS , SharmaA , ChoudhuryR , TripathiS , Al WayliH , AmrithrajA , et al. Is superselective neck dissection safer than supraomohyoid neck dissection for oral carcinoma patients with N0 neck in terms of shoulder morbidity and recurrence rate?Journal of Oral and Maxillofacial Surgery2018;76(3):647-55. [DOI: 10.1016/j.joms.2017.08.002]">Rastogi 2018</a>; <a href="./references#CD006205-bbs2-0015" title="YuenAP , HoCM , ChowTL , TangLC , CheungWY , NgRW , et al. Prospective randomized study of selective neck dissection versus observation for N0 neck of early tongue carcinoma. Head &amp; Neck2009;31(6):765-72. ">Yuen 2009</a>); three included people with oral cavity or oropharyngeal cancer (<a href="./references#CD006205-bbs2-0005" title="GarrelR , PerriardF , FavierV , RichardF , Pierre DauresJ , De BoutrayM . Equivalence randomized trial comparing treatment based on sentinel node biopsy versus neck dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States2020;38(Suppl 15):6501. GarrelR , PoissonnetG , Moyà PlanaA , FakhryN , DolivetG , LallemantB , et al. Equivalence randomized trial to compare treatment on the basis of sentinel node biopsy versus neck node dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology2020;38(34):4010-18. [DOI: 10.1200/JCO.20.01661]NCT02855723. Randomized, open-label economic and medical study on the lymph node management of squamous cell carcinoma of the oral cavity and oropharynx tumor Stage 1 or 2, nodes 0 (T1-T2 N0) operable (SentiMERORL). clinicaltrials.gov/ct2/show/NCT02855723 (first received 4 August 2016). ">Garrel 2020</a>; <a href="./references#CD006205-bbs2-0006" title="GuoCB , FengZ , ZhangJG , PengX , CaiZG , MaoC , et al. Supraomohyoid neck dissection and modified radical neck dissection for clinically node-negative oral squamous cell carcinoma: a prospective study of prognosis, complications and quality of life. Journal of Craniofacial Surgery2014;42(8):1885-90. [DOI: 10.1016/j.jcms.2014.07.007]">Guo 2014</a>; <a href="./references#CD006205-bbs2-0014" title="Dr Robertson. Personal communication2006. RobertsonAG , SoutarDS , PaulJ , WebsterM , LeonardAG , MooreKP , et al. Early closure of a randomized trial: surgery and postoperative radiotherapy versus radiotherapy in the management of intra-oral tumours. Clinical Oncology (Royal College of Radiologists (Great Britain))1998;10(3):155-60. ">Robertson 1998</a>); one included people with cancer of the oral cavity, oropharynx, hypopharynx, larynx, and maxillary sinus (<a href="./references#CD006205-bbs2-0008" title="IyerNG , TanDS , TanVK , WangW , HwangJ , Tan N-C, et al. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. Cancer2015;121(10):1599-607. SooKC , TanEH , WeeJ , LimD , TaiBC , Khoo ML et al. Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison. British Journal of Cancer2005;8(93):279-86. [DOI: 10.1038/sj.bjc.6602696] [PMCID: PMC2361563] [PMID: 16012523]">Iyer 2015</a>); one included people with cancer of the oral cavity, tonsil, base of tongue, supraglottis, and glottis or subglottis (<a href="./references#CD006205-bbs2-0010" title='ISRCTN13735240. A multicentre randomised phase III trial comparing positron emission tomography–computed tomography guided watch and wait policy versus planned NECK dissection for the management of locally advanced (N2/N3) nodal metastases in patients with head and neck squamous cancer. www.isrctn.com/ISRCTN13735240 (first received 21 May 2007). MehannaH , McConkeyCC , RahmanJK , Wong W-L, SmithAF , NuttingC , et al. PET-NECK a multicentre randomised phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer. Health Technology Assessment2017;21:17. [DOI: 10.3310/hta21170]MehannaH , Wong W-L, McConkeyCC , RahmanJK , RobinsonM , HartleyAG , et al. PET-CT surveillance versus neck dissection in advanced head and neck cancer. New England Journal of Medicine2016;374(15):1444-54. [DOI: 10.1056/NEJMoa1514493]MehannaH . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 31 January 2023. '>Mehanna 2017</a>); and one included people with oropharyngeal cancer (<a href="./references#CD006205-bbs2-0011" title="FabianA , KrugD . Radiotherapy versus transoral robotic surgery for primary treatment of oropharyngeal squamous cell carcinoma: randomisation decides. Strahlentherapie und Onkologie2019;196(2):202-4. NCT01590355. A phase II randomized trial for early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs trans-oral robotic surgery (ORATOR). clinicaltrials.gov/ct2/show/NCT01590355 (first received 2 May 2012). NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. Lancet Oncology2019;20(10):1349-59. [DOI: 10.1016/S1470-2045(19)30410-3] [PMID: 31416685]NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Randomized trial of radiotherapy versus transoral robotic surgery for oropharyngeal squamous cell carcinoma: long-term results of the ORATOR trial. Journal of Clinical Oncology2022;40(8):866-75. [DOI: 10.1200/JCO.21.01961]NicholsAC , YooJ , HammondJA , FungK , WinquistE , ReadN , et al. Early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs. trans-oral robotic surgery (ORATOR) – study protocol for a randomized phase II trial. BMC Cancer2013;13:133. [DOI: 10.1186/1471-2407-13-133]PalmaDA , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus trans-oral robotic surgery for oropharyngeal squamous cell carcinoma: results of a randomized trial. Radiotherapy and Oncology2019;139(Supp 1):S39-40. ">Nichols 2019</a>). <a href="#CD006205-tbl-0010">Table 1</a> shows the cancer type, stage, and nodal status of participants in the 15 included trials. </p> <div class="table" id="CD006205-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Stage of cancer</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Cancer types</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>TNM stage</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Nodal status</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006205-bbs2-0001" title="Brazilian Head and Neck Cancer Study Group. Results of a prospective trial on elective modified radical classical versus supraomohyoid neck dissection in the management of oral squamous carcinoma. American Journal of Surgery1998;176(5):422-7. ">BHNCSG 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral cavity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T2–T4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative neck</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006205-bbs2-0002" title='BierJ , HowaldtHP , PitzH , 4th German-Austrian-Swiss Study Group therapy study. Prospective, randomized, clinical study of squamous cell cancer of the mouth: "Radical neck dissection versus conservative neck dissection". Fortschritte der Kiefer- und Gesichts-Chirurgie1992;37:108-10. BierJ , SchlumsD , MetelmannH , HowaldtHP , PitzH . A comparison of radical and conservative neck dissection. International Journal of Oral &amp; Maxillofacial Surgery1993;22(2):102-7. BierJ . Radical neck dissection versus conservative neck dissection for squamous cell carcinoma of the oral cavity. Recent Results in Cancer Research1994;134:57-62. '>Bier 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral cavity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative or positive neck, range unspecified</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006205-bbs2-0003" title="D'CruzA . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment&quot; [personal communication]. Email to: H Worthington 6 February 2023. D'CruzAK , VaishR , KapreN , DandekarM , GuptaS , HawaldarR , et al. Elective versus therapeutic neck dissection in node-negative oral cancer. New England Journal of Medicine2015;373(6):521-9. [DOI: 10.1056/NEJMoa1506007]NCT00193765. Elective vs therapeutic neck dissection in treatment of early node negative squamous carcinoma of oral cavity. www.clinicaltrials.gov/ct2/show/NCT00193765 (first received 19 September 2005). ">D'Cruz 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral cavity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T1–T2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative neck</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006205-bbs2-0004" title="FakihAR , RaoRS , BorgesAM , PatelAR . Elective versus therapeutic neck dissection in early carcinoma of the oral tongue. American Journal of Surgery1989;158(4):309-13. FakihAR , RaoRS , PatelAR . Prophylactic neck dissection in squamous cell carcinoma of oral tongue: a prospective randomized study. Seminars in Surgical Oncology1989;5(5):327-30. ">Fakih 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral cavity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T1–T2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative neck</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006205-bbs2-0005" title="GarrelR , PerriardF , FavierV , RichardF , Pierre DauresJ , De BoutrayM . Equivalence randomized trial comparing treatment based on sentinel node biopsy versus neck dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States2020;38(Suppl 15):6501. GarrelR , PoissonnetG , Moyà PlanaA , FakhryN , DolivetG , LallemantB , et al. Equivalence randomized trial to compare treatment on the basis of sentinel node biopsy versus neck node dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology2020;38(34):4010-18. [DOI: 10.1200/JCO.20.01661]NCT02855723. Randomized, open-label economic and medical study on the lymph node management of squamous cell carcinoma of the oral cavity and oropharynx tumor Stage 1 or 2, nodes 0 (T1-T2 N0) operable (SentiMERORL). clinicaltrials.gov/ct2/show/NCT02855723 (first received 4 August 2016). ">Garrel 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral cavity/oropharyngeal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T1–T2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative neck</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006205-bbs2-0006" title="GuoCB , FengZ , ZhangJG , PengX , CaiZG , MaoC , et al. Supraomohyoid neck dissection and modified radical neck dissection for clinically node-negative oral squamous cell carcinoma: a prospective study of prognosis, complications and quality of life. Journal of Craniofacial Surgery2014;42(8):1885-90. [DOI: 10.1016/j.jcms.2014.07.007]">Guo 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral cavity/oropharyngeal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T1–T4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N0‐2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006205-bbs2-0007" title="HutchisonIL , RidoutF , CheungSM , ShahN , HardeeP , SurwaldC , et al. Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort. British Journal of Cancer2019;121(10):827-36. [DOI: 0.1038/s41416-019-0587-2] [PMID: 31611612]ISRCTN65018995. The role of selective neck dissection in patients with early oral squamous cell carcinoma (1-3cm primary size) and no clinical evidence of lymph node metastases in the neck (N0). www.isrctn.com/ISRCTN65018995 (first received 23 April 2010). NCT00571883. Neck surgery in treating patients with early-stage oral cancer. clinicaltrials.gov/ct2/show/NCT00571883 (first received 12 December 2007). ">Hutchison 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral cavity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T1–T2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative neck</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006205-bbs2-0008" title="IyerNG , TanDS , TanVK , WangW , HwangJ , Tan N-C, et al. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. Cancer2015;121(10):1599-607. SooKC , TanEH , WeeJ , LimD , TaiBC , Khoo ML et al. Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison. British Journal of Cancer2005;8(93):279-86. [DOI: 10.1038/sj.bjc.6602696] [PMCID: PMC2361563] [PMID: 16012523]">Iyer 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral cavity (other cancer types included in the study but only data for oral cavity cancer included in the review) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T1–T4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N0‐3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006205-bbs2-0009" title="Dr Kilgerman. Personal communcation2006. KligermanJ , LimaRA , SoaresJR , PradoL , DiasFL , FreitasEQ , et al. Supraomohyoid neck dissection in the treatment of T1/T2 squamous cell carcinoma of oral cavity. American Journal of Surgery1994;168(5):391-4. ">Kligerman 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral cavity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T1–T2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative neck</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006205-bbs2-0010" title='ISRCTN13735240. A multicentre randomised phase III trial comparing positron emission tomography–computed tomography guided watch and wait policy versus planned NECK dissection for the management of locally advanced (N2/N3) nodal metastases in patients with head and neck squamous cancer. www.isrctn.com/ISRCTN13735240 (first received 21 May 2007). MehannaH , McConkeyCC , RahmanJK , Wong W-L, SmithAF , NuttingC , et al. PET-NECK a multicentre randomised phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer. Health Technology Assessment2017;21:17. [DOI: 10.3310/hta21170]MehannaH , Wong W-L, McConkeyCC , RahmanJK , RobinsonM , HartleyAG , et al. PET-CT surveillance versus neck dissection in advanced head and neck cancer. New England Journal of Medicine2016;374(15):1444-54. [DOI: 10.1056/NEJMoa1514493]MehannaH . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 31 January 2023. '>Mehanna 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral cavity, tonsil, base of tongue, supraglottis and glottis or subglottis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T1–T4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N2‐3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006205-bbs2-0011" title="FabianA , KrugD . Radiotherapy versus transoral robotic surgery for primary treatment of oropharyngeal squamous cell carcinoma: randomisation decides. Strahlentherapie und Onkologie2019;196(2):202-4. NCT01590355. A phase II randomized trial for early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs trans-oral robotic surgery (ORATOR). clinicaltrials.gov/ct2/show/NCT01590355 (first received 2 May 2012). NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. Lancet Oncology2019;20(10):1349-59. [DOI: 10.1016/S1470-2045(19)30410-3] [PMID: 31416685]NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Randomized trial of radiotherapy versus transoral robotic surgery for oropharyngeal squamous cell carcinoma: long-term results of the ORATOR trial. Journal of Clinical Oncology2022;40(8):866-75. [DOI: 10.1200/JCO.21.01961]NicholsAC , YooJ , HammondJA , FungK , WinquistE , ReadN , et al. Early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs. trans-oral robotic surgery (ORATOR) – study protocol for a randomized phase II trial. BMC Cancer2013;13:133. [DOI: 10.1186/1471-2407-13-133]PalmaDA , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus trans-oral robotic surgery for oropharyngeal squamous cell carcinoma: results of a randomized trial. Radiotherapy and Oncology2019;139(Supp 1):S39-40. ">Nichols 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oropharyngeal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T1–T2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N0‐2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006205-bbs2-0012" title='NCT00847717. Trial of IIb preserving neck dissection. clinicaltrials.gov/ct2/show/NCT00847717 (first received 19 February 2009). PandeyM , KarthikeyanS , JoshiD , KumarM , ShuklaM . Results of a randomized controlled trial of level IIb preserving neck dissection in clinically node-negative squamous carcinoma of the oral cavity. World Journal of Surgical Oncology2018;16(1):219. [DOI: 10.1186/s12957-018-1518-z] [PMID: 30409212]PandeyM . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 2 February 2023. '>Pandey 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral cavity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T1–T4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative neck</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006205-bbs2-0013" title="RastogiS , SharmaA , ChoudhuryR , TripathiS , Al WayliH , AmrithrajA , et al. Is superselective neck dissection safer than supraomohyoid neck dissection for oral carcinoma patients with N0 neck in terms of shoulder morbidity and recurrence rate?Journal of Oral and Maxillofacial Surgery2018;76(3):647-55. [DOI: 10.1016/j.joms.2017.08.002]">Rastogi 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral cavity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T1–T3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative neck</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006205-bbs2-0014" title="Dr Robertson. Personal communication2006. RobertsonAG , SoutarDS , PaulJ , WebsterM , LeonardAG , MooreKP , et al. Early closure of a randomized trial: surgery and postoperative radiotherapy versus radiotherapy in the management of intra-oral tumours. Clinical Oncology (Royal College of Radiologists (Great Britain))1998;10(3):155-60. ">Robertson 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral cavity/oropharyngeal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T2–T4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N0‐2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006205-bbs2-0015" title="YuenAP , HoCM , ChowTL , TangLC , CheungWY , NgRW , et al. Prospective randomized study of selective neck dissection versus observation for N0 neck of early tongue carcinoma. Head &amp; Neck2009;31(6):765-72. ">Yuen 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral cavity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T1–T2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative neck</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>In the TNM cancer staging system, T defines tumour size and any spread of cancer into nearby tissue, N defines spread of cancer to nearby lymph nodes; and M defines metastasis. </p> </div> </div> </section> <section id="CD006205-sec-0044"> <h5 class="title">Interventions</h5> <p>No included trials compared different surgical approaches to the excision of the primary tumour. </p> <p>Eleven trials of participants with oral cavity cancers compared either different surgical techniques for management of the lymph nodes in the neck or different timing of removal of the lymph nodes in the neck (<a href="./references#CD006205-bbs2-0001" title="Brazilian Head and Neck Cancer Study Group. Results of a prospective trial on elective modified radical classical versus supraomohyoid neck dissection in the management of oral squamous carcinoma. American Journal of Surgery1998;176(5):422-7. ">BHNCSG 1998</a>; <a href="./references#CD006205-bbs2-0002" title='BierJ , HowaldtHP , PitzH , 4th German-Austrian-Swiss Study Group therapy study. Prospective, randomized, clinical study of squamous cell cancer of the mouth: "Radical neck dissection versus conservative neck dissection". Fortschritte der Kiefer- und Gesichts-Chirurgie1992;37:108-10. BierJ , SchlumsD , MetelmannH , HowaldtHP , PitzH . A comparison of radical and conservative neck dissection. International Journal of Oral &amp; Maxillofacial Surgery1993;22(2):102-7. BierJ . Radical neck dissection versus conservative neck dissection for squamous cell carcinoma of the oral cavity. Recent Results in Cancer Research1994;134:57-62. '>Bier 1994</a>; <a href="./references#CD006205-bbs2-0003" title="D'CruzA . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment&quot; [personal communication]. Email to: H Worthington 6 February 2023. D'CruzAK , VaishR , KapreN , DandekarM , GuptaS , HawaldarR , et al. Elective versus therapeutic neck dissection in node-negative oral cancer. New England Journal of Medicine2015;373(6):521-9. [DOI: 10.1056/NEJMoa1506007]NCT00193765. Elective vs therapeutic neck dissection in treatment of early node negative squamous carcinoma of oral cavity. www.clinicaltrials.gov/ct2/show/NCT00193765 (first received 19 September 2005). ">D'Cruz 2015</a>; <a href="./references#CD006205-bbs2-0004" title="FakihAR , RaoRS , BorgesAM , PatelAR . Elective versus therapeutic neck dissection in early carcinoma of the oral tongue. American Journal of Surgery1989;158(4):309-13. FakihAR , RaoRS , PatelAR . Prophylactic neck dissection in squamous cell carcinoma of oral tongue: a prospective randomized study. Seminars in Surgical Oncology1989;5(5):327-30. ">Fakih 1989</a>; <a href="./references#CD006205-bbs2-0005" title="GarrelR , PerriardF , FavierV , RichardF , Pierre DauresJ , De BoutrayM . Equivalence randomized trial comparing treatment based on sentinel node biopsy versus neck dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States2020;38(Suppl 15):6501. GarrelR , PoissonnetG , Moyà PlanaA , FakhryN , DolivetG , LallemantB , et al. Equivalence randomized trial to compare treatment on the basis of sentinel node biopsy versus neck node dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology2020;38(34):4010-18. [DOI: 10.1200/JCO.20.01661]NCT02855723. Randomized, open-label economic and medical study on the lymph node management of squamous cell carcinoma of the oral cavity and oropharynx tumor Stage 1 or 2, nodes 0 (T1-T2 N0) operable (SentiMERORL). clinicaltrials.gov/ct2/show/NCT02855723 (first received 4 August 2016). ">Garrel 2020</a>; <a href="./references#CD006205-bbs2-0006" title="GuoCB , FengZ , ZhangJG , PengX , CaiZG , MaoC , et al. Supraomohyoid neck dissection and modified radical neck dissection for clinically node-negative oral squamous cell carcinoma: a prospective study of prognosis, complications and quality of life. Journal of Craniofacial Surgery2014;42(8):1885-90. [DOI: 10.1016/j.jcms.2014.07.007]">Guo 2014</a>; <a href="./references#CD006205-bbs2-0007" title="HutchisonIL , RidoutF , CheungSM , ShahN , HardeeP , SurwaldC , et al. Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort. British Journal of Cancer2019;121(10):827-36. [DOI: 0.1038/s41416-019-0587-2] [PMID: 31611612]ISRCTN65018995. The role of selective neck dissection in patients with early oral squamous cell carcinoma (1-3cm primary size) and no clinical evidence of lymph node metastases in the neck (N0). www.isrctn.com/ISRCTN65018995 (first received 23 April 2010). NCT00571883. Neck surgery in treating patients with early-stage oral cancer. clinicaltrials.gov/ct2/show/NCT00571883 (first received 12 December 2007). ">Hutchison 2019</a>; <a href="./references#CD006205-bbs2-0009" title="Dr Kilgerman. Personal communcation2006. KligermanJ , LimaRA , SoaresJR , PradoL , DiasFL , FreitasEQ , et al. Supraomohyoid neck dissection in the treatment of T1/T2 squamous cell carcinoma of oral cavity. American Journal of Surgery1994;168(5):391-4. ">Kligerman 1994</a>; <a href="./references#CD006205-bbs2-0012" title='NCT00847717. Trial of IIb preserving neck dissection. clinicaltrials.gov/ct2/show/NCT00847717 (first received 19 February 2009). PandeyM , KarthikeyanS , JoshiD , KumarM , ShuklaM . Results of a randomized controlled trial of level IIb preserving neck dissection in clinically node-negative squamous carcinoma of the oral cavity. World Journal of Surgical Oncology2018;16(1):219. [DOI: 10.1186/s12957-018-1518-z] [PMID: 30409212]PandeyM . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 2 February 2023. '>Pandey 2018</a>; <a href="./references#CD006205-bbs2-0013" title="RastogiS , SharmaA , ChoudhuryR , TripathiS , Al WayliH , AmrithrajA , et al. Is superselective neck dissection safer than supraomohyoid neck dissection for oral carcinoma patients with N0 neck in terms of shoulder morbidity and recurrence rate?Journal of Oral and Maxillofacial Surgery2018;76(3):647-55. [DOI: 10.1016/j.joms.2017.08.002]">Rastogi 2018</a>; <a href="./references#CD006205-bbs2-0015" title="YuenAP , HoCM , ChowTL , TangLC , CheungWY , NgRW , et al. Prospective randomized study of selective neck dissection versus observation for N0 neck of early tongue carcinoma. Head &amp; Neck2009;31(6):765-72. ">Yuen 2009</a>). </p> <p>Five trials compared the timing of neck dissection, evaluating elective neck dissection at the same time as primary tumour excision versus therapeutic neck dissection (<a href="./references#CD006205-bbs2-0003" title="D'CruzA . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment&quot; [personal communication]. Email to: H Worthington 6 February 2023. D'CruzAK , VaishR , KapreN , DandekarM , GuptaS , HawaldarR , et al. Elective versus therapeutic neck dissection in node-negative oral cancer. New England Journal of Medicine2015;373(6):521-9. [DOI: 10.1056/NEJMoa1506007]NCT00193765. Elective vs therapeutic neck dissection in treatment of early node negative squamous carcinoma of oral cavity. www.clinicaltrials.gov/ct2/show/NCT00193765 (first received 19 September 2005). ">D'Cruz 2015</a>; <a href="./references#CD006205-bbs2-0004" title="FakihAR , RaoRS , BorgesAM , PatelAR . Elective versus therapeutic neck dissection in early carcinoma of the oral tongue. American Journal of Surgery1989;158(4):309-13. FakihAR , RaoRS , PatelAR . Prophylactic neck dissection in squamous cell carcinoma of oral tongue: a prospective randomized study. Seminars in Surgical Oncology1989;5(5):327-30. ">Fakih 1989</a>; <a href="./references#CD006205-bbs2-0007" title="HutchisonIL , RidoutF , CheungSM , ShahN , HardeeP , SurwaldC , et al. Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort. British Journal of Cancer2019;121(10):827-36. [DOI: 0.1038/s41416-019-0587-2] [PMID: 31611612]ISRCTN65018995. The role of selective neck dissection in patients with early oral squamous cell carcinoma (1-3cm primary size) and no clinical evidence of lymph node metastases in the neck (N0). www.isrctn.com/ISRCTN65018995 (first received 23 April 2010). NCT00571883. Neck surgery in treating patients with early-stage oral cancer. clinicaltrials.gov/ct2/show/NCT00571883 (first received 12 December 2007). ">Hutchison 2019</a>; <a href="./references#CD006205-bbs2-0009" title="Dr Kilgerman. Personal communcation2006. KligermanJ , LimaRA , SoaresJR , PradoL , DiasFL , FreitasEQ , et al. Supraomohyoid neck dissection in the treatment of T1/T2 squamous cell carcinoma of oral cavity. American Journal of Surgery1994;168(5):391-4. ">Kligerman 1994</a>; <a href="./references#CD006205-bbs2-0015" title="YuenAP , HoCM , ChowTL , TangLC , CheungWY , NgRW , et al. Prospective randomized study of selective neck dissection versus observation for N0 neck of early tongue carcinoma. Head &amp; Neck2009;31(6):765-72. ">Yuen 2009</a>). <a href="./references#CD006205-bbs2-0009" title="Dr Kilgerman. Personal communcation2006. KligermanJ , LimaRA , SoaresJR , PradoL , DiasFL , FreitasEQ , et al. Supraomohyoid neck dissection in the treatment of T1/T2 squamous cell carcinoma of oral cavity. American Journal of Surgery1994;168(5):391-4. ">Kligerman 1994</a> evaluated the supraomohyoid approach to elective neck dissection in a group of participants with clinically negative neck nodes versus therapeutic neck dissection if the nodes became clinically positive. <a href="./references#CD006205-bbs2-0015" title="YuenAP , HoCM , ChowTL , TangLC , CheungWY , NgRW , et al. Prospective randomized study of selective neck dissection versus observation for N0 neck of early tongue carcinoma. Head &amp; Neck2009;31(6):765-72. ">Yuen 2009</a> evaluated elective selective neck dissection at the time of glossectomy versus glossectomy plus therapeutic neck dissection if nodes became clinically positive. <a href="./references#CD006205-bbs2-0004" title="FakihAR , RaoRS , BorgesAM , PatelAR . Elective versus therapeutic neck dissection in early carcinoma of the oral tongue. American Journal of Surgery1989;158(4):309-13. FakihAR , RaoRS , PatelAR . Prophylactic neck dissection in squamous cell carcinoma of oral tongue: a prospective randomized study. Seminars in Surgical Oncology1989;5(5):327-30. ">Fakih 1989</a> used elective radical neck dissection at the same time as primary tumour resection in a group with clinically negative neck nodes versus the same procedure if the neck nodes become positive in the other group. <a href="./references#CD006205-bbs2-0003" title="D'CruzA . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment&quot; [personal communication]. Email to: H Worthington 6 February 2023. D'CruzAK , VaishR , KapreN , DandekarM , GuptaS , HawaldarR , et al. Elective versus therapeutic neck dissection in node-negative oral cancer. New England Journal of Medicine2015;373(6):521-9. [DOI: 10.1056/NEJMoa1506007]NCT00193765. Elective vs therapeutic neck dissection in treatment of early node negative squamous carcinoma of oral cavity. www.clinicaltrials.gov/ct2/show/NCT00193765 (first received 19 September 2005). ">D'Cruz 2015</a> and <a href="./references#CD006205-bbs2-0007" title="HutchisonIL , RidoutF , CheungSM , ShahN , HardeeP , SurwaldC , et al. Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort. British Journal of Cancer2019;121(10):827-36. [DOI: 0.1038/s41416-019-0587-2] [PMID: 31611612]ISRCTN65018995. The role of selective neck dissection in patients with early oral squamous cell carcinoma (1-3cm primary size) and no clinical evidence of lymph node metastases in the neck (N0). www.isrctn.com/ISRCTN65018995 (first received 23 April 2010). NCT00571883. Neck surgery in treating patients with early-stage oral cancer. clinicaltrials.gov/ct2/show/NCT00571883 (first received 12 December 2007). ">Hutchison 2019</a> evaluated selective neck dissection versus modified therapeutic neck dissection. <a href="./references#CD006205-bbs2-0005" title="GarrelR , PerriardF , FavierV , RichardF , Pierre DauresJ , De BoutrayM . Equivalence randomized trial comparing treatment based on sentinel node biopsy versus neck dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States2020;38(Suppl 15):6501. GarrelR , PoissonnetG , Moyà PlanaA , FakhryN , DolivetG , LallemantB , et al. Equivalence randomized trial to compare treatment on the basis of sentinel node biopsy versus neck node dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology2020;38(34):4010-18. [DOI: 10.1200/JCO.20.01661]NCT02855723. Randomized, open-label economic and medical study on the lymph node management of squamous cell carcinoma of the oral cavity and oropharynx tumor Stage 1 or 2, nodes 0 (T1-T2 N0) operable (SentiMERORL). clinicaltrials.gov/ct2/show/NCT02855723 (first received 4 August 2016). ">Garrel 2020</a> evaluated treatment on the basis of sentinel node biopsy versus radical neck dissection. </p> <p>Four trials compared different types of neck dissection surgery at the time of removal of the primary tumour (<a href="./references#CD006205-bbs2-0001" title="Brazilian Head and Neck Cancer Study Group. Results of a prospective trial on elective modified radical classical versus supraomohyoid neck dissection in the management of oral squamous carcinoma. American Journal of Surgery1998;176(5):422-7. ">BHNCSG 1998</a>; <a href="./references#CD006205-bbs2-0002" title='BierJ , HowaldtHP , PitzH , 4th German-Austrian-Swiss Study Group therapy study. Prospective, randomized, clinical study of squamous cell cancer of the mouth: "Radical neck dissection versus conservative neck dissection". Fortschritte der Kiefer- und Gesichts-Chirurgie1992;37:108-10. BierJ , SchlumsD , MetelmannH , HowaldtHP , PitzH . A comparison of radical and conservative neck dissection. International Journal of Oral &amp; Maxillofacial Surgery1993;22(2):102-7. BierJ . Radical neck dissection versus conservative neck dissection for squamous cell carcinoma of the oral cavity. Recent Results in Cancer Research1994;134:57-62. '>Bier 1994</a>; <a href="./references#CD006205-bbs2-0006" title="GuoCB , FengZ , ZhangJG , PengX , CaiZG , MaoC , et al. Supraomohyoid neck dissection and modified radical neck dissection for clinically node-negative oral squamous cell carcinoma: a prospective study of prognosis, complications and quality of life. Journal of Craniofacial Surgery2014;42(8):1885-90. [DOI: 10.1016/j.jcms.2014.07.007]">Guo 2014</a>; <a href="./references#CD006205-bbs2-0013" title="RastogiS , SharmaA , ChoudhuryR , TripathiS , Al WayliH , AmrithrajA , et al. Is superselective neck dissection safer than supraomohyoid neck dissection for oral carcinoma patients with N0 neck in terms of shoulder morbidity and recurrence rate?Journal of Oral and Maxillofacial Surgery2018;76(3):647-55. [DOI: 10.1016/j.joms.2017.08.002]">Rastogi 2018</a>). In <a href="./references#CD006205-bbs2-0002" title='BierJ , HowaldtHP , PitzH , 4th German-Austrian-Swiss Study Group therapy study. Prospective, randomized, clinical study of squamous cell cancer of the mouth: "Radical neck dissection versus conservative neck dissection". Fortschritte der Kiefer- und Gesichts-Chirurgie1992;37:108-10. BierJ , SchlumsD , MetelmannH , HowaldtHP , PitzH . A comparison of radical and conservative neck dissection. International Journal of Oral &amp; Maxillofacial Surgery1993;22(2):102-7. BierJ . Radical neck dissection versus conservative neck dissection for squamous cell carcinoma of the oral cavity. Recent Results in Cancer Research1994;134:57-62. '>Bier 1994</a>, both groups had radical resection of the primary tumour; in addition, one group had radical neck dissection while the other had selective neck dissection. The Brazilian Study group compared modified radical neck dissection with supraomohyoid neck dissection in conjunction with resection of the primary tumour (<a href="./references#CD006205-bbs2-0001" title="Brazilian Head and Neck Cancer Study Group. Results of a prospective trial on elective modified radical classical versus supraomohyoid neck dissection in the management of oral squamous carcinoma. American Journal of Surgery1998;176(5):422-7. ">BHNCSG 1998</a>). <a href="./references#CD006205-bbs2-0012" title='NCT00847717. Trial of IIb preserving neck dissection. clinicaltrials.gov/ct2/show/NCT00847717 (first received 19 February 2009). PandeyM , KarthikeyanS , JoshiD , KumarM , ShuklaM . Results of a randomized controlled trial of level IIb preserving neck dissection in clinically node-negative squamous carcinoma of the oral cavity. World Journal of Surgical Oncology2018;16(1):219. [DOI: 10.1186/s12957-018-1518-z] [PMID: 30409212]PandeyM . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 2 February 2023. '>Pandey 2018</a> and <a href="./references#CD006205-bbs2-0013" title="RastogiS , SharmaA , ChoudhuryR , TripathiS , Al WayliH , AmrithrajA , et al. Is superselective neck dissection safer than supraomohyoid neck dissection for oral carcinoma patients with N0 neck in terms of shoulder morbidity and recurrence rate?Journal of Oral and Maxillofacial Surgery2018;76(3):647-55. [DOI: 10.1016/j.joms.2017.08.002]">Rastogi 2018</a> compared superselective neck dissection with supraomohyoid neck dissection in conjunction with resection of the primary tumour. <a href="./references#CD006205-bbs2-0006" title="GuoCB , FengZ , ZhangJG , PengX , CaiZG , MaoC , et al. Supraomohyoid neck dissection and modified radical neck dissection for clinically node-negative oral squamous cell carcinoma: a prospective study of prognosis, complications and quality of life. Journal of Craniofacial Surgery2014;42(8):1885-90. [DOI: 10.1016/j.jcms.2014.07.007]">Guo 2014</a> compared supraomohyoid neck dissection with modified radical neck dissection in conjunction with resection of the primary tumour. </p> <p><a href="./references#CD006205-bbs2-0014" title="Dr Robertson. Personal communication2006. RobertsonAG , SoutarDS , PaulJ , WebsterM , LeonardAG , MooreKP , et al. Early closure of a randomized trial: surgery and postoperative radiotherapy versus radiotherapy in the management of intra-oral tumours. Clinical Oncology (Royal College of Radiologists (Great Britain))1998;10(3):155-60. ">Robertson 1998</a> compared surgery followed by radiotherapy with radiotherapy alone in a group of participants with oral cavity or oropharyngeal cancer. <a href="./references#CD006205-bbs2-0011" title="FabianA , KrugD . Radiotherapy versus transoral robotic surgery for primary treatment of oropharyngeal squamous cell carcinoma: randomisation decides. Strahlentherapie und Onkologie2019;196(2):202-4. NCT01590355. A phase II randomized trial for early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs trans-oral robotic surgery (ORATOR). clinicaltrials.gov/ct2/show/NCT01590355 (first received 2 May 2012). NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. Lancet Oncology2019;20(10):1349-59. [DOI: 10.1016/S1470-2045(19)30410-3] [PMID: 31416685]NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Randomized trial of radiotherapy versus transoral robotic surgery for oropharyngeal squamous cell carcinoma: long-term results of the ORATOR trial. Journal of Clinical Oncology2022;40(8):866-75. [DOI: 10.1200/JCO.21.01961]NicholsAC , YooJ , HammondJA , FungK , WinquistE , ReadN , et al. Early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs. trans-oral robotic surgery (ORATOR) – study protocol for a randomized phase II trial. BMC Cancer2013;13:133. [DOI: 10.1186/1471-2407-13-133]PalmaDA , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus trans-oral robotic surgery for oropharyngeal squamous cell carcinoma: results of a randomized trial. Radiotherapy and Oncology2019;139(Supp 1):S39-40. ">Nichols 2019</a> compared robotic surgery with radiotherapy alone. <a href="./references#CD006205-bbs2-0008" title="IyerNG , TanDS , TanVK , WangW , HwangJ , Tan N-C, et al. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. Cancer2015;121(10):1599-607. SooKC , TanEH , WeeJ , LimD , TaiBC , Khoo ML et al. Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison. British Journal of Cancer2005;8(93):279-86. [DOI: 10.1038/sj.bjc.6602696] [PMCID: PMC2361563] [PMID: 16012523]">Iyer 2015</a> compared surgery and adjuvant radiotherapy with concurrent chemoradiotherapy. <a href="./references#CD006205-bbs2-0010" title='ISRCTN13735240. A multicentre randomised phase III trial comparing positron emission tomography–computed tomography guided watch and wait policy versus planned NECK dissection for the management of locally advanced (N2/N3) nodal metastases in patients with head and neck squamous cancer. www.isrctn.com/ISRCTN13735240 (first received 21 May 2007). MehannaH , McConkeyCC , RahmanJK , Wong W-L, SmithAF , NuttingC , et al. PET-NECK a multicentre randomised phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer. Health Technology Assessment2017;21:17. [DOI: 10.3310/hta21170]MehannaH , Wong W-L, McConkeyCC , RahmanJK , RobinsonM , HartleyAG , et al. PET-CT surveillance versus neck dissection in advanced head and neck cancer. New England Journal of Medicine2016;374(15):1444-54. [DOI: 10.1056/NEJMoa1514493]MehannaH . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 31 January 2023. '>Mehanna 2017</a> evaluated a positron emission tomography‐computed tomography (PET‐CT)‐guided 'watch and wait' policy (with neck dissection undertaken only if no/incomplete response to chemoradiotherapy identified) versus planned neck dissection before or after radical chemoradiotherapy for locally advanced head and neck SCC. </p> </section> <section id="CD006205-sec-0045"> <h5 class="title">Outcome measures</h5> <p>The duration of follow‐up in the included trials ranged from approximately 15 months (<a href="./references#CD006205-bbs2-0002" title='BierJ , HowaldtHP , PitzH , 4th German-Austrian-Swiss Study Group therapy study. Prospective, randomized, clinical study of squamous cell cancer of the mouth: "Radical neck dissection versus conservative neck dissection". Fortschritte der Kiefer- und Gesichts-Chirurgie1992;37:108-10. BierJ , SchlumsD , MetelmannH , HowaldtHP , PitzH . A comparison of radical and conservative neck dissection. International Journal of Oral &amp; Maxillofacial Surgery1993;22(2):102-7. BierJ . Radical neck dissection versus conservative neck dissection for squamous cell carcinoma of the oral cavity. Recent Results in Cancer Research1994;134:57-62. '>Bier 1994</a>) to 122 months (<a href="./references#CD006205-bbs2-0015" title="YuenAP , HoCM , ChowTL , TangLC , CheungWY , NgRW , et al. Prospective randomized study of selective neck dissection versus observation for N0 neck of early tongue carcinoma. Head &amp; Neck2009;31(6):765-72. ">Yuen 2009</a>). Three trials did not report total mortality or overall survival (<a href="./references#CD006205-bbs2-0012" title='NCT00847717. Trial of IIb preserving neck dissection. clinicaltrials.gov/ct2/show/NCT00847717 (first received 19 February 2009). PandeyM , KarthikeyanS , JoshiD , KumarM , ShuklaM . Results of a randomized controlled trial of level IIb preserving neck dissection in clinically node-negative squamous carcinoma of the oral cavity. World Journal of Surgical Oncology2018;16(1):219. [DOI: 10.1186/s12957-018-1518-z] [PMID: 30409212]PandeyM . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 2 February 2023. '>Pandey 2018</a>; <a href="./references#CD006205-bbs2-0013" title="RastogiS , SharmaA , ChoudhuryR , TripathiS , Al WayliH , AmrithrajA , et al. Is superselective neck dissection safer than supraomohyoid neck dissection for oral carcinoma patients with N0 neck in terms of shoulder morbidity and recurrence rate?Journal of Oral and Maxillofacial Surgery2018;76(3):647-55. [DOI: 10.1016/j.joms.2017.08.002]">Rastogi 2018</a>; <a href="./references#CD006205-bbs2-0015" title="YuenAP , HoCM , ChowTL , TangLC , CheungWY , NgRW , et al. Prospective randomized study of selective neck dissection versus observation for N0 neck of early tongue carcinoma. Head &amp; Neck2009;31(6):765-72. ">Yuen 2009</a>); not all the remaining trials provided data in a form suitable for inclusion in meta‐analysis. Five trials did not report disease‐free survival (<a href="./references#CD006205-bbs2-0001" title="Brazilian Head and Neck Cancer Study Group. Results of a prospective trial on elective modified radical classical versus supraomohyoid neck dissection in the management of oral squamous carcinoma. American Journal of Surgery1998;176(5):422-7. ">BHNCSG 1998</a>; <a href="./references#CD006205-bbs2-0010" title='ISRCTN13735240. A multicentre randomised phase III trial comparing positron emission tomography–computed tomography guided watch and wait policy versus planned NECK dissection for the management of locally advanced (N2/N3) nodal metastases in patients with head and neck squamous cancer. www.isrctn.com/ISRCTN13735240 (first received 21 May 2007). MehannaH , McConkeyCC , RahmanJK , Wong W-L, SmithAF , NuttingC , et al. PET-NECK a multicentre randomised phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer. Health Technology Assessment2017;21:17. [DOI: 10.3310/hta21170]MehannaH , Wong W-L, McConkeyCC , RahmanJK , RobinsonM , HartleyAG , et al. PET-CT surveillance versus neck dissection in advanced head and neck cancer. New England Journal of Medicine2016;374(15):1444-54. [DOI: 10.1056/NEJMoa1514493]MehannaH . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 31 January 2023. '>Mehanna 2017</a>; <a href="./references#CD006205-bbs2-0012" title='NCT00847717. Trial of IIb preserving neck dissection. clinicaltrials.gov/ct2/show/NCT00847717 (first received 19 February 2009). PandeyM , KarthikeyanS , JoshiD , KumarM , ShuklaM . Results of a randomized controlled trial of level IIb preserving neck dissection in clinically node-negative squamous carcinoma of the oral cavity. World Journal of Surgical Oncology2018;16(1):219. [DOI: 10.1186/s12957-018-1518-z] [PMID: 30409212]PandeyM . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 2 February 2023. '>Pandey 2018</a>; <a href="./references#CD006205-bbs2-0013" title="RastogiS , SharmaA , ChoudhuryR , TripathiS , Al WayliH , AmrithrajA , et al. Is superselective neck dissection safer than supraomohyoid neck dissection for oral carcinoma patients with N0 neck in terms of shoulder morbidity and recurrence rate?Journal of Oral and Maxillofacial Surgery2018;76(3):647-55. [DOI: 10.1016/j.joms.2017.08.002]">Rastogi 2018</a>; <a href="./references#CD006205-bbs2-0014" title="Dr Robertson. Personal communication2006. RobertsonAG , SoutarDS , PaulJ , WebsterM , LeonardAG , MooreKP , et al. Early closure of a randomized trial: surgery and postoperative radiotherapy versus radiotherapy in the management of intra-oral tumours. Clinical Oncology (Royal College of Radiologists (Great Britain))1998;10(3):155-60. ">Robertson 1998</a>), and four trials did not report locoregional recurrence (<a href="./references#CD006205-bbs2-0001" title="Brazilian Head and Neck Cancer Study Group. Results of a prospective trial on elective modified radical classical versus supraomohyoid neck dissection in the management of oral squamous carcinoma. American Journal of Surgery1998;176(5):422-7. ">BHNCSG 1998</a>; <a href="./references#CD006205-bbs2-0006" title="GuoCB , FengZ , ZhangJG , PengX , CaiZG , MaoC , et al. Supraomohyoid neck dissection and modified radical neck dissection for clinically node-negative oral squamous cell carcinoma: a prospective study of prognosis, complications and quality of life. Journal of Craniofacial Surgery2014;42(8):1885-90. [DOI: 10.1016/j.jcms.2014.07.007]">Guo 2014</a>; <a href="./references#CD006205-bbs2-0014" title="Dr Robertson. Personal communication2006. RobertsonAG , SoutarDS , PaulJ , WebsterM , LeonardAG , MooreKP , et al. Early closure of a randomized trial: surgery and postoperative radiotherapy versus radiotherapy in the management of intra-oral tumours. Clinical Oncology (Royal College of Radiologists (Great Britain))1998;10(3):155-60. ">Robertson 1998</a>; <a href="./references#CD006205-bbs2-0015" title="YuenAP , HoCM , ChowTL , TangLC , CheungWY , NgRW , et al. Prospective randomized study of selective neck dissection versus observation for N0 neck of early tongue carcinoma. Head &amp; Neck2009;31(6):765-72. ">Yuen 2009</a>). </p> <p>Five trials did not mention adverse events (<a href="./references#CD006205-bbs2-0002" title='BierJ , HowaldtHP , PitzH , 4th German-Austrian-Swiss Study Group therapy study. Prospective, randomized, clinical study of squamous cell cancer of the mouth: "Radical neck dissection versus conservative neck dissection". Fortschritte der Kiefer- und Gesichts-Chirurgie1992;37:108-10. BierJ , SchlumsD , MetelmannH , HowaldtHP , PitzH . A comparison of radical and conservative neck dissection. International Journal of Oral &amp; Maxillofacial Surgery1993;22(2):102-7. BierJ . Radical neck dissection versus conservative neck dissection for squamous cell carcinoma of the oral cavity. Recent Results in Cancer Research1994;134:57-62. '>Bier 1994</a>; <a href="./references#CD006205-bbs2-0004" title="FakihAR , RaoRS , BorgesAM , PatelAR . Elective versus therapeutic neck dissection in early carcinoma of the oral tongue. American Journal of Surgery1989;158(4):309-13. FakihAR , RaoRS , PatelAR . Prophylactic neck dissection in squamous cell carcinoma of oral tongue: a prospective randomized study. Seminars in Surgical Oncology1989;5(5):327-30. ">Fakih 1989</a>; <a href="./references#CD006205-bbs2-0008" title="IyerNG , TanDS , TanVK , WangW , HwangJ , Tan N-C, et al. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. Cancer2015;121(10):1599-607. SooKC , TanEH , WeeJ , LimD , TaiBC , Khoo ML et al. Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison. British Journal of Cancer2005;8(93):279-86. [DOI: 10.1038/sj.bjc.6602696] [PMCID: PMC2361563] [PMID: 16012523]">Iyer 2015</a>; <a href="./references#CD006205-bbs2-0009" title="Dr Kilgerman. Personal communcation2006. KligermanJ , LimaRA , SoaresJR , PradoL , DiasFL , FreitasEQ , et al. Supraomohyoid neck dissection in the treatment of T1/T2 squamous cell carcinoma of oral cavity. American Journal of Surgery1994;168(5):391-4. ">Kligerman 1994</a>; <a href="./references#CD006205-bbs2-0015" title="YuenAP , HoCM , ChowTL , TangLC , CheungWY , NgRW , et al. Prospective randomized study of selective neck dissection versus observation for N0 neck of early tongue carcinoma. Head &amp; Neck2009;31(6):765-72. ">Yuen 2009</a>), and nine trials did not report quality of life measures (<a href="./references#CD006205-bbs2-0001" title="Brazilian Head and Neck Cancer Study Group. Results of a prospective trial on elective modified radical classical versus supraomohyoid neck dissection in the management of oral squamous carcinoma. American Journal of Surgery1998;176(5):422-7. ">BHNCSG 1998</a>; <a href="./references#CD006205-bbs2-0002" title='BierJ , HowaldtHP , PitzH , 4th German-Austrian-Swiss Study Group therapy study. Prospective, randomized, clinical study of squamous cell cancer of the mouth: "Radical neck dissection versus conservative neck dissection". Fortschritte der Kiefer- und Gesichts-Chirurgie1992;37:108-10. BierJ , SchlumsD , MetelmannH , HowaldtHP , PitzH . A comparison of radical and conservative neck dissection. International Journal of Oral &amp; Maxillofacial Surgery1993;22(2):102-7. BierJ . Radical neck dissection versus conservative neck dissection for squamous cell carcinoma of the oral cavity. Recent Results in Cancer Research1994;134:57-62. '>Bier 1994</a>; <a href="./references#CD006205-bbs2-0003" title="D'CruzA . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment&quot; [personal communication]. Email to: H Worthington 6 February 2023. D'CruzAK , VaishR , KapreN , DandekarM , GuptaS , HawaldarR , et al. Elective versus therapeutic neck dissection in node-negative oral cancer. New England Journal of Medicine2015;373(6):521-9. [DOI: 10.1056/NEJMoa1506007]NCT00193765. Elective vs therapeutic neck dissection in treatment of early node negative squamous carcinoma of oral cavity. www.clinicaltrials.gov/ct2/show/NCT00193765 (first received 19 September 2005). ">D'Cruz 2015</a>; <a href="./references#CD006205-bbs2-0004" title="FakihAR , RaoRS , BorgesAM , PatelAR . Elective versus therapeutic neck dissection in early carcinoma of the oral tongue. American Journal of Surgery1989;158(4):309-13. FakihAR , RaoRS , PatelAR . Prophylactic neck dissection in squamous cell carcinoma of oral tongue: a prospective randomized study. Seminars in Surgical Oncology1989;5(5):327-30. ">Fakih 1989</a>; <a href="./references#CD006205-bbs2-0005" title="GarrelR , PerriardF , FavierV , RichardF , Pierre DauresJ , De BoutrayM . Equivalence randomized trial comparing treatment based on sentinel node biopsy versus neck dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States2020;38(Suppl 15):6501. GarrelR , PoissonnetG , Moyà PlanaA , FakhryN , DolivetG , LallemantB , et al. Equivalence randomized trial to compare treatment on the basis of sentinel node biopsy versus neck node dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology2020;38(34):4010-18. [DOI: 10.1200/JCO.20.01661]NCT02855723. Randomized, open-label economic and medical study on the lymph node management of squamous cell carcinoma of the oral cavity and oropharynx tumor Stage 1 or 2, nodes 0 (T1-T2 N0) operable (SentiMERORL). clinicaltrials.gov/ct2/show/NCT02855723 (first received 4 August 2016). ">Garrel 2020</a>; <a href="./references#CD006205-bbs2-0008" title="IyerNG , TanDS , TanVK , WangW , HwangJ , Tan N-C, et al. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. Cancer2015;121(10):1599-607. SooKC , TanEH , WeeJ , LimD , TaiBC , Khoo ML et al. Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison. British Journal of Cancer2005;8(93):279-86. [DOI: 10.1038/sj.bjc.6602696] [PMCID: PMC2361563] [PMID: 16012523]">Iyer 2015</a>; <a href="./references#CD006205-bbs2-0009" title="Dr Kilgerman. Personal communcation2006. KligermanJ , LimaRA , SoaresJR , PradoL , DiasFL , FreitasEQ , et al. Supraomohyoid neck dissection in the treatment of T1/T2 squamous cell carcinoma of oral cavity. American Journal of Surgery1994;168(5):391-4. ">Kligerman 1994</a>; <a href="./references#CD006205-bbs2-0014" title="Dr Robertson. Personal communication2006. RobertsonAG , SoutarDS , PaulJ , WebsterM , LeonardAG , MooreKP , et al. Early closure of a randomized trial: surgery and postoperative radiotherapy versus radiotherapy in the management of intra-oral tumours. Clinical Oncology (Royal College of Radiologists (Great Britain))1998;10(3):155-60. ">Robertson 1998</a>; <a href="./references#CD006205-bbs2-0015" title="YuenAP , HoCM , ChowTL , TangLC , CheungWY , NgRW , et al. Prospective randomized study of selective neck dissection versus observation for N0 neck of early tongue carcinoma. Head &amp; Neck2009;31(6):765-72. ">Yuen 2009</a>). </p> </section> </section> <section id="CD006205-sec-0046"> <h4 class="title">Excluded studies</h4> <p>We excluded 26 studies (five from the searches for this update) for the following reasons. </p> <p> <ul id="CD006205-list-0010"> <li> <p>Not an RCT (<a href="./references#CD006205-bbs2-0029" title="JinyunL , WenxiaoH , JieC , RonghuaB . Clinical application of the combined radical operation without breaking lower lip and mandible for tongue and lingual root carcinoma. Chinese Journal of Otorhinolaryngology Head and Neck Surgery2015;50(3):225-9. [DOI: 10.3760/cma. j. issn. 1673-0860. 2015. 03. 010] [PMID: 26268496]">Jinyun 2015</a>) </p> </li> <li> <p>Short‐term outcome measures (<a href="./references#CD006205-bbs2-0017" title="BatraJ , BekalRK , ByadgiS , AttreshG , SambyalS , VakadeCD . Comparison of skin staples and standard sutures for closing incisions after head and neck cancer surgery: a double-blind, randomized and prospective study. Journal of Maxillofacial and Oral Surgery2016;15(2):243-50. [DOI: 10.1007/s12663-015-0809-y]">Batra 2016</a>; <a href="./references#CD006205-bbs2-0020" title="DeanA , AlamillosF , CentellaI , Garcia-AlvarezS . Neck dissection with the harmonic scalpel in patients with squamous cell carcinoma of the oral cavity. Journal of Cranio-maxillo-facial Surgery2013;42(1):84-7. [DOI: 10.1016/j.jcms.2013.02.007]">Dean 2013</a>; <a href="./references#CD006205-bbs2-0022" title="DziegielewskiPT , McNeelyML , AshworthN , O'ConnellDA , BarberB , CourneyaKS , et al. 2b or not 2b? Shoulder function after level 2b neck dissection: a double-blind randomized controlled clinical trial. Cancer2020;126(7):1492-501. ">Dziegielewski 2019</a>; <a href="./references#CD006205-bbs2-0023" title="FanS , ZhongJL , ChenWX , ChenWL , LiQX , WangYY , et al. Postoperative immune response and surgical stress in selective neck dissection: comparison between endoscopically assisted dissection and open techniques in cT1-2N0 oral squamous cell carcinoma. Journal of Cranio-maxillo-facial Surgery2017;45(8):1112-6. [DOI: 10.1016/j.jcms.2016.11.021]">Fan 2017</a>; <a href="./references#CD006205-bbs2-0024" title="FritzDK , MatthewsTW , ChandaranaSP , NakoneshnySC , DortJC . Harmonic scalpel impact on blood loss and operating time in major head and neck surgery: a randomized clinical trial. Journal of Otolaryngology – Head &amp; Neck Surgery2016;45(58):1-6. [DOI: 10.1186/s40463-016-0173-z]">Fritz 2016</a>; <a href="./references#CD006205-bbs2-0025" title="FunaharaM , YanamotoS , UedaM , SuzukiT , OtaY , NishimakiF , et al. Prevention of surgical site infection after oral cancer surgery by topical tetracycline: results of a multicenter randomized controlled trial. Medicine2017;96(48):1-6. [DOI: 10.1097%2FMD.0000000000008891]">Funahara 2017</a>; <a href="./references#CD006205-bbs2-0031" title="LinWJ , WangCC , JiangRS , HuangYC , HoHC , LiuSA . A prospective randomised trial of LigaSure Small Jaw® versus conventional neck dissection in head and neck cancer patients. Clinical Otolaryngology2016;42(2):245-51. ">Lin 2016</a>; <a href="./references#CD006205-bbs2-0034" title="MinkovichL , DjaianiG , McCluskeySA , MitsakakisN , GilbertRW , BeattleWS . Frequent malpositions of peripherally inserted central venous catheters in patients undergoing head and neck surgery [Mauvais positionnements frequents des catheters veineux centraux inseres par voie peripherique chez les patients subissantune chirurgie au niveau de la tete et du cou]. Canadian Journal of Anesthesia2011;58:709-13. ">Minkovich 2011</a>; <a href="./references#CD006205-bbs2-0035" title="OswalS , BorleR , BholaN , JadhavA , SuranaS , OswalR . Surgical staples: a superior alternative to sutures for skin closure after neck dissection – a single-blinded prospective randomized clinical study. Journal of Oral and Maxillofacial Surgery2017;75(12):2707.e1-6. [DOI: 10.1016/j.joms.2017.08.004]">Oswal 2017</a>; <a href="./references#CD006205-bbs2-0038" title="VermaRK , MathiazhaganA , PandaNK . Neck dissection with harmonic scalpel and electrocautery? A randomised study. Auris Nasus Larynx2017;44(5):590-5. [DOI: 10.1016/j.anl.2016.11.004]">Verma 2017</a>; <a href="./references#CD006205-bbs2-0039" title="WalenSG , RudmikLR , DixonE , MatthewsTW , NakoneshnySC , DortJC . The utility of the harmonic scalpel in selective neck dissection: a prospective, randomized trial. Otolaryngology and Head and Neck Surgery2011;144(6):894-9. [DOI: 10.1177/0194599811403874]">Walen 2011</a>) </p> </li> <li> <p>Less than 50% of participants with oral cancer (<a href="./references#CD006205-bbs2-0016" title="AladashiOQ , ShindyMI , NoamanSA , AlqutaibiAY , RefaheeSM . Effect of submental flap reconstruction versus obturator rehabilitation after maxillectomy on quality of life: a randomized clinical trial. International Journal of Oral and Maxillofacial Surgery2021;50(9):1156-60. [DOI: 10.1016/j.ijom.2020.12.008]">Aladashi 2020</a>; <a href="./references#CD006205-bbs2-0027" title="HintzB , CharyuluK , ChandlerJR , SudarsanamA , GarcigaC . Randomized study of local control and survival following radical surgery or radiation therapy in oral and laryngeal carcinomas. Journal of Surgical Oncology1979;12(1):61-74. ">Hintz 1979a</a>; <a href="./references#CD006205-bbs2-0028" title="HintzB , CharyuluK , ChandlerJR , SudarsanamA , GarcigaC . Randomized study of control of the primary tumor and survival using preoperative radiation, radiation alone, or surgery alone in head and neck carcinomas. Journal of Surgical Oncology1979;12(1):75-85. ">Hintz 1979b</a>) </p> </li> <li> <p>Abstract only or insufficient information (<a href="./references#CD006205-bbs2-0019" title="ChristensenA , JuhlK , KissK , LelkaitisG , CharabiBW , MortensenJ , et al. Near-infrared fluorescence imaging improves the nodal yield in neck dissection in oral cavity cancer – a randomized study. European Journal of Surgical Oncology2019;45(11):2151-8. ">Christensen 2019</a>; <a href="./references#CD006205-bbs2-0026" title="GundaleA , Rajdeep, VasanthanL , TirkeyAK , RajinikanthJ . A randomised controlled trial of intraoperative brief electrical stimulation vs no stimulation of spinal accessory nerve for prevention of shoulder dysfunction after oncologic neck dissection in oral cavity squamous cell carcinomas-an interim report. Head &amp; Neck2017;39(S1):224. ">Gundale 2017</a>; <a href="./references#CD006205-bbs2-0030" title="KramerS , GelberRD , SnowJB , MarcialVA , LowryLD , DavisLW , et al. Combined radiation therapy and surgery in the management of advanced head and neck cancer: final report of study 73-03 of the Radiation Therapy Oncology Group. Head &amp; Neck Surgery1987;10(1):19-30. ">Kramer 1987</a>; <a href="./references#CD006205-bbs2-0032" title="McCaulJA , KulkamiR , GouldesbroughD , BoyeT , SuttonD , Abdel-GalilK , et al. LIHNCS; randomised control trial in oral and maxillofacial surgery interim data and recruitment report. British Journal of Oral &amp; Maxillofacial Surgery2012;50(Suppl 1):S22. [DOI: 10.1016/j.bjoms.2012.04.203]">McCaul 2012</a>; <a href="./references#CD006205-bbs2-0033" title="McCaulJA , McMahonJM , QuantrillJ , GilbertK , MehannaHM , ShawR , et al. LIHNCS: Lugol's iodine in head and neck cancer surgery – a multi-centre, randomised, controlled trial assessing the effectiveness of Lugol's iodine to assist excision of moderate dysplasia, severe dysplasia and carcinoma in-situ at mucosal resection margin of oral and oropharyngeal squamous cell carcinoma. Journal of Clinical Oncology2017;35(Suppl 15):6065. [DOI: 10.1200/JCO.2017.35.15_suppl.6065]">McCaul 2017</a>; <a href="./references#CD006205-bbs2-0040" title="ZhangF , YangK , LiY , ChenDR , XiangL . Comparison of surgical effects on patients with oral squamous cell carcinoma in cN0 stage operated in two kinds of neck dissection. Stomatology2010;30(2):98-100. ">Zhang 2010</a>) </p> </li> <li> <p>Full‐text article unavailable (<a href="./references#CD006205-bbs2-0036" title="UppalA , KakarFD , UppalSA , MajeedR . Comparison of the complication between the radical neck dissection &amp; selective neck dissection for the patient of oral squamous cell carcinoma. Medical Forum Monthly2012;23(1):31-4. ">Uppal 2012</a>) </p> </li> <li> <p>Focus of the trial was evaluation of presurgical chemotherapy (<a href="./references#CD006205-bbs2-0018" title="ChaukarD , PaiPS , ChaturvediP , PantvaidyaG , DeshmukhA , NairD , et al. A prospective phase II open-label randomized controlled trial to compare mandibular preservation in upfront surgery to neoadjuvant chemotherapy followed by surgery in operable oral cavity cancer. Journal of Clinical Oncology Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States2020;38(Suppl 15):6518. ChaukarD , PrabashK , RaneP , PatilVM , ThiagarajanS , Ghosh-LaskarS , et al. Prospective phase II open-label randomized controlled trial to compare mandibular preservation in upfront surgery with neoadjuvant chemotherapy followed by surgery in operable oral cavity cancer. Journal of Clinical Oncology2021;40(3):272-81. ">Chaukar 2021</a>; <a href="./references#CD006205-bbs2-0041" title="ZhongLP , ZhangCP , RenGX , GuoW , William WN Jr, HongCS , et al. Long-term results of a randomized phase III trial of TPF induction chemotherapy followed by surgery and radiation in locally advanced oral squamous cell carcinoma. Oncotarget2015;6(21):18707-14. [DOI: 10.18632/oncotarget.4531]ZhongLP , ZhangCP , RenGX , GuoW , William WN Jr, SunJ , et al. Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. Journal of Clinical Oncology2013;31(6):744-51. [DOI: 10.1200/jco.2012.43.8820]">Zhong 2013</a>) </p> </li> <li> <p>Inappropriate intervention (diagnostic aid) and same treatment for both groups (<a href="./references#CD006205-bbs2-0021" title="DurhamJS , BrasherP , AndersonDW , YooJ , HartR , DortJC , et al. Effect of fluorescence visualization-guided surgery on local recurrence of oral squamous cell carcinoma: a randomized clinical trial. JAMA Otolaryngology – Head &amp; Neck Surgery2020;146(12):1149-55. [DOI: 10.1001/jamaoto.2020.3147] [PMID: 33034628]PohCF , DurhamJS , BrasherPM , AndersonDW , BereanKW , MacAulayCE , et al. Canadian Optically-guided approach for Oral Lesions Surgical (COOLS) trial: study protocol for a randomized controlled trial. BMC Cancer2011;11:462. [DOI: 10.1186/1471-2407-11-462]">Durham 2020</a>) </p> </li> <li> <p>Primary site delivered interstitial radiotherapy rather than surgery (<a href="./references#CD006205-bbs2-0037" title="VandenbrouckC , Sancho-GarnierH , ChassagneD , SaravaneD , CachinY , MicheauC . Elective versus therapeutic radical neck dissection in epidermoid carcinoma of the oral cavity: results of a randomized clinical trial. Cancer1980;46(2):386-90. ">Vandenbrouck 1980</a>) </p> </li> </ul> </p> </section> </section> <section id="CD006205-sec-0047"> <h3 class="title">Risk of bias in included studies</h3> <p><a href="#CD006205-fig-0002">Figure 2</a> and <a href="#CD006205-fig-0003">Figure 3</a> present the risk of bias assessment results visually. </p> <div class="figure" id="CD006205-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD006205-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_n/nCD006205-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD006205-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD006205-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_n/nCD006205-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD006205-sec-0048"> <h4 class="title">Allocation</h4> <p>Eight trials reported adequate sequence generation methods (<a href="./references#CD006205-bbs2-0003" title="D'CruzA . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment&quot; [personal communication]. Email to: H Worthington 6 February 2023. D'CruzAK , VaishR , KapreN , DandekarM , GuptaS , HawaldarR , et al. Elective versus therapeutic neck dissection in node-negative oral cancer. New England Journal of Medicine2015;373(6):521-9. [DOI: 10.1056/NEJMoa1506007]NCT00193765. Elective vs therapeutic neck dissection in treatment of early node negative squamous carcinoma of oral cavity. www.clinicaltrials.gov/ct2/show/NCT00193765 (first received 19 September 2005). ">D'Cruz 2015</a>; <a href="./references#CD006205-bbs2-0004" title="FakihAR , RaoRS , BorgesAM , PatelAR . Elective versus therapeutic neck dissection in early carcinoma of the oral tongue. American Journal of Surgery1989;158(4):309-13. FakihAR , RaoRS , PatelAR . Prophylactic neck dissection in squamous cell carcinoma of oral tongue: a prospective randomized study. Seminars in Surgical Oncology1989;5(5):327-30. ">Fakih 1989</a>; <a href="./references#CD006205-bbs2-0005" title="GarrelR , PerriardF , FavierV , RichardF , Pierre DauresJ , De BoutrayM . Equivalence randomized trial comparing treatment based on sentinel node biopsy versus neck dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States2020;38(Suppl 15):6501. GarrelR , PoissonnetG , Moyà PlanaA , FakhryN , DolivetG , LallemantB , et al. Equivalence randomized trial to compare treatment on the basis of sentinel node biopsy versus neck node dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology2020;38(34):4010-18. [DOI: 10.1200/JCO.20.01661]NCT02855723. Randomized, open-label economic and medical study on the lymph node management of squamous cell carcinoma of the oral cavity and oropharynx tumor Stage 1 or 2, nodes 0 (T1-T2 N0) operable (SentiMERORL). clinicaltrials.gov/ct2/show/NCT02855723 (first received 4 August 2016). ">Garrel 2020</a>; <a href="./references#CD006205-bbs2-0007" title="HutchisonIL , RidoutF , CheungSM , ShahN , HardeeP , SurwaldC , et al. Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort. British Journal of Cancer2019;121(10):827-36. [DOI: 0.1038/s41416-019-0587-2] [PMID: 31611612]ISRCTN65018995. The role of selective neck dissection in patients with early oral squamous cell carcinoma (1-3cm primary size) and no clinical evidence of lymph node metastases in the neck (N0). www.isrctn.com/ISRCTN65018995 (first received 23 April 2010). NCT00571883. Neck surgery in treating patients with early-stage oral cancer. clinicaltrials.gov/ct2/show/NCT00571883 (first received 12 December 2007). ">Hutchison 2019</a>; <a href="./references#CD006205-bbs2-0010" title='ISRCTN13735240. A multicentre randomised phase III trial comparing positron emission tomography–computed tomography guided watch and wait policy versus planned NECK dissection for the management of locally advanced (N2/N3) nodal metastases in patients with head and neck squamous cancer. www.isrctn.com/ISRCTN13735240 (first received 21 May 2007). MehannaH , McConkeyCC , RahmanJK , Wong W-L, SmithAF , NuttingC , et al. PET-NECK a multicentre randomised phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer. Health Technology Assessment2017;21:17. [DOI: 10.3310/hta21170]MehannaH , Wong W-L, McConkeyCC , RahmanJK , RobinsonM , HartleyAG , et al. PET-CT surveillance versus neck dissection in advanced head and neck cancer. New England Journal of Medicine2016;374(15):1444-54. [DOI: 10.1056/NEJMoa1514493]MehannaH . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 31 January 2023. '>Mehanna 2017</a>; <a href="./references#CD006205-bbs2-0011" title="FabianA , KrugD . Radiotherapy versus transoral robotic surgery for primary treatment of oropharyngeal squamous cell carcinoma: randomisation decides. Strahlentherapie und Onkologie2019;196(2):202-4. NCT01590355. A phase II randomized trial for early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs trans-oral robotic surgery (ORATOR). clinicaltrials.gov/ct2/show/NCT01590355 (first received 2 May 2012). NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. Lancet Oncology2019;20(10):1349-59. [DOI: 10.1016/S1470-2045(19)30410-3] [PMID: 31416685]NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Randomized trial of radiotherapy versus transoral robotic surgery for oropharyngeal squamous cell carcinoma: long-term results of the ORATOR trial. Journal of Clinical Oncology2022;40(8):866-75. [DOI: 10.1200/JCO.21.01961]NicholsAC , YooJ , HammondJA , FungK , WinquistE , ReadN , et al. Early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs. trans-oral robotic surgery (ORATOR) – study protocol for a randomized phase II trial. BMC Cancer2013;13:133. [DOI: 10.1186/1471-2407-13-133]PalmaDA , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus trans-oral robotic surgery for oropharyngeal squamous cell carcinoma: results of a randomized trial. Radiotherapy and Oncology2019;139(Supp 1):S39-40. ">Nichols 2019</a>; <a href="./references#CD006205-bbs2-0012" title='NCT00847717. Trial of IIb preserving neck dissection. clinicaltrials.gov/ct2/show/NCT00847717 (first received 19 February 2009). PandeyM , KarthikeyanS , JoshiD , KumarM , ShuklaM . Results of a randomized controlled trial of level IIb preserving neck dissection in clinically node-negative squamous carcinoma of the oral cavity. World Journal of Surgical Oncology2018;16(1):219. [DOI: 10.1186/s12957-018-1518-z] [PMID: 30409212]PandeyM . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 2 February 2023. '>Pandey 2018</a>; <a href="./references#CD006205-bbs2-0014" title="Dr Robertson. Personal communication2006. RobertsonAG , SoutarDS , PaulJ , WebsterM , LeonardAG , MooreKP , et al. Early closure of a randomized trial: surgery and postoperative radiotherapy versus radiotherapy in the management of intra-oral tumours. Clinical Oncology (Royal College of Radiologists (Great Britain))1998;10(3):155-60. ">Robertson 1998</a>). Three trials reported adequate allocation concealment (<a href="./references#CD006205-bbs2-0007" title="HutchisonIL , RidoutF , CheungSM , ShahN , HardeeP , SurwaldC , et al. Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort. British Journal of Cancer2019;121(10):827-36. [DOI: 0.1038/s41416-019-0587-2] [PMID: 31611612]ISRCTN65018995. The role of selective neck dissection in patients with early oral squamous cell carcinoma (1-3cm primary size) and no clinical evidence of lymph node metastases in the neck (N0). www.isrctn.com/ISRCTN65018995 (first received 23 April 2010). NCT00571883. Neck surgery in treating patients with early-stage oral cancer. clinicaltrials.gov/ct2/show/NCT00571883 (first received 12 December 2007). ">Hutchison 2019</a>; <a href="./references#CD006205-bbs2-0011" title="FabianA , KrugD . Radiotherapy versus transoral robotic surgery for primary treatment of oropharyngeal squamous cell carcinoma: randomisation decides. Strahlentherapie und Onkologie2019;196(2):202-4. NCT01590355. A phase II randomized trial for early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs trans-oral robotic surgery (ORATOR). clinicaltrials.gov/ct2/show/NCT01590355 (first received 2 May 2012). NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. Lancet Oncology2019;20(10):1349-59. [DOI: 10.1016/S1470-2045(19)30410-3] [PMID: 31416685]NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Randomized trial of radiotherapy versus transoral robotic surgery for oropharyngeal squamous cell carcinoma: long-term results of the ORATOR trial. Journal of Clinical Oncology2022;40(8):866-75. [DOI: 10.1200/JCO.21.01961]NicholsAC , YooJ , HammondJA , FungK , WinquistE , ReadN , et al. Early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs. trans-oral robotic surgery (ORATOR) – study protocol for a randomized phase II trial. BMC Cancer2013;13:133. [DOI: 10.1186/1471-2407-13-133]PalmaDA , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus trans-oral robotic surgery for oropharyngeal squamous cell carcinoma: results of a randomized trial. Radiotherapy and Oncology2019;139(Supp 1):S39-40. ">Nichols 2019</a>: <a href="./references#CD006205-bbs2-0014" title="Dr Robertson. Personal communication2006. RobertsonAG , SoutarDS , PaulJ , WebsterM , LeonardAG , MooreKP , et al. Early closure of a randomized trial: surgery and postoperative radiotherapy versus radiotherapy in the management of intra-oral tumours. Clinical Oncology (Royal College of Radiologists (Great Britain))1998;10(3):155-60. ">Robertson 1998</a>), and the authors of another two trials confirmed adequate allocation concealment (<a href="./references#CD006205-bbs2-0010" title='ISRCTN13735240. A multicentre randomised phase III trial comparing positron emission tomography–computed tomography guided watch and wait policy versus planned NECK dissection for the management of locally advanced (N2/N3) nodal metastases in patients with head and neck squamous cancer. www.isrctn.com/ISRCTN13735240 (first received 21 May 2007). MehannaH , McConkeyCC , RahmanJK , Wong W-L, SmithAF , NuttingC , et al. PET-NECK a multicentre randomised phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer. Health Technology Assessment2017;21:17. [DOI: 10.3310/hta21170]MehannaH , Wong W-L, McConkeyCC , RahmanJK , RobinsonM , HartleyAG , et al. PET-CT surveillance versus neck dissection in advanced head and neck cancer. New England Journal of Medicine2016;374(15):1444-54. [DOI: 10.1056/NEJMoa1514493]MehannaH . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 31 January 2023. '>Mehanna 2017</a>; <a href="./references#CD006205-bbs2-0012" title='NCT00847717. Trial of IIb preserving neck dissection. clinicaltrials.gov/ct2/show/NCT00847717 (first received 19 February 2009). PandeyM , KarthikeyanS , JoshiD , KumarM , ShuklaM . Results of a randomized controlled trial of level IIb preserving neck dissection in clinically node-negative squamous carcinoma of the oral cavity. World Journal of Surgical Oncology2018;16(1):219. [DOI: 10.1186/s12957-018-1518-z] [PMID: 30409212]PandeyM . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 2 February 2023. '>Pandey 2018</a>). Therefore, we judged five trials at overall low risk of selection bias (<a href="./references#CD006205-bbs2-0007" title="HutchisonIL , RidoutF , CheungSM , ShahN , HardeeP , SurwaldC , et al. Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort. British Journal of Cancer2019;121(10):827-36. [DOI: 0.1038/s41416-019-0587-2] [PMID: 31611612]ISRCTN65018995. The role of selective neck dissection in patients with early oral squamous cell carcinoma (1-3cm primary size) and no clinical evidence of lymph node metastases in the neck (N0). www.isrctn.com/ISRCTN65018995 (first received 23 April 2010). NCT00571883. Neck surgery in treating patients with early-stage oral cancer. clinicaltrials.gov/ct2/show/NCT00571883 (first received 12 December 2007). ">Hutchison 2019</a>; <a href="./references#CD006205-bbs2-0010" title='ISRCTN13735240. A multicentre randomised phase III trial comparing positron emission tomography–computed tomography guided watch and wait policy versus planned NECK dissection for the management of locally advanced (N2/N3) nodal metastases in patients with head and neck squamous cancer. www.isrctn.com/ISRCTN13735240 (first received 21 May 2007). MehannaH , McConkeyCC , RahmanJK , Wong W-L, SmithAF , NuttingC , et al. PET-NECK a multicentre randomised phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer. Health Technology Assessment2017;21:17. [DOI: 10.3310/hta21170]MehannaH , Wong W-L, McConkeyCC , RahmanJK , RobinsonM , HartleyAG , et al. PET-CT surveillance versus neck dissection in advanced head and neck cancer. New England Journal of Medicine2016;374(15):1444-54. [DOI: 10.1056/NEJMoa1514493]MehannaH . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 31 January 2023. '>Mehanna 2017</a>; <a href="./references#CD006205-bbs2-0011" title="FabianA , KrugD . Radiotherapy versus transoral robotic surgery for primary treatment of oropharyngeal squamous cell carcinoma: randomisation decides. Strahlentherapie und Onkologie2019;196(2):202-4. NCT01590355. A phase II randomized trial for early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs trans-oral robotic surgery (ORATOR). clinicaltrials.gov/ct2/show/NCT01590355 (first received 2 May 2012). NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. Lancet Oncology2019;20(10):1349-59. [DOI: 10.1016/S1470-2045(19)30410-3] [PMID: 31416685]NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Randomized trial of radiotherapy versus transoral robotic surgery for oropharyngeal squamous cell carcinoma: long-term results of the ORATOR trial. Journal of Clinical Oncology2022;40(8):866-75. [DOI: 10.1200/JCO.21.01961]NicholsAC , YooJ , HammondJA , FungK , WinquistE , ReadN , et al. Early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs. trans-oral robotic surgery (ORATOR) – study protocol for a randomized phase II trial. BMC Cancer2013;13:133. [DOI: 10.1186/1471-2407-13-133]PalmaDA , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus trans-oral robotic surgery for oropharyngeal squamous cell carcinoma: results of a randomized trial. Radiotherapy and Oncology2019;139(Supp 1):S39-40. ">Nichols 2019</a>; <a href="./references#CD006205-bbs2-0012" title='NCT00847717. Trial of IIb preserving neck dissection. clinicaltrials.gov/ct2/show/NCT00847717 (first received 19 February 2009). PandeyM , KarthikeyanS , JoshiD , KumarM , ShuklaM . Results of a randomized controlled trial of level IIb preserving neck dissection in clinically node-negative squamous carcinoma of the oral cavity. World Journal of Surgical Oncology2018;16(1):219. [DOI: 10.1186/s12957-018-1518-z] [PMID: 30409212]PandeyM . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 2 February 2023. '>Pandey 2018</a>; <a href="./references#CD006205-bbs2-0014" title="Dr Robertson. Personal communication2006. RobertsonAG , SoutarDS , PaulJ , WebsterM , LeonardAG , MooreKP , et al. Early closure of a randomized trial: surgery and postoperative radiotherapy versus radiotherapy in the management of intra-oral tumours. Clinical Oncology (Royal College of Radiologists (Great Britain))1998;10(3):155-60. ">Robertson 1998</a>), and the other 10 studies at unclear risk. </p> </section> <section id="CD006205-sec-0049"> <h4 class="title">Blinding</h4> <p>Blinding of participants and clinicians is not feasible in surgical trials, but blinding of outcome assessment is both possible and desirable. As mortality is the primary outcome that is most frequently and reliably reported, we decided to judge all trials at low risk of bias for the objective outcomes. </p> <p>We assessed six trials at high risk of bias for blinding of subjective participant‐reported outcomes (<a href="./references#CD006205-bbs2-0005" title="GarrelR , PerriardF , FavierV , RichardF , Pierre DauresJ , De BoutrayM . Equivalence randomized trial comparing treatment based on sentinel node biopsy versus neck dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States2020;38(Suppl 15):6501. GarrelR , PoissonnetG , Moyà PlanaA , FakhryN , DolivetG , LallemantB , et al. Equivalence randomized trial to compare treatment on the basis of sentinel node biopsy versus neck node dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology2020;38(34):4010-18. [DOI: 10.1200/JCO.20.01661]NCT02855723. Randomized, open-label economic and medical study on the lymph node management of squamous cell carcinoma of the oral cavity and oropharynx tumor Stage 1 or 2, nodes 0 (T1-T2 N0) operable (SentiMERORL). clinicaltrials.gov/ct2/show/NCT02855723 (first received 4 August 2016). ">Garrel 2020</a>; <a href="./references#CD006205-bbs2-0006" title="GuoCB , FengZ , ZhangJG , PengX , CaiZG , MaoC , et al. Supraomohyoid neck dissection and modified radical neck dissection for clinically node-negative oral squamous cell carcinoma: a prospective study of prognosis, complications and quality of life. Journal of Craniofacial Surgery2014;42(8):1885-90. [DOI: 10.1016/j.jcms.2014.07.007]">Guo 2014</a>; <a href="./references#CD006205-bbs2-0010" title='ISRCTN13735240. A multicentre randomised phase III trial comparing positron emission tomography–computed tomography guided watch and wait policy versus planned NECK dissection for the management of locally advanced (N2/N3) nodal metastases in patients with head and neck squamous cancer. www.isrctn.com/ISRCTN13735240 (first received 21 May 2007). MehannaH , McConkeyCC , RahmanJK , Wong W-L, SmithAF , NuttingC , et al. PET-NECK a multicentre randomised phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer. Health Technology Assessment2017;21:17. [DOI: 10.3310/hta21170]MehannaH , Wong W-L, McConkeyCC , RahmanJK , RobinsonM , HartleyAG , et al. PET-CT surveillance versus neck dissection in advanced head and neck cancer. New England Journal of Medicine2016;374(15):1444-54. [DOI: 10.1056/NEJMoa1514493]MehannaH . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 31 January 2023. '>Mehanna 2017</a>; <a href="./references#CD006205-bbs2-0011" title="FabianA , KrugD . Radiotherapy versus transoral robotic surgery for primary treatment of oropharyngeal squamous cell carcinoma: randomisation decides. Strahlentherapie und Onkologie2019;196(2):202-4. NCT01590355. A phase II randomized trial for early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs trans-oral robotic surgery (ORATOR). clinicaltrials.gov/ct2/show/NCT01590355 (first received 2 May 2012). NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. Lancet Oncology2019;20(10):1349-59. [DOI: 10.1016/S1470-2045(19)30410-3] [PMID: 31416685]NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Randomized trial of radiotherapy versus transoral robotic surgery for oropharyngeal squamous cell carcinoma: long-term results of the ORATOR trial. Journal of Clinical Oncology2022;40(8):866-75. [DOI: 10.1200/JCO.21.01961]NicholsAC , YooJ , HammondJA , FungK , WinquistE , ReadN , et al. Early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs. trans-oral robotic surgery (ORATOR) – study protocol for a randomized phase II trial. BMC Cancer2013;13:133. [DOI: 10.1186/1471-2407-13-133]PalmaDA , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus trans-oral robotic surgery for oropharyngeal squamous cell carcinoma: results of a randomized trial. Radiotherapy and Oncology2019;139(Supp 1):S39-40. ">Nichols 2019</a>; <a href="./references#CD006205-bbs2-0012" title='NCT00847717. Trial of IIb preserving neck dissection. clinicaltrials.gov/ct2/show/NCT00847717 (first received 19 February 2009). PandeyM , KarthikeyanS , JoshiD , KumarM , ShuklaM . Results of a randomized controlled trial of level IIb preserving neck dissection in clinically node-negative squamous carcinoma of the oral cavity. World Journal of Surgical Oncology2018;16(1):219. [DOI: 10.1186/s12957-018-1518-z] [PMID: 30409212]PandeyM . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 2 February 2023. '>Pandey 2018</a>; <a href="./references#CD006205-bbs2-0013" title="RastogiS , SharmaA , ChoudhuryR , TripathiS , Al WayliH , AmrithrajA , et al. Is superselective neck dissection safer than supraomohyoid neck dissection for oral carcinoma patients with N0 neck in terms of shoulder morbidity and recurrence rate?Journal of Oral and Maxillofacial Surgery2018;76(3):647-55. [DOI: 10.1016/j.joms.2017.08.002]">Rastogi 2018</a>). </p> </section> <section id="CD006205-sec-0050"> <h4 class="title">Incomplete outcome data</h4> <p>We judged 12 trials at low risk of bias with regard to incomplete outcome data because all the randomised participants were adequately accounted for in the outcome evaluation. Of the remaining trials, we assessed two at high risk of attrition bias (<a href="./references#CD006205-bbs2-0002" title='BierJ , HowaldtHP , PitzH , 4th German-Austrian-Swiss Study Group therapy study. Prospective, randomized, clinical study of squamous cell cancer of the mouth: "Radical neck dissection versus conservative neck dissection". Fortschritte der Kiefer- und Gesichts-Chirurgie1992;37:108-10. BierJ , SchlumsD , MetelmannH , HowaldtHP , PitzH . A comparison of radical and conservative neck dissection. International Journal of Oral &amp; Maxillofacial Surgery1993;22(2):102-7. BierJ . Radical neck dissection versus conservative neck dissection for squamous cell carcinoma of the oral cavity. Recent Results in Cancer Research1994;134:57-62. '>Bier 1994</a>; <a href="./references#CD006205-bbs2-0004" title="FakihAR , RaoRS , BorgesAM , PatelAR . Elective versus therapeutic neck dissection in early carcinoma of the oral tongue. American Journal of Surgery1989;158(4):309-13. FakihAR , RaoRS , PatelAR . Prophylactic neck dissection in squamous cell carcinoma of oral tongue: a prospective randomized study. Seminars in Surgical Oncology1989;5(5):327-30. ">Fakih 1989</a>), and one at unclear risk (<a href="./references#CD006205-bbs2-0003" title="D'CruzA . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment&quot; [personal communication]. Email to: H Worthington 6 February 2023. D'CruzAK , VaishR , KapreN , DandekarM , GuptaS , HawaldarR , et al. Elective versus therapeutic neck dissection in node-negative oral cancer. New England Journal of Medicine2015;373(6):521-9. [DOI: 10.1056/NEJMoa1506007]NCT00193765. Elective vs therapeutic neck dissection in treatment of early node negative squamous carcinoma of oral cavity. www.clinicaltrials.gov/ct2/show/NCT00193765 (first received 19 September 2005). ">D'Cruz 2015</a>). Both <a href="./references#CD006205-bbs2-0002" title='BierJ , HowaldtHP , PitzH , 4th German-Austrian-Swiss Study Group therapy study. Prospective, randomized, clinical study of squamous cell cancer of the mouth: "Radical neck dissection versus conservative neck dissection". Fortschritte der Kiefer- und Gesichts-Chirurgie1992;37:108-10. BierJ , SchlumsD , MetelmannH , HowaldtHP , PitzH . A comparison of radical and conservative neck dissection. International Journal of Oral &amp; Maxillofacial Surgery1993;22(2):102-7. BierJ . Radical neck dissection versus conservative neck dissection for squamous cell carcinoma of the oral cavity. Recent Results in Cancer Research1994;134:57-62. '>Bier 1994</a> and <a href="./references#CD006205-bbs2-0004" title="FakihAR , RaoRS , BorgesAM , PatelAR . Elective versus therapeutic neck dissection in early carcinoma of the oral tongue. American Journal of Surgery1989;158(4):309-13. FakihAR , RaoRS , PatelAR . Prophylactic neck dissection in squamous cell carcinoma of oral tongue: a prospective randomized study. Seminars in Surgical Oncology1989;5(5):327-30. ">Fakih 1989</a> presented an interim analysis of a subgroup of participants and have not published the final analysis as far as we are aware. In both trials, it was unclear how many participants were randomly allocated to each intervention group, and how many in each group were subsequently excluded from the analysis or analysed in a group other than that to which they were originally allocated (or both). It is likely that those excluded from the analysis (because they refused surgery or had extracapsular rupture during surgery) had a different outcome from those included in the analysis. </p> </section> <section id="CD006205-sec-0051"> <h4 class="title">Selective reporting</h4> <p>We considered 14 trials at low risk of reporting bias because they reported expected, clinically important outcomes. <a href="./references#CD006205-bbs2-0012" title='NCT00847717. Trial of IIb preserving neck dissection. clinicaltrials.gov/ct2/show/NCT00847717 (first received 19 February 2009). PandeyM , KarthikeyanS , JoshiD , KumarM , ShuklaM . Results of a randomized controlled trial of level IIb preserving neck dissection in clinically node-negative squamous carcinoma of the oral cavity. World Journal of Surgical Oncology2018;16(1):219. [DOI: 10.1186/s12957-018-1518-z] [PMID: 30409212]PandeyM . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 2 February 2023. '>Pandey 2018</a> presented insufficient data on survival so was at unclear risk. </p> </section> <section id="CD006205-sec-0052"> <h4 class="title">Other potential sources of bias</h4> <p>We judged nine trials at low risk of other bias because the intervention groups appeared to be similar at baseline, and we identified no other sources of bias (<a href="./references#CD006205-bbs2-0001" title="Brazilian Head and Neck Cancer Study Group. Results of a prospective trial on elective modified radical classical versus supraomohyoid neck dissection in the management of oral squamous carcinoma. American Journal of Surgery1998;176(5):422-7. ">BHNCSG 1998</a>; <a href="./references#CD006205-bbs2-0003" title="D'CruzA . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment&quot; [personal communication]. Email to: H Worthington 6 February 2023. D'CruzAK , VaishR , KapreN , DandekarM , GuptaS , HawaldarR , et al. Elective versus therapeutic neck dissection in node-negative oral cancer. New England Journal of Medicine2015;373(6):521-9. [DOI: 10.1056/NEJMoa1506007]NCT00193765. Elective vs therapeutic neck dissection in treatment of early node negative squamous carcinoma of oral cavity. www.clinicaltrials.gov/ct2/show/NCT00193765 (first received 19 September 2005). ">D'Cruz 2015</a>; <a href="./references#CD006205-bbs2-0005" title="GarrelR , PerriardF , FavierV , RichardF , Pierre DauresJ , De BoutrayM . Equivalence randomized trial comparing treatment based on sentinel node biopsy versus neck dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States2020;38(Suppl 15):6501. GarrelR , PoissonnetG , Moyà PlanaA , FakhryN , DolivetG , LallemantB , et al. Equivalence randomized trial to compare treatment on the basis of sentinel node biopsy versus neck node dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology2020;38(34):4010-18. [DOI: 10.1200/JCO.20.01661]NCT02855723. Randomized, open-label economic and medical study on the lymph node management of squamous cell carcinoma of the oral cavity and oropharynx tumor Stage 1 or 2, nodes 0 (T1-T2 N0) operable (SentiMERORL). clinicaltrials.gov/ct2/show/NCT02855723 (first received 4 August 2016). ">Garrel 2020</a>; <a href="./references#CD006205-bbs2-0006" title="GuoCB , FengZ , ZhangJG , PengX , CaiZG , MaoC , et al. Supraomohyoid neck dissection and modified radical neck dissection for clinically node-negative oral squamous cell carcinoma: a prospective study of prognosis, complications and quality of life. Journal of Craniofacial Surgery2014;42(8):1885-90. [DOI: 10.1016/j.jcms.2014.07.007]">Guo 2014</a>; <a href="./references#CD006205-bbs2-0007" title="HutchisonIL , RidoutF , CheungSM , ShahN , HardeeP , SurwaldC , et al. Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort. British Journal of Cancer2019;121(10):827-36. [DOI: 0.1038/s41416-019-0587-2] [PMID: 31611612]ISRCTN65018995. The role of selective neck dissection in patients with early oral squamous cell carcinoma (1-3cm primary size) and no clinical evidence of lymph node metastases in the neck (N0). www.isrctn.com/ISRCTN65018995 (first received 23 April 2010). NCT00571883. Neck surgery in treating patients with early-stage oral cancer. clinicaltrials.gov/ct2/show/NCT00571883 (first received 12 December 2007). ">Hutchison 2019</a>; <a href="./references#CD006205-bbs2-0010" title='ISRCTN13735240. A multicentre randomised phase III trial comparing positron emission tomography–computed tomography guided watch and wait policy versus planned NECK dissection for the management of locally advanced (N2/N3) nodal metastases in patients with head and neck squamous cancer. www.isrctn.com/ISRCTN13735240 (first received 21 May 2007). MehannaH , McConkeyCC , RahmanJK , Wong W-L, SmithAF , NuttingC , et al. PET-NECK a multicentre randomised phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer. Health Technology Assessment2017;21:17. [DOI: 10.3310/hta21170]MehannaH , Wong W-L, McConkeyCC , RahmanJK , RobinsonM , HartleyAG , et al. PET-CT surveillance versus neck dissection in advanced head and neck cancer. New England Journal of Medicine2016;374(15):1444-54. [DOI: 10.1056/NEJMoa1514493]MehannaH . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 31 January 2023. '>Mehanna 2017</a>; <a href="./references#CD006205-bbs2-0011" title="FabianA , KrugD . Radiotherapy versus transoral robotic surgery for primary treatment of oropharyngeal squamous cell carcinoma: randomisation decides. Strahlentherapie und Onkologie2019;196(2):202-4. NCT01590355. A phase II randomized trial for early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs trans-oral robotic surgery (ORATOR). clinicaltrials.gov/ct2/show/NCT01590355 (first received 2 May 2012). NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. Lancet Oncology2019;20(10):1349-59. [DOI: 10.1016/S1470-2045(19)30410-3] [PMID: 31416685]NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Randomized trial of radiotherapy versus transoral robotic surgery for oropharyngeal squamous cell carcinoma: long-term results of the ORATOR trial. Journal of Clinical Oncology2022;40(8):866-75. [DOI: 10.1200/JCO.21.01961]NicholsAC , YooJ , HammondJA , FungK , WinquistE , ReadN , et al. Early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs. trans-oral robotic surgery (ORATOR) – study protocol for a randomized phase II trial. BMC Cancer2013;13:133. [DOI: 10.1186/1471-2407-13-133]PalmaDA , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus trans-oral robotic surgery for oropharyngeal squamous cell carcinoma: results of a randomized trial. Radiotherapy and Oncology2019;139(Supp 1):S39-40. ">Nichols 2019</a>; <a href="./references#CD006205-bbs2-0013" title="RastogiS , SharmaA , ChoudhuryR , TripathiS , Al WayliH , AmrithrajA , et al. Is superselective neck dissection safer than supraomohyoid neck dissection for oral carcinoma patients with N0 neck in terms of shoulder morbidity and recurrence rate?Journal of Oral and Maxillofacial Surgery2018;76(3):647-55. [DOI: 10.1016/j.joms.2017.08.002]">Rastogi 2018</a>; <a href="./references#CD006205-bbs2-0015" title="YuenAP , HoCM , ChowTL , TangLC , CheungWY , NgRW , et al. Prospective randomized study of selective neck dissection versus observation for N0 neck of early tongue carcinoma. Head &amp; Neck2009;31(6):765-72. ">Yuen 2009</a>). </p> <p>Three trials provided no information regarding the baseline characteristics of participants in each group, so these trials were at unclear risk of other bias (<a href="./references#CD006205-bbs2-0002" title='BierJ , HowaldtHP , PitzH , 4th German-Austrian-Swiss Study Group therapy study. Prospective, randomized, clinical study of squamous cell cancer of the mouth: "Radical neck dissection versus conservative neck dissection". Fortschritte der Kiefer- und Gesichts-Chirurgie1992;37:108-10. BierJ , SchlumsD , MetelmannH , HowaldtHP , PitzH . A comparison of radical and conservative neck dissection. International Journal of Oral &amp; Maxillofacial Surgery1993;22(2):102-7. BierJ . Radical neck dissection versus conservative neck dissection for squamous cell carcinoma of the oral cavity. Recent Results in Cancer Research1994;134:57-62. '>Bier 1994</a>; <a href="./references#CD006205-bbs2-0004" title="FakihAR , RaoRS , BorgesAM , PatelAR . Elective versus therapeutic neck dissection in early carcinoma of the oral tongue. American Journal of Surgery1989;158(4):309-13. FakihAR , RaoRS , PatelAR . Prophylactic neck dissection in squamous cell carcinoma of oral tongue: a prospective randomized study. Seminars in Surgical Oncology1989;5(5):327-30. ">Fakih 1989</a>; <a href="./references#CD006205-bbs2-0009" title="Dr Kilgerman. Personal communcation2006. KligermanJ , LimaRA , SoaresJR , PradoL , DiasFL , FreitasEQ , et al. Supraomohyoid neck dissection in the treatment of T1/T2 squamous cell carcinoma of oral cavity. American Journal of Surgery1994;168(5):391-4. ">Kligerman 1994</a>). <a href="./references#CD006205-bbs2-0012" title='NCT00847717. Trial of IIb preserving neck dissection. clinicaltrials.gov/ct2/show/NCT00847717 (first received 19 February 2009). PandeyM , KarthikeyanS , JoshiD , KumarM , ShuklaM . Results of a randomized controlled trial of level IIb preserving neck dissection in clinically node-negative squamous carcinoma of the oral cavity. World Journal of Surgical Oncology2018;16(1):219. [DOI: 10.1186/s12957-018-1518-z] [PMID: 30409212]PandeyM . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 2 February 2023. '>Pandey 2018</a> was also at unclear risk because it provided insufficient details of the trial, and the report was published nine years after recruitment ended. </p> <p>We assessed <a href="./references#CD006205-bbs2-0014" title="Dr Robertson. Personal communication2006. RobertsonAG , SoutarDS , PaulJ , WebsterM , LeonardAG , MooreKP , et al. Early closure of a randomized trial: surgery and postoperative radiotherapy versus radiotherapy in the management of intra-oral tumours. Clinical Oncology (Royal College of Radiologists (Great Britain))1998;10(3):155-60. ">Robertson 1998</a> at high risk of other bias because it was stopped with only 35 people recruited (the planned sample size was 350 participants) because clinicians felt it was unethical to continue. While the investigators followed appropriate procedures and conducted and reported an interim analysis, it is unclear from this report whether a priori stopping rules were in place. Additionally, more than half of the participants in this trial did not receive radiotherapy as planned owing to problems with faulty equipment. This likely had a greater effect on the outcomes of the radiotherapy‐only arm of the trial. We assessed <a href="./references#CD006205-bbs2-0008" title="IyerNG , TanDS , TanVK , WangW , HwangJ , Tan N-C, et al. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. Cancer2015;121(10):1599-607. SooKC , TanEH , WeeJ , LimD , TaiBC , Khoo ML et al. Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison. British Journal of Cancer2005;8(93):279-86. [DOI: 10.1038/sj.bjc.6602696] [PMCID: PMC2361563] [PMID: 16012523]">Iyer 2015</a> at high risk of other bias because it was stopped early due to poor accrual. </p> </section> <section id="CD006205-sec-0053"> <h4 class="title">Overall risk of bias</h4> <p>We assessed four studies at high overall risk of bias (<a href="./references#CD006205-bbs2-0002" title='BierJ , HowaldtHP , PitzH , 4th German-Austrian-Swiss Study Group therapy study. Prospective, randomized, clinical study of squamous cell cancer of the mouth: "Radical neck dissection versus conservative neck dissection". Fortschritte der Kiefer- und Gesichts-Chirurgie1992;37:108-10. BierJ , SchlumsD , MetelmannH , HowaldtHP , PitzH . A comparison of radical and conservative neck dissection. International Journal of Oral &amp; Maxillofacial Surgery1993;22(2):102-7. BierJ . Radical neck dissection versus conservative neck dissection for squamous cell carcinoma of the oral cavity. Recent Results in Cancer Research1994;134:57-62. '>Bier 1994</a>; <a href="./references#CD006205-bbs2-0004" title="FakihAR , RaoRS , BorgesAM , PatelAR . Elective versus therapeutic neck dissection in early carcinoma of the oral tongue. American Journal of Surgery1989;158(4):309-13. FakihAR , RaoRS , PatelAR . Prophylactic neck dissection in squamous cell carcinoma of oral tongue: a prospective randomized study. Seminars in Surgical Oncology1989;5(5):327-30. ">Fakih 1989</a>; <a href="./references#CD006205-bbs2-0008" title="IyerNG , TanDS , TanVK , WangW , HwangJ , Tan N-C, et al. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. Cancer2015;121(10):1599-607. SooKC , TanEH , WeeJ , LimD , TaiBC , Khoo ML et al. Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison. British Journal of Cancer2005;8(93):279-86. [DOI: 10.1038/sj.bjc.6602696] [PMCID: PMC2361563] [PMID: 16012523]">Iyer 2015</a>; <a href="./references#CD006205-bbs2-0014" title="Dr Robertson. Personal communication2006. RobertsonAG , SoutarDS , PaulJ , WebsterM , LeonardAG , MooreKP , et al. Early closure of a randomized trial: surgery and postoperative radiotherapy versus radiotherapy in the management of intra-oral tumours. Clinical Oncology (Royal College of Radiologists (Great Britain))1998;10(3):155-60. ">Robertson 1998</a>), and three trials at low overall risk of bias (<a href="./references#CD006205-bbs2-0007" title="HutchisonIL , RidoutF , CheungSM , ShahN , HardeeP , SurwaldC , et al. Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort. British Journal of Cancer2019;121(10):827-36. [DOI: 0.1038/s41416-019-0587-2] [PMID: 31611612]ISRCTN65018995. The role of selective neck dissection in patients with early oral squamous cell carcinoma (1-3cm primary size) and no clinical evidence of lymph node metastases in the neck (N0). www.isrctn.com/ISRCTN65018995 (first received 23 April 2010). NCT00571883. Neck surgery in treating patients with early-stage oral cancer. clinicaltrials.gov/ct2/show/NCT00571883 (first received 12 December 2007). ">Hutchison 2019</a>; <a href="./references#CD006205-bbs2-0010" title='ISRCTN13735240. A multicentre randomised phase III trial comparing positron emission tomography–computed tomography guided watch and wait policy versus planned NECK dissection for the management of locally advanced (N2/N3) nodal metastases in patients with head and neck squamous cancer. www.isrctn.com/ISRCTN13735240 (first received 21 May 2007). MehannaH , McConkeyCC , RahmanJK , Wong W-L, SmithAF , NuttingC , et al. PET-NECK a multicentre randomised phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer. Health Technology Assessment2017;21:17. [DOI: 10.3310/hta21170]MehannaH , Wong W-L, McConkeyCC , RahmanJK , RobinsonM , HartleyAG , et al. PET-CT surveillance versus neck dissection in advanced head and neck cancer. New England Journal of Medicine2016;374(15):1444-54. [DOI: 10.1056/NEJMoa1514493]MehannaH . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 31 January 2023. '>Mehanna 2017</a>; <a href="./references#CD006205-bbs2-0011" title="FabianA , KrugD . Radiotherapy versus transoral robotic surgery for primary treatment of oropharyngeal squamous cell carcinoma: randomisation decides. Strahlentherapie und Onkologie2019;196(2):202-4. NCT01590355. A phase II randomized trial for early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs trans-oral robotic surgery (ORATOR). clinicaltrials.gov/ct2/show/NCT01590355 (first received 2 May 2012). NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. Lancet Oncology2019;20(10):1349-59. [DOI: 10.1016/S1470-2045(19)30410-3] [PMID: 31416685]NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Randomized trial of radiotherapy versus transoral robotic surgery for oropharyngeal squamous cell carcinoma: long-term results of the ORATOR trial. Journal of Clinical Oncology2022;40(8):866-75. [DOI: 10.1200/JCO.21.01961]NicholsAC , YooJ , HammondJA , FungK , WinquistE , ReadN , et al. Early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs. trans-oral robotic surgery (ORATOR) – study protocol for a randomized phase II trial. BMC Cancer2013;13:133. [DOI: 10.1186/1471-2407-13-133]PalmaDA , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus trans-oral robotic surgery for oropharyngeal squamous cell carcinoma: results of a randomized trial. Radiotherapy and Oncology2019;139(Supp 1):S39-40. ">Nichols 2019</a>), for the objective outcomes. The remaining eight trials were at unclear overall risk of bias for the objective outcomes. When considering subjective outcomes, six trials were at high risk of bias (<a href="./references#CD006205-bbs2-0005" title="GarrelR , PerriardF , FavierV , RichardF , Pierre DauresJ , De BoutrayM . Equivalence randomized trial comparing treatment based on sentinel node biopsy versus neck dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States2020;38(Suppl 15):6501. GarrelR , PoissonnetG , Moyà PlanaA , FakhryN , DolivetG , LallemantB , et al. Equivalence randomized trial to compare treatment on the basis of sentinel node biopsy versus neck node dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology2020;38(34):4010-18. [DOI: 10.1200/JCO.20.01661]NCT02855723. Randomized, open-label economic and medical study on the lymph node management of squamous cell carcinoma of the oral cavity and oropharynx tumor Stage 1 or 2, nodes 0 (T1-T2 N0) operable (SentiMERORL). clinicaltrials.gov/ct2/show/NCT02855723 (first received 4 August 2016). ">Garrel 2020</a>; <a href="./references#CD006205-bbs2-0006" title="GuoCB , FengZ , ZhangJG , PengX , CaiZG , MaoC , et al. Supraomohyoid neck dissection and modified radical neck dissection for clinically node-negative oral squamous cell carcinoma: a prospective study of prognosis, complications and quality of life. Journal of Craniofacial Surgery2014;42(8):1885-90. [DOI: 10.1016/j.jcms.2014.07.007]">Guo 2014</a>; <a href="./references#CD006205-bbs2-0010" title='ISRCTN13735240. A multicentre randomised phase III trial comparing positron emission tomography–computed tomography guided watch and wait policy versus planned NECK dissection for the management of locally advanced (N2/N3) nodal metastases in patients with head and neck squamous cancer. www.isrctn.com/ISRCTN13735240 (first received 21 May 2007). MehannaH , McConkeyCC , RahmanJK , Wong W-L, SmithAF , NuttingC , et al. PET-NECK a multicentre randomised phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer. Health Technology Assessment2017;21:17. [DOI: 10.3310/hta21170]MehannaH , Wong W-L, McConkeyCC , RahmanJK , RobinsonM , HartleyAG , et al. PET-CT surveillance versus neck dissection in advanced head and neck cancer. New England Journal of Medicine2016;374(15):1444-54. [DOI: 10.1056/NEJMoa1514493]MehannaH . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 31 January 2023. '>Mehanna 2017</a>; <a href="./references#CD006205-bbs2-0011" title="FabianA , KrugD . Radiotherapy versus transoral robotic surgery for primary treatment of oropharyngeal squamous cell carcinoma: randomisation decides. Strahlentherapie und Onkologie2019;196(2):202-4. NCT01590355. A phase II randomized trial for early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs trans-oral robotic surgery (ORATOR). clinicaltrials.gov/ct2/show/NCT01590355 (first received 2 May 2012). NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. Lancet Oncology2019;20(10):1349-59. [DOI: 10.1016/S1470-2045(19)30410-3] [PMID: 31416685]NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Randomized trial of radiotherapy versus transoral robotic surgery for oropharyngeal squamous cell carcinoma: long-term results of the ORATOR trial. Journal of Clinical Oncology2022;40(8):866-75. [DOI: 10.1200/JCO.21.01961]NicholsAC , YooJ , HammondJA , FungK , WinquistE , ReadN , et al. Early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs. trans-oral robotic surgery (ORATOR) – study protocol for a randomized phase II trial. BMC Cancer2013;13:133. [DOI: 10.1186/1471-2407-13-133]PalmaDA , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus trans-oral robotic surgery for oropharyngeal squamous cell carcinoma: results of a randomized trial. Radiotherapy and Oncology2019;139(Supp 1):S39-40. ">Nichols 2019</a>; <a href="./references#CD006205-bbs2-0012" title='NCT00847717. Trial of IIb preserving neck dissection. clinicaltrials.gov/ct2/show/NCT00847717 (first received 19 February 2009). PandeyM , KarthikeyanS , JoshiD , KumarM , ShuklaM . Results of a randomized controlled trial of level IIb preserving neck dissection in clinically node-negative squamous carcinoma of the oral cavity. World Journal of Surgical Oncology2018;16(1):219. [DOI: 10.1186/s12957-018-1518-z] [PMID: 30409212]PandeyM . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 2 February 2023. '>Pandey 2018</a>; <a href="./references#CD006205-bbs2-0013" title="RastogiS , SharmaA , ChoudhuryR , TripathiS , Al WayliH , AmrithrajA , et al. Is superselective neck dissection safer than supraomohyoid neck dissection for oral carcinoma patients with N0 neck in terms of shoulder morbidity and recurrence rate?Journal of Oral and Maxillofacial Surgery2018;76(3):647-55. [DOI: 10.1016/j.joms.2017.08.002]">Rastogi 2018</a>), and only <a href="./references#CD006205-bbs2-0007" title="HutchisonIL , RidoutF , CheungSM , ShahN , HardeeP , SurwaldC , et al. Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort. British Journal of Cancer2019;121(10):827-36. [DOI: 0.1038/s41416-019-0587-2] [PMID: 31611612]ISRCTN65018995. The role of selective neck dissection in patients with early oral squamous cell carcinoma (1-3cm primary size) and no clinical evidence of lymph node metastases in the neck (N0). www.isrctn.com/ISRCTN65018995 (first received 23 April 2010). NCT00571883. Neck surgery in treating patients with early-stage oral cancer. clinicaltrials.gov/ct2/show/NCT00571883 (first received 12 December 2007). ">Hutchison 2019</a> was at low risk of bias overall. </p> </section> </section> <section id="CD006205-sec-0054"> <h3 class="title" id="CD006205-sec-0054">Effects of interventions</h3> <p>See: <a href="./full#CD006205-tbl-0001"><b>Summary of findings 1</b> Elective neck dissection versus therapeutic (delayed) neck dissection</a>; <a href="./full#CD006205-tbl-0002"><b>Summary of findings 2</b> Elective radical neck dissection versus elective selective neck dissection</a>; <a href="./full#CD006205-tbl-0003"><b>Summary of findings 3</b> Superselective neck dissection versus selective neck dissection</a>; <a href="./full#CD006205-tbl-0004"><b>Summary of findings 4</b> Supraomohyoid neck dissection versus modified radical neck dissection</a>; <a href="./full#CD006205-tbl-0005"><b>Summary of findings 5</b> Sentinel node biopsy versus elective neck dissection</a>; <a href="./full#CD006205-tbl-0006"><b>Summary of findings 6</b> PET‐CT following chemoradiotherapy versus planned neck dissection before or after chemoradiotherapy</a>; <a href="./full#CD006205-tbl-0007"><b>Summary of findings 7</b> Surgery plus radiotherapy versus radiotherapy alone</a>; <a href="./full#CD006205-tbl-0008"><b>Summary of findings 8</b> Surgery versus radiotherapy alone</a>; <a href="./full#CD006205-tbl-0009"><b>Summary of findings 9</b> Surgery plus adjuvant radiotherapy versus chemotherapy</a> </p> <section id="CD006205-sec-0055"> <h4 class="title">Comparison 1: elective neck dissection versus therapeutic (delayed) neck dissection</h4> <p>See <a href="./full#CD006205-tbl-0001">summary of findings Table 1</a>. </p> <p>Five trials compared the timing of the neck dissection: one group had neck dissection at the same time as primary tumour resection, while the other group had a separate procedure for neck dissection after primary tumour resection only when there was clinical evidence of disease in the neck nodes (<a href="./references#CD006205-bbs2-0003" title="D'CruzA . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment&quot; [personal communication]. Email to: H Worthington 6 February 2023. D'CruzAK , VaishR , KapreN , DandekarM , GuptaS , HawaldarR , et al. Elective versus therapeutic neck dissection in node-negative oral cancer. New England Journal of Medicine2015;373(6):521-9. [DOI: 10.1056/NEJMoa1506007]NCT00193765. Elective vs therapeutic neck dissection in treatment of early node negative squamous carcinoma of oral cavity. www.clinicaltrials.gov/ct2/show/NCT00193765 (first received 19 September 2005). ">D'Cruz 2015</a>; <a href="./references#CD006205-bbs2-0004" title="FakihAR , RaoRS , BorgesAM , PatelAR . Elective versus therapeutic neck dissection in early carcinoma of the oral tongue. American Journal of Surgery1989;158(4):309-13. FakihAR , RaoRS , PatelAR . Prophylactic neck dissection in squamous cell carcinoma of oral tongue: a prospective randomized study. Seminars in Surgical Oncology1989;5(5):327-30. ">Fakih 1989</a>; <a href="./references#CD006205-bbs2-0007" title="HutchisonIL , RidoutF , CheungSM , ShahN , HardeeP , SurwaldC , et al. Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort. British Journal of Cancer2019;121(10):827-36. [DOI: 0.1038/s41416-019-0587-2] [PMID: 31611612]ISRCTN65018995. The role of selective neck dissection in patients with early oral squamous cell carcinoma (1-3cm primary size) and no clinical evidence of lymph node metastases in the neck (N0). www.isrctn.com/ISRCTN65018995 (first received 23 April 2010). NCT00571883. Neck surgery in treating patients with early-stage oral cancer. clinicaltrials.gov/ct2/show/NCT00571883 (first received 12 December 2007). ">Hutchison 2019</a>; <a href="./references#CD006205-bbs2-0009" title="Dr Kilgerman. Personal communcation2006. KligermanJ , LimaRA , SoaresJR , PradoL , DiasFL , FreitasEQ , et al. Supraomohyoid neck dissection in the treatment of T1/T2 squamous cell carcinoma of oral cavity. American Journal of Surgery1994;168(5):391-4. ">Kligerman 1994</a>; <a href="./references#CD006205-bbs2-0015" title="YuenAP , HoCM , ChowTL , TangLC , CheungWY , NgRW , et al. Prospective randomized study of selective neck dissection versus observation for N0 neck of early tongue carcinoma. Head &amp; Neck2009;31(6):765-72. ">Yuen 2009</a>). All participants had oral cavity cancers (specifically tongue or floor of mouth tumours) and clinically negative neck nodes on study entry. </p> <p><a href="./references#CD006205-bbs2-0004" title="FakihAR , RaoRS , BorgesAM , PatelAR . Elective versus therapeutic neck dissection in early carcinoma of the oral tongue. American Journal of Surgery1989;158(4):309-13. FakihAR , RaoRS , PatelAR . Prophylactic neck dissection in squamous cell carcinoma of oral tongue: a prospective randomized study. Seminars in Surgical Oncology1989;5(5):327-30. ">Fakih 1989</a> performed classical radical neck dissection procedures and pooled data after one year of follow‐up. <a href="./references#CD006205-bbs2-0003" title="D'CruzA . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment&quot; [personal communication]. Email to: H Worthington 6 February 2023. D'CruzAK , VaishR , KapreN , DandekarM , GuptaS , HawaldarR , et al. Elective versus therapeutic neck dissection in node-negative oral cancer. New England Journal of Medicine2015;373(6):521-9. [DOI: 10.1056/NEJMoa1506007]NCT00193765. Elective vs therapeutic neck dissection in treatment of early node negative squamous carcinoma of oral cavity. www.clinicaltrials.gov/ct2/show/NCT00193765 (first received 19 September 2005). ">D'Cruz 2015</a>, <a href="./references#CD006205-bbs2-0007" title="HutchisonIL , RidoutF , CheungSM , ShahN , HardeeP , SurwaldC , et al. Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort. British Journal of Cancer2019;121(10):827-36. [DOI: 0.1038/s41416-019-0587-2] [PMID: 31611612]ISRCTN65018995. The role of selective neck dissection in patients with early oral squamous cell carcinoma (1-3cm primary size) and no clinical evidence of lymph node metastases in the neck (N0). www.isrctn.com/ISRCTN65018995 (first received 23 April 2010). NCT00571883. Neck surgery in treating patients with early-stage oral cancer. clinicaltrials.gov/ct2/show/NCT00571883 (first received 12 December 2007). ">Hutchison 2019</a>, and <a href="./references#CD006205-bbs2-0015" title="YuenAP , HoCM , ChowTL , TangLC , CheungWY , NgRW , et al. Prospective randomized study of selective neck dissection versus observation for N0 neck of early tongue carcinoma. Head &amp; Neck2009;31(6):765-72. ">Yuen 2009</a> performed elective selective neck dissection of level I to III nodes; <a href="./references#CD006205-bbs2-0003" title="D'CruzA . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment&quot; [personal communication]. Email to: H Worthington 6 February 2023. D'CruzAK , VaishR , KapreN , DandekarM , GuptaS , HawaldarR , et al. Elective versus therapeutic neck dissection in node-negative oral cancer. New England Journal of Medicine2015;373(6):521-9. [DOI: 10.1056/NEJMoa1506007]NCT00193765. Elective vs therapeutic neck dissection in treatment of early node negative squamous carcinoma of oral cavity. www.clinicaltrials.gov/ct2/show/NCT00193765 (first received 19 September 2005). ">D'Cruz 2015</a> reported data at three years, <a href="./references#CD006205-bbs2-0015" title="YuenAP , HoCM , ChowTL , TangLC , CheungWY , NgRW , et al. Prospective randomized study of selective neck dissection versus observation for N0 neck of early tongue carcinoma. Head &amp; Neck2009;31(6):765-72. ">Yuen 2009</a> presented disease‐free survival data at five years, and <a href="./references#CD006205-bbs2-0007" title="HutchisonIL , RidoutF , CheungSM , ShahN , HardeeP , SurwaldC , et al. Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort. British Journal of Cancer2019;121(10):827-36. [DOI: 0.1038/s41416-019-0587-2] [PMID: 31611612]ISRCTN65018995. The role of selective neck dissection in patients with early oral squamous cell carcinoma (1-3cm primary size) and no clinical evidence of lymph node metastases in the neck (N0). www.isrctn.com/ISRCTN65018995 (first received 23 April 2010). NCT00571883. Neck surgery in treating patients with early-stage oral cancer. clinicaltrials.gov/ct2/show/NCT00571883 (first received 12 December 2007). ">Hutchison 2019</a> reported data at five years. <a href="./references#CD006205-bbs2-0009" title="Dr Kilgerman. Personal communcation2006. KligermanJ , LimaRA , SoaresJR , PradoL , DiasFL , FreitasEQ , et al. Supraomohyoid neck dissection in the treatment of T1/T2 squamous cell carcinoma of oral cavity. American Journal of Surgery1994;168(5):391-4. ">Kligerman 1994</a> used a supraomohyoid elective neck dissection procedure, and reported data after 3.5 years of follow‐up. </p> <section id="CD006205-sec-0056"> <h5 class="title">Primary outcomes</h5> <section id="CD006205-sec-0057"> <h6 class="title">Overall survival (or total mortality)</h6> <p>Four trials presented overall survival data, two as HRs (<a href="./references#CD006205-bbs2-0003" title="D'CruzA . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment&quot; [personal communication]. Email to: H Worthington 6 February 2023. D'CruzAK , VaishR , KapreN , DandekarM , GuptaS , HawaldarR , et al. Elective versus therapeutic neck dissection in node-negative oral cancer. New England Journal of Medicine2015;373(6):521-9. [DOI: 10.1056/NEJMoa1506007]NCT00193765. Elective vs therapeutic neck dissection in treatment of early node negative squamous carcinoma of oral cavity. www.clinicaltrials.gov/ct2/show/NCT00193765 (first received 19 September 2005). ">D'Cruz 2015</a>; <a href="./references#CD006205-bbs2-0007" title="HutchisonIL , RidoutF , CheungSM , ShahN , HardeeP , SurwaldC , et al. Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort. British Journal of Cancer2019;121(10):827-36. [DOI: 0.1038/s41416-019-0587-2] [PMID: 31611612]ISRCTN65018995. The role of selective neck dissection in patients with early oral squamous cell carcinoma (1-3cm primary size) and no clinical evidence of lymph node metastases in the neck (N0). www.isrctn.com/ISRCTN65018995 (first received 23 April 2010). NCT00571883. Neck surgery in treating patients with early-stage oral cancer. clinicaltrials.gov/ct2/show/NCT00571883 (first received 12 December 2007). ">Hutchison 2019</a>), and two as binary data over fixed time periods (<a href="./references#CD006205-bbs2-0004" title="FakihAR , RaoRS , BorgesAM , PatelAR . Elective versus therapeutic neck dissection in early carcinoma of the oral tongue. American Journal of Surgery1989;158(4):309-13. FakihAR , RaoRS , PatelAR . Prophylactic neck dissection in squamous cell carcinoma of oral tongue: a prospective randomized study. Seminars in Surgical Oncology1989;5(5):327-30. ">Fakih 1989</a> at one year, <a href="./references#CD006205-bbs2-0009" title="Dr Kilgerman. Personal communcation2006. KligermanJ , LimaRA , SoaresJR , PradoL , DiasFL , FreitasEQ , et al. Supraomohyoid neck dissection in the treatment of T1/T2 squamous cell carcinoma of oral cavity. American Journal of Surgery1994;168(5):391-4. ">Kligerman 1994</a> at three years), which we entered as HR data. The pooled HR for mortality showed evidence of a benefit for elective neck dissection over therapeutic neck dissection (HR 0.64, 95% CI 0.50 to 0.83; P &lt; 0.001, I<sup>2</sup> = 0%; 4 trials, 883 participants; moderate‐certainty evidence; <a href="./references#CD006205-fig-0004" title="">Analysis 1.1</a>). </p> </section> <section id="CD006205-sec-0058"> <h6 class="title">Disease‐free survival (or new disease, progression, and mortality)</h6> <p>Five trials provided data for disease‐free survival, two as HRs (<a href="./references#CD006205-bbs2-0003" title="D'CruzA . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment&quot; [personal communication]. Email to: H Worthington 6 February 2023. D'CruzAK , VaishR , KapreN , DandekarM , GuptaS , HawaldarR , et al. Elective versus therapeutic neck dissection in node-negative oral cancer. New England Journal of Medicine2015;373(6):521-9. [DOI: 10.1056/NEJMoa1506007]NCT00193765. Elective vs therapeutic neck dissection in treatment of early node negative squamous carcinoma of oral cavity. www.clinicaltrials.gov/ct2/show/NCT00193765 (first received 19 September 2005). ">D'Cruz 2015</a>; <a href="./references#CD006205-bbs2-0007" title="HutchisonIL , RidoutF , CheungSM , ShahN , HardeeP , SurwaldC , et al. Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort. British Journal of Cancer2019;121(10):827-36. [DOI: 0.1038/s41416-019-0587-2] [PMID: 31611612]ISRCTN65018995. The role of selective neck dissection in patients with early oral squamous cell carcinoma (1-3cm primary size) and no clinical evidence of lymph node metastases in the neck (N0). www.isrctn.com/ISRCTN65018995 (first received 23 April 2010). NCT00571883. Neck surgery in treating patients with early-stage oral cancer. clinicaltrials.gov/ct2/show/NCT00571883 (first received 12 December 2007). ">Hutchison 2019</a>), and three as binary data over fixed time periods (<a href="./references#CD006205-bbs2-0004" title="FakihAR , RaoRS , BorgesAM , PatelAR . Elective versus therapeutic neck dissection in early carcinoma of the oral tongue. American Journal of Surgery1989;158(4):309-13. FakihAR , RaoRS , PatelAR . Prophylactic neck dissection in squamous cell carcinoma of oral tongue: a prospective randomized study. Seminars in Surgical Oncology1989;5(5):327-30. ">Fakih 1989</a> at one year, <a href="./references#CD006205-bbs2-0009" title="Dr Kilgerman. Personal communcation2006. KligermanJ , LimaRA , SoaresJR , PradoL , DiasFL , FreitasEQ , et al. Supraomohyoid neck dissection in the treatment of T1/T2 squamous cell carcinoma of oral cavity. American Journal of Surgery1994;168(5):391-4. ">Kligerman 1994</a> at three years, <a href="./references#CD006205-bbs2-0015" title="YuenAP , HoCM , ChowTL , TangLC , CheungWY , NgRW , et al. Prospective randomized study of selective neck dissection versus observation for N0 neck of early tongue carcinoma. Head &amp; Neck2009;31(6):765-72. ">Yuen 2009</a> at five years), which we entered as HR data. The pooled HR for new disease, progression, and mortality showed evidence of benefit for elective neck dissection over therapeutic neck dissection (HR 0.56, 95% CI 0.45 to 0.70; P &lt; 0.001, I<sup>2</sup> = 12%; 5 trials, 954 participants; moderate‐certainty evidence; <a href="./references#CD006205-fig-0005" title="">Analysis 1.2</a>). </p> </section> <section id="CD006205-sec-0059"> <h6 class="title">Locoregional recurrence</h6> <p>Four trials reported data for locoregional recurrence; one trial presented HR data (<a href="./references#CD006205-bbs2-0007" title="HutchisonIL , RidoutF , CheungSM , ShahN , HardeeP , SurwaldC , et al. Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort. British Journal of Cancer2019;121(10):827-36. [DOI: 0.1038/s41416-019-0587-2] [PMID: 31611612]ISRCTN65018995. The role of selective neck dissection in patients with early oral squamous cell carcinoma (1-3cm primary size) and no clinical evidence of lymph node metastases in the neck (N0). www.isrctn.com/ISRCTN65018995 (first received 23 April 2010). NCT00571883. Neck surgery in treating patients with early-stage oral cancer. clinicaltrials.gov/ct2/show/NCT00571883 (first received 12 December 2007). ">Hutchison 2019</a>), and three trials presented binary data over fixed time periods, which we entered as HR data (<a href="./references#CD006205-bbs2-0003" title="D'CruzA . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment&quot; [personal communication]. Email to: H Worthington 6 February 2023. D'CruzAK , VaishR , KapreN , DandekarM , GuptaS , HawaldarR , et al. Elective versus therapeutic neck dissection in node-negative oral cancer. New England Journal of Medicine2015;373(6):521-9. [DOI: 10.1056/NEJMoa1506007]NCT00193765. Elective vs therapeutic neck dissection in treatment of early node negative squamous carcinoma of oral cavity. www.clinicaltrials.gov/ct2/show/NCT00193765 (first received 19 September 2005). ">D'Cruz 2015</a>; <a href="./references#CD006205-bbs2-0004" title="FakihAR , RaoRS , BorgesAM , PatelAR . Elective versus therapeutic neck dissection in early carcinoma of the oral tongue. American Journal of Surgery1989;158(4):309-13. FakihAR , RaoRS , PatelAR . Prophylactic neck dissection in squamous cell carcinoma of oral tongue: a prospective randomized study. Seminars in Surgical Oncology1989;5(5):327-30. ">Fakih 1989</a>; <a href="./references#CD006205-bbs2-0009" title="Dr Kilgerman. Personal communcation2006. KligermanJ , LimaRA , SoaresJR , PradoL , DiasFL , FreitasEQ , et al. Supraomohyoid neck dissection in the treatment of T1/T2 squamous cell carcinoma of oral cavity. American Journal of Surgery1994;168(5):391-4. ">Kligerman 1994</a>). The pooled HR showed evidence of a benefit for elective neck dissection over therapeutic neck dissection (HR 0.58, 95% CI 0.43 to 0.78; P &lt; 0.001, I<sup>2</sup> = 0%; 4 trials, 458 participants; moderate‐certainty evidence; <a href="./references#CD006205-fig-0006" title="">Analysis 1.3</a>). </p> </section> <section id="CD006205-sec-0060"> <h6 class="title">Recurrence</h6> <p>All five trials reported recurrence (as distinct from locoregional recurrence); however, we were unable to use the data from <a href="./references#CD006205-bbs2-0007" title="HutchisonIL , RidoutF , CheungSM , ShahN , HardeeP , SurwaldC , et al. Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort. British Journal of Cancer2019;121(10):827-36. [DOI: 0.1038/s41416-019-0587-2] [PMID: 31611612]ISRCTN65018995. The role of selective neck dissection in patients with early oral squamous cell carcinoma (1-3cm primary size) and no clinical evidence of lymph node metastases in the neck (N0). www.isrctn.com/ISRCTN65018995 (first received 23 April 2010). NCT00571883. Neck surgery in treating patients with early-stage oral cancer. clinicaltrials.gov/ct2/show/NCT00571883 (first received 12 December 2007). ">Hutchison 2019</a> (Table 2 in supplemental data) or <a href="./references#CD006205-bbs2-0015" title="YuenAP , HoCM , ChowTL , TangLC , CheungWY , NgRW , et al. Prospective randomized study of selective neck dissection versus observation for N0 neck of early tongue carcinoma. Head &amp; Neck2009;31(6):765-72. ">Yuen 2009</a>, as the time points of measurement differed amongst participants. The remaining three trials reported recurrence over fixed time periods (<a href="./references#CD006205-bbs2-0003" title="D'CruzA . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment&quot; [personal communication]. Email to: H Worthington 6 February 2023. D'CruzAK , VaishR , KapreN , DandekarM , GuptaS , HawaldarR , et al. Elective versus therapeutic neck dissection in node-negative oral cancer. New England Journal of Medicine2015;373(6):521-9. [DOI: 10.1056/NEJMoa1506007]NCT00193765. Elective vs therapeutic neck dissection in treatment of early node negative squamous carcinoma of oral cavity. www.clinicaltrials.gov/ct2/show/NCT00193765 (first received 19 September 2005). ">D'Cruz 2015</a>; <a href="./references#CD006205-bbs2-0004" title="FakihAR , RaoRS , BorgesAM , PatelAR . Elective versus therapeutic neck dissection in early carcinoma of the oral tongue. American Journal of Surgery1989;158(4):309-13. FakihAR , RaoRS , PatelAR . Prophylactic neck dissection in squamous cell carcinoma of oral tongue: a prospective randomized study. Seminars in Surgical Oncology1989;5(5):327-30. ">Fakih 1989</a>; <a href="./references#CD006205-bbs2-0009" title="Dr Kilgerman. Personal communcation2006. KligermanJ , LimaRA , SoaresJR , PradoL , DiasFL , FreitasEQ , et al. Supraomohyoid neck dissection in the treatment of T1/T2 squamous cell carcinoma of oral cavity. American Journal of Surgery1994;168(5):391-4. ">Kligerman 1994</a>). There was evidence of a reduction in disease recurrence in the elective neck dissection group (RR 0.58, 95% CI 0.48 to 0.70; P &lt; 0.001, I<sup>2</sup> = 0%; 3 trials, 633 participants; moderate‐certainty evidence; <a href="./references#CD006205-fig-0007" title="">Analysis 1.4</a>). </p> </section> </section> <section id="CD006205-sec-0061"> <h5 class="title">Secondary outcomes</h5> <section id="CD006205-sec-0062"> <h6 class="title">Adverse events associated with treatment</h6> <p>In <a href="./references#CD006205-bbs2-0003" title="D'CruzA . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment&quot; [personal communication]. Email to: H Worthington 6 February 2023. D'CruzAK , VaishR , KapreN , DandekarM , GuptaS , HawaldarR , et al. Elective versus therapeutic neck dissection in node-negative oral cancer. New England Journal of Medicine2015;373(6):521-9. [DOI: 10.1056/NEJMoa1506007]NCT00193765. Elective vs therapeutic neck dissection in treatment of early node negative squamous carcinoma of oral cavity. www.clinicaltrials.gov/ct2/show/NCT00193765 (first received 19 September 2005). ">D'Cruz 2015</a>, 6.6% of elective surgery participants and 3.6% of therapeutic surgery participants reported adverse events. These included neck haematoma, chyle leak, oral bleeding, postoperative infection, and anaphylaxis. <a href="./references#CD006205-bbs2-0007" title="HutchisonIL , RidoutF , CheungSM , ShahN , HardeeP , SurwaldC , et al. Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort. British Journal of Cancer2019;121(10):827-36. [DOI: 0.1038/s41416-019-0587-2] [PMID: 31611612]ISRCTN65018995. The role of selective neck dissection in patients with early oral squamous cell carcinoma (1-3cm primary size) and no clinical evidence of lymph node metastases in the neck (N0). www.isrctn.com/ISRCTN65018995 (first received 23 April 2010). NCT00571883. Neck surgery in treating patients with early-stage oral cancer. clinicaltrials.gov/ct2/show/NCT00571883 (first received 12 December 2007). ">Hutchison 2019</a> found that adverse events of any grade were more frequent in the elective neck dissection arm, and most were low‐grade events. Neck sensory and motor nerve abnormalities and problems with swallowing were more common in the elective neck dissection arm. A meta‐analysis of total adverse events showed they were more common in the elective arms (RR 1.31, 95% CI 1.11 to 1.54; P = 0.002, I<sup>2</sup> = 0; 2 trials, 746 participants; moderate‐certainty evidence; <a href="./references#CD006205-fig-0008" title="">Analysis 1.5</a>). </p> <p>The other three trials did not report adverse events (<a href="./references#CD006205-bbs2-0004" title="FakihAR , RaoRS , BorgesAM , PatelAR . Elective versus therapeutic neck dissection in early carcinoma of the oral tongue. American Journal of Surgery1989;158(4):309-13. FakihAR , RaoRS , PatelAR . Prophylactic neck dissection in squamous cell carcinoma of oral tongue: a prospective randomized study. Seminars in Surgical Oncology1989;5(5):327-30. ">Fakih 1989</a>; <a href="./references#CD006205-bbs2-0009" title="Dr Kilgerman. Personal communcation2006. KligermanJ , LimaRA , SoaresJR , PradoL , DiasFL , FreitasEQ , et al. Supraomohyoid neck dissection in the treatment of T1/T2 squamous cell carcinoma of oral cavity. American Journal of Surgery1994;168(5):391-4. ">Kligerman 1994</a>; <a href="./references#CD006205-bbs2-0015" title="YuenAP , HoCM , ChowTL , TangLC , CheungWY , NgRW , et al. Prospective randomized study of selective neck dissection versus observation for N0 neck of early tongue carcinoma. Head &amp; Neck2009;31(6):765-72. ">Yuen 2009</a>). </p> </section> <section id="CD006205-sec-0063"> <h6 class="title">Quality of life</h6> <p>Only <a href="./references#CD006205-bbs2-0007" title="HutchisonIL , RidoutF , CheungSM , ShahN , HardeeP , SurwaldC , et al. Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort. British Journal of Cancer2019;121(10):827-36. [DOI: 0.1038/s41416-019-0587-2] [PMID: 31611612]ISRCTN65018995. The role of selective neck dissection in patients with early oral squamous cell carcinoma (1-3cm primary size) and no clinical evidence of lymph node metastases in the neck (N0). www.isrctn.com/ISRCTN65018995 (first received 23 April 2010). NCT00571883. Neck surgery in treating patients with early-stage oral cancer. clinicaltrials.gov/ct2/show/NCT00571883 (first received 12 December 2007). ">Hutchison 2019</a> reported quality of life, finding similar scores in the two groups for many measures, such as emotional functioning and problems swallowing. The only statistically significant differences were for dry mouth (elective group worse) and nausea (elective group better). </p> </section> <section id="CD006205-sec-0064"> <h6 class="title">Direct and indirect costs to patients and health services</h6> <p>Only <a href="./references#CD006205-bbs2-0007" title="HutchisonIL , RidoutF , CheungSM , ShahN , HardeeP , SurwaldC , et al. Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort. British Journal of Cancer2019;121(10):827-36. [DOI: 0.1038/s41416-019-0587-2] [PMID: 31611612]ISRCTN65018995. The role of selective neck dissection in patients with early oral squamous cell carcinoma (1-3cm primary size) and no clinical evidence of lymph node metastases in the neck (N0). www.isrctn.com/ISRCTN65018995 (first received 23 April 2010). NCT00571883. Neck surgery in treating patients with early-stage oral cancer. clinicaltrials.gov/ct2/show/NCT00571883 (first received 12 December 2007). ">Hutchison 2019</a> reported resource use. The participants who had elective neck dissection spent a median of six days in hospital for the procedure, compared with two days for those who had primary tumour resection only (Wilcoxon P &lt; 0.001). </p> </section> <section id="CD006205-sec-0065"> <h6 class="title">Participant satisfaction</h6> <p>No trials reported participant satisfaction.</p> </section> </section> </section> <section id="CD006205-sec-0066"> <h4 class="title">Comparison 2: elective radical neck dissection versus elective selective neck dissection</h4> <p>See <a href="./full#CD006205-tbl-0002">summary of findings Table 2</a>. </p> <p>Two trials compared neck dissection surgery of differing extent (<a href="./references#CD006205-bbs2-0001" title="Brazilian Head and Neck Cancer Study Group. Results of a prospective trial on elective modified radical classical versus supraomohyoid neck dissection in the management of oral squamous carcinoma. American Journal of Surgery1998;176(5):422-7. ">BHNCSG 1998</a>; <a href="./references#CD006205-bbs2-0002" title='BierJ , HowaldtHP , PitzH , 4th German-Austrian-Swiss Study Group therapy study. Prospective, randomized, clinical study of squamous cell cancer of the mouth: "Radical neck dissection versus conservative neck dissection". Fortschritte der Kiefer- und Gesichts-Chirurgie1992;37:108-10. BierJ , SchlumsD , MetelmannH , HowaldtHP , PitzH . A comparison of radical and conservative neck dissection. International Journal of Oral &amp; Maxillofacial Surgery1993;22(2):102-7. BierJ . Radical neck dissection versus conservative neck dissection for squamous cell carcinoma of the oral cavity. Recent Results in Cancer Research1994;134:57-62. '>Bier 1994</a>). Owing to differences between two studies with regard to participant characteristics at baseline and surgical procedures, we did not meta‐analyse their results. </p> <p><a href="./references#CD006205-bbs2-0001" title="Brazilian Head and Neck Cancer Study Group. Results of a prospective trial on elective modified radical classical versus supraomohyoid neck dissection in the management of oral squamous carcinoma. American Journal of Surgery1998;176(5):422-7. ">BHNCSG 1998</a> evaluated a modified classical neck dissection procedure with accessory nerve preservation versus a supraomohyoid neck dissection to achieve compartmental excision of levels I to III neck nodes in 148 participants with T2 to T4 primary lesions in the oral cavity and clinically negative nodes. Following intraoperative frozen sections of the nodes, three participants in the supraomohyoid neck dissection group with histologically positive nodes underwent the modified classical neck dissection instead. </p> <p>In <a href="./references#CD006205-bbs2-0002" title='BierJ , HowaldtHP , PitzH , 4th German-Austrian-Swiss Study Group therapy study. Prospective, randomized, clinical study of squamous cell cancer of the mouth: "Radical neck dissection versus conservative neck dissection". Fortschritte der Kiefer- und Gesichts-Chirurgie1992;37:108-10. BierJ , SchlumsD , MetelmannH , HowaldtHP , PitzH . A comparison of radical and conservative neck dissection. International Journal of Oral &amp; Maxillofacial Surgery1993;22(2):102-7. BierJ . Radical neck dissection versus conservative neck dissection for squamous cell carcinoma of the oral cavity. Recent Results in Cancer Research1994;134:57-62. '>Bier 1994</a>, 104 participants with either clinically negative or positive but movable neck nodes were randomised to either a radical neck dissection or a selective neck dissection where the platysma, sternocleidomastoid muscle, internal jugular vein, and accessory nerve were left in place. Primary tumours were in the oral cavity. </p> <section id="CD006205-sec-0067"> <h5 class="title">Primary outcomes</h5> <section id="CD006205-sec-0068"> <h6 class="title">Overall survival (or total mortality)</h6> <p>There was very low‐certainty evidence of little or no difference in the HR for mortality between radical and selective neck dissection in <a href="./references#CD006205-bbs2-0001" title="Brazilian Head and Neck Cancer Study Group. Results of a prospective trial on elective modified radical classical versus supraomohyoid neck dissection in the management of oral squamous carcinoma. American Journal of Surgery1998;176(5):422-7. ">BHNCSG 1998</a> (HR 1.14, 95% CI 0.70 to 1.86; P = 0.60; 148 participants; <a href="./references#CD006205-fig-0009" title="">Analysis 2.1</a>) and in <a href="./references#CD006205-bbs2-0002" title='BierJ , HowaldtHP , PitzH , 4th German-Austrian-Swiss Study Group therapy study. Prospective, randomized, clinical study of squamous cell cancer of the mouth: "Radical neck dissection versus conservative neck dissection". Fortschritte der Kiefer- und Gesichts-Chirurgie1992;37:108-10. BierJ , SchlumsD , MetelmannH , HowaldtHP , PitzH . A comparison of radical and conservative neck dissection. International Journal of Oral &amp; Maxillofacial Surgery1993;22(2):102-7. BierJ . Radical neck dissection versus conservative neck dissection for squamous cell carcinoma of the oral cavity. Recent Results in Cancer Research1994;134:57-62. '>Bier 1994</a> (HR 0.87, 95% CI 0.41 to 1.83; P = 0.71; 104 participants; <a href="./references#CD006205-fig-0009" title="">Analysis 2.1</a>). </p> </section> <section id="CD006205-sec-0069"> <h6 class="title">Disease‐free survival (or new disease, progression, and mortality)</h6> <p>Only <a href="./references#CD006205-bbs2-0002" title='BierJ , HowaldtHP , PitzH , 4th German-Austrian-Swiss Study Group therapy study. Prospective, randomized, clinical study of squamous cell cancer of the mouth: "Radical neck dissection versus conservative neck dissection". Fortschritte der Kiefer- und Gesichts-Chirurgie1992;37:108-10. BierJ , SchlumsD , MetelmannH , HowaldtHP , PitzH . A comparison of radical and conservative neck dissection. International Journal of Oral &amp; Maxillofacial Surgery1993;22(2):102-7. BierJ . Radical neck dissection versus conservative neck dissection for squamous cell carcinoma of the oral cavity. Recent Results in Cancer Research1994;134:57-62. '>Bier 1994</a> reported disease‐free survival. There was very low‐certainty evidence of little or no difference between radical and selective neck dissection in the HR for new disease, progression, and mortality (HR 0.57, 95% CI 0.29 to 1.11; P = 0.10; 104 participants; <a href="./references#CD006205-fig-0010" title="">Analysis 2.2</a>). </p> </section> <section id="CD006205-sec-0070"> <h6 class="title">Locoregional recurrence</h6> <p>Neither trial reported locoregional recurrence.</p> </section> <section id="CD006205-sec-0071"> <h6 class="title">Recurrence</h6> <p>Only <a href="./references#CD006205-bbs2-0001" title="Brazilian Head and Neck Cancer Study Group. Results of a prospective trial on elective modified radical classical versus supraomohyoid neck dissection in the management of oral squamous carcinoma. American Journal of Surgery1998;176(5):422-7. ">BHNCSG 1998</a> provided binary data for recurrence at a fixed time point (five years). There was very low‐certainty evidence of little or no difference between radical and selective neck dissection in recurrence (RR 1.21, 95% CI 0.63 to 2.33; P = 0.56; 143 participants; <a href="./references#CD006205-fig-0011" title="">Analysis 2.3</a>). <a href="./references#CD006205-bbs2-0002" title='BierJ , HowaldtHP , PitzH , 4th German-Austrian-Swiss Study Group therapy study. Prospective, randomized, clinical study of squamous cell cancer of the mouth: "Radical neck dissection versus conservative neck dissection". Fortschritte der Kiefer- und Gesichts-Chirurgie1992;37:108-10. BierJ , SchlumsD , MetelmannH , HowaldtHP , PitzH . A comparison of radical and conservative neck dissection. International Journal of Oral &amp; Maxillofacial Surgery1993;22(2):102-7. BierJ . Radical neck dissection versus conservative neck dissection for squamous cell carcinoma of the oral cavity. Recent Results in Cancer Research1994;134:57-62. '>Bier 1994</a> reported recurrence at variable follow‐up times, so we were unable to use the data. </p> </section> </section> <section id="CD006205-sec-0072"> <h5 class="title">Secondary outcomes</h5> <section id="CD006205-sec-0073"> <h6 class="title">Adverse events associated with treatment</h6> <p><a href="./references#CD006205-bbs2-0001" title="Brazilian Head and Neck Cancer Study Group. Results of a prospective trial on elective modified radical classical versus supraomohyoid neck dissection in the management of oral squamous carcinoma. American Journal of Surgery1998;176(5):422-7. ">BHNCSG 1998</a> reported the following adverse events: flap necrosis, wound infection, fistula, vascular rupture, haematoma, seroma, and chyle fistula. There were no complications in 45/76 participants in the modified radical neck dissection group and in 54/72 participants in the supraomohyoid neck dissection group. There were two postoperative deaths in the modified radical neck dissection group and one in the supraomohyoid neck dissection group. </p> </section> <section id="CD006205-sec-0074"> <h6 class="title">Quality of life</h6> <p>Neither trial reported quality of life.</p> </section> <section id="CD006205-sec-0075"> <h6 class="title">Direct and indirect costs to patients and health services</h6> <p>Neither trial reported costs.</p> </section> <section id="CD006205-sec-0076"> <h6 class="title">Participant satisfaction</h6> <p>Neither trial reported participant satisfaction.</p> </section> </section> </section> <section id="CD006205-sec-0077"> <h4 class="title">Comparison 3: superselective neck dissection versus selective neck dissection</h4> <p>See <a href="./full#CD006205-tbl-0003">summary of findings Table 3</a>. </p> <p>Two trials evaluated superselective neck dissection versus selective neck dissection in participants with oral cavity cancer and clinically negative neck nodes (<a href="./references#CD006205-bbs2-0012" title='NCT00847717. Trial of IIb preserving neck dissection. clinicaltrials.gov/ct2/show/NCT00847717 (first received 19 February 2009). PandeyM , KarthikeyanS , JoshiD , KumarM , ShuklaM . Results of a randomized controlled trial of level IIb preserving neck dissection in clinically node-negative squamous carcinoma of the oral cavity. World Journal of Surgical Oncology2018;16(1):219. [DOI: 10.1186/s12957-018-1518-z] [PMID: 30409212]PandeyM . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 2 February 2023. '>Pandey 2018</a>; <a href="./references#CD006205-bbs2-0013" title="RastogiS , SharmaA , ChoudhuryR , TripathiS , Al WayliH , AmrithrajA , et al. Is superselective neck dissection safer than supraomohyoid neck dissection for oral carcinoma patients with N0 neck in terms of shoulder morbidity and recurrence rate?Journal of Oral and Maxillofacial Surgery2018;76(3):647-55. [DOI: 10.1016/j.joms.2017.08.002]">Rastogi 2018</a>). Both were small studies: <a href="./references#CD006205-bbs2-0012" title='NCT00847717. Trial of IIb preserving neck dissection. clinicaltrials.gov/ct2/show/NCT00847717 (first received 19 February 2009). PandeyM , KarthikeyanS , JoshiD , KumarM , ShuklaM . Results of a randomized controlled trial of level IIb preserving neck dissection in clinically node-negative squamous carcinoma of the oral cavity. World Journal of Surgical Oncology2018;16(1):219. [DOI: 10.1186/s12957-018-1518-z] [PMID: 30409212]PandeyM . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 2 February 2023. '>Pandey 2018</a> included 32 people and <a href="./references#CD006205-bbs2-0013" title="RastogiS , SharmaA , ChoudhuryR , TripathiS , Al WayliH , AmrithrajA , et al. Is superselective neck dissection safer than supraomohyoid neck dissection for oral carcinoma patients with N0 neck in terms of shoulder morbidity and recurrence rate?Journal of Oral and Maxillofacial Surgery2018;76(3):647-55. [DOI: 10.1016/j.joms.2017.08.002]">Rastogi 2018</a> included 40 people. </p> <section id="CD006205-sec-0078"> <h5 class="title">Primary outcomes</h5> <section id="CD006205-sec-0079"> <h6 class="title">Overall survival (or total mortality)</h6> <p>Neither study reported overall survival.</p> </section> <section id="CD006205-sec-0080"> <h6 class="title">Disease‐free survival (or new disease, progression, and mortality)</h6> <p>Only <a href="./references#CD006205-bbs2-0012" title='NCT00847717. Trial of IIb preserving neck dissection. clinicaltrials.gov/ct2/show/NCT00847717 (first received 19 February 2009). PandeyM , KarthikeyanS , JoshiD , KumarM , ShuklaM . Results of a randomized controlled trial of level IIb preserving neck dissection in clinically node-negative squamous carcinoma of the oral cavity. World Journal of Surgical Oncology2018;16(1):219. [DOI: 10.1186/s12957-018-1518-z] [PMID: 30409212]PandeyM . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 2 February 2023. '>Pandey 2018</a> reported disease‐free survival. At a median of 36 months of follow‐up, disease‐free survival was 83% in the superselective neck dissection group and 91% in the selective neck dissection group; the difference in survival between the two groups was not statistically significant (P = 0.69; very low‐certainty evidence). Due to variable follow‐up, we were unable to analyse these data. </p> </section> <section id="CD006205-sec-0081"> <h6 class="title">Locoregional recurrence</h6> <p><a href="./references#CD006205-bbs2-0012" title='NCT00847717. Trial of IIb preserving neck dissection. clinicaltrials.gov/ct2/show/NCT00847717 (first received 19 February 2009). PandeyM , KarthikeyanS , JoshiD , KumarM , ShuklaM . Results of a randomized controlled trial of level IIb preserving neck dissection in clinically node-negative squamous carcinoma of the oral cavity. World Journal of Surgical Oncology2018;16(1):219. [DOI: 10.1186/s12957-018-1518-z] [PMID: 30409212]PandeyM . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 2 February 2023. '>Pandey 2018</a> found no difference in locoregional failure between the groups: three of 12 participants in the superselective neck dissection group and three of 20 participants in the selective neck dissection group had locoregional failure. </p> <p><a href="./references#CD006205-bbs2-0013" title="RastogiS , SharmaA , ChoudhuryR , TripathiS , Al WayliH , AmrithrajA , et al. Is superselective neck dissection safer than supraomohyoid neck dissection for oral carcinoma patients with N0 neck in terms of shoulder morbidity and recurrence rate?Journal of Oral and Maxillofacial Surgery2018;76(3):647-55. [DOI: 10.1016/j.joms.2017.08.002]">Rastogi 2018</a> investigated locoregional recurrence for 2.5 years using a survival analysis regression model (Kaplan‐Meier); however, we were unable to calculate HRs from the data provided. The study report stated "the P value by Kaplan‐Meier survival analysis was less than.05. Therefore, the SSND (super selective) group showed a lower rate of recurrence compared with the SND (selective group (P &lt; .5)." </p> <p>The findings from both studies were inconclusive (very low‐certainty evidence).</p> </section> <section id="CD006205-sec-0082"> <h6 class="title">Recurrence</h6> <p>Only <a href="./references#CD006205-bbs2-0012" title='NCT00847717. Trial of IIb preserving neck dissection. clinicaltrials.gov/ct2/show/NCT00847717 (first received 19 February 2009). PandeyM , KarthikeyanS , JoshiD , KumarM , ShuklaM . Results of a randomized controlled trial of level IIb preserving neck dissection in clinically node-negative squamous carcinoma of the oral cavity. World Journal of Surgical Oncology2018;16(1):219. [DOI: 10.1186/s12957-018-1518-z] [PMID: 30409212]PandeyM . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 2 February 2023. '>Pandey 2018</a> reported recurrence, but the participants had variable follow‐up times, so we were unable to use the data. </p> </section> </section> <section id="CD006205-sec-0083"> <h5 class="title">Secondary outcomes</h5> <section id="CD006205-sec-0084"> <h6 class="title">Adverse events associated with treatment</h6> <p>Neither study reported adverse events.</p> </section> <section id="CD006205-sec-0085"> <h6 class="title">Quality of life</h6> <p>Both studies investigated shoulder function. <a href="./references#CD006205-bbs2-0012" title='NCT00847717. Trial of IIb preserving neck dissection. clinicaltrials.gov/ct2/show/NCT00847717 (first received 19 February 2009). PandeyM , KarthikeyanS , JoshiD , KumarM , ShuklaM . Results of a randomized controlled trial of level IIb preserving neck dissection in clinically node-negative squamous carcinoma of the oral cavity. World Journal of Surgical Oncology2018;16(1):219. [DOI: 10.1186/s12957-018-1518-z] [PMID: 30409212]PandeyM . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 2 February 2023. '>Pandey 2018</a> reported significant differences in shoulder abduction between one and six months favouring the superselective group, but not at 12 months. There were no reported differences for shoulder flexion. <a href="./references#CD006205-bbs2-0013" title="RastogiS , SharmaA , ChoudhuryR , TripathiS , Al WayliH , AmrithrajA , et al. Is superselective neck dissection safer than supraomohyoid neck dissection for oral carcinoma patients with N0 neck in terms of shoulder morbidity and recurrence rate?Journal of Oral and Maxillofacial Surgery2018;76(3):647-55. [DOI: 10.1016/j.joms.2017.08.002]">Rastogi 2018</a> analysed data for shoulder morbidity subjectively and objectively. The results for both measures showed less shoulder morbidity and improved quality of life for superselective neck dissection compared with selective neck dissection. Only P values were presented, so we were unable to use the data. </p> <p><a href="./references#CD006205-bbs2-0013" title="RastogiS , SharmaA , ChoudhuryR , TripathiS , Al WayliH , AmrithrajA , et al. Is superselective neck dissection safer than supraomohyoid neck dissection for oral carcinoma patients with N0 neck in terms of shoulder morbidity and recurrence rate?Journal of Oral and Maxillofacial Surgery2018;76(3):647-55. [DOI: 10.1016/j.joms.2017.08.002]">Rastogi 2018</a> performed subjective analysis measuring shoulder morbidity using the Neck Dissection Quality of Life (ND‐QOL) questionnaire. Data showed that the mean score for the superselective neck dissection group (30.4) was significantly higher (P = 0.01) than for the selective neck dissection group (19.4). </p> <p><a href="./references#CD006205-bbs2-0012" title='NCT00847717. Trial of IIb preserving neck dissection. clinicaltrials.gov/ct2/show/NCT00847717 (first received 19 February 2009). PandeyM , KarthikeyanS , JoshiD , KumarM , ShuklaM . Results of a randomized controlled trial of level IIb preserving neck dissection in clinically node-negative squamous carcinoma of the oral cavity. World Journal of Surgical Oncology2018;16(1):219. [DOI: 10.1186/s12957-018-1518-z] [PMID: 30409212]PandeyM . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 2 February 2023. '>Pandey 2018</a> found no significant difference in quality of life between the two groups. <a href="./references#CD006205-bbs2-0013" title="RastogiS , SharmaA , ChoudhuryR , TripathiS , Al WayliH , AmrithrajA , et al. Is superselective neck dissection safer than supraomohyoid neck dissection for oral carcinoma patients with N0 neck in terms of shoulder morbidity and recurrence rate?Journal of Oral and Maxillofacial Surgery2018;76(3):647-55. [DOI: 10.1016/j.joms.2017.08.002]">Rastogi 2018</a> stated that quality of life measured by the ND‐QOL was significantly better in the superselective neck dissection group than in the selective neck dissection group. There were no other data presented to confirm this position, other than the scores on the ND‐QOL questionnaire. </p> <p>The findings from both studies were inconclusive (very low‐certainty evidence).</p> </section> <section id="CD006205-sec-0086"> <h6 class="title">Direct and indirect costs to patients and health services</h6> <p>Neither study reported costs.</p> </section> <section id="CD006205-sec-0087"> <h6 class="title">Participant satisfaction</h6> <p>Neither study reported participant satisfaction.</p> </section> </section> </section> <section id="CD006205-sec-0088"> <h4 class="title">Comparison 4: supraomohyoid neck dissection versus modified radical neck dissection</h4> <p>See <a href="./full#CD006205-tbl-0004">summary of findings Table 4</a>. </p> <p>One trial evaluated supraomohyoid neck dissection versus modified radical neck dissection (<a href="./references#CD006205-bbs2-0006" title="GuoCB , FengZ , ZhangJG , PengX , CaiZG , MaoC , et al. Supraomohyoid neck dissection and modified radical neck dissection for clinically node-negative oral squamous cell carcinoma: a prospective study of prognosis, complications and quality of life. Journal of Craniofacial Surgery2014;42(8):1885-90. [DOI: 10.1016/j.jcms.2014.07.007]">Guo 2014</a>). Participants had oral cavity or oropharyngeal cancer, T1 to T4 tumours, and neck nodes clinically staged as N0 to N2. </p> <section id="CD006205-sec-0089"> <h5 class="title">Primary outcomes</h5> <section id="CD006205-sec-0090"> <h6 class="title">Overall survival (or total mortality)</h6> <p><a href="./references#CD006205-bbs2-0006" title="GuoCB , FengZ , ZhangJG , PengX , CaiZG , MaoC , et al. Supraomohyoid neck dissection and modified radical neck dissection for clinically node-negative oral squamous cell carcinoma: a prospective study of prognosis, complications and quality of life. Journal of Craniofacial Surgery2014;42(8):1885-90. [DOI: 10.1016/j.jcms.2014.07.007]">Guo 2014</a> reported overall survival during the follow‐up period but with different follow‐up times, so we could not analyse the data. The study report stated "During the follow‐up period 113 (35.1%) of the 322 patients died (SOND [supraomohyoid neck dissection]: 53 cases, MRND [modified radical neck dissection]: 60 cases)". </p> </section> <section id="CD006205-sec-0091"> <h6 class="title">Disease‐free survival (or new disease, progression, and mortality)</h6> <p><a href="./references#CD006205-bbs2-0006" title="GuoCB , FengZ , ZhangJG , PengX , CaiZG , MaoC , et al. Supraomohyoid neck dissection and modified radical neck dissection for clinically node-negative oral squamous cell carcinoma: a prospective study of prognosis, complications and quality of life. Journal of Craniofacial Surgery2014;42(8):1885-90. [DOI: 10.1016/j.jcms.2014.07.007]">Guo 2014</a> did not report disease‐free survival. It did report three‐year disease‐specific survival rates, but disease‐specific survival was not an outcome of this review. </p> </section> <section id="CD006205-sec-0092"> <h6 class="title">Locoregional recurrence</h6> <p><a href="./references#CD006205-bbs2-0006" title="GuoCB , FengZ , ZhangJG , PengX , CaiZG , MaoC , et al. Supraomohyoid neck dissection and modified radical neck dissection for clinically node-negative oral squamous cell carcinoma: a prospective study of prognosis, complications and quality of life. Journal of Craniofacial Surgery2014;42(8):1885-90. [DOI: 10.1016/j.jcms.2014.07.007]">Guo 2014</a> reported locoregional recurrence, but the participants had variable follow‐up times, so we were unable to use the data. </p> </section> <section id="CD006205-sec-0093"> <h6 class="title">Recurrence</h6> <p><a href="./references#CD006205-bbs2-0006" title="GuoCB , FengZ , ZhangJG , PengX , CaiZG , MaoC , et al. Supraomohyoid neck dissection and modified radical neck dissection for clinically node-negative oral squamous cell carcinoma: a prospective study of prognosis, complications and quality of life. Journal of Craniofacial Surgery2014;42(8):1885-90. [DOI: 10.1016/j.jcms.2014.07.007]">Guo 2014</a> reported recurrence, but the participants had variable follow‐up times, so we were unable to use the data. </p> </section> </section> <section id="CD006205-sec-0094"> <h5 class="title">Secondary outcomes</h5> <section id="CD006205-sec-0095"> <h6 class="title">Adverse events associated with treatment</h6> <p><a href="./references#CD006205-bbs2-0006" title="GuoCB , FengZ , ZhangJG , PengX , CaiZG , MaoC , et al. Supraomohyoid neck dissection and modified radical neck dissection for clinically node-negative oral squamous cell carcinoma: a prospective study of prognosis, complications and quality of life. Journal of Craniofacial Surgery2014;42(8):1885-90. [DOI: 10.1016/j.jcms.2014.07.007]">Guo 2014</a> provided limited information on adverse events. The study report stated "There was a significant difference in the complication rates between both groups (SOND [supraomohyoid neck dissection] group vs. MRND [modified radical neck dissection] group: 13.0% vs. 21.9%, P = 0.040). The most frequent complication was wound infection." The report summarised other significant complications. </p> </section> <section id="CD006205-sec-0096"> <h6 class="title">Quality of life</h6> <p><a href="./references#CD006205-bbs2-0006" title="GuoCB , FengZ , ZhangJG , PengX , CaiZG , MaoC , et al. Supraomohyoid neck dissection and modified radical neck dissection for clinically node-negative oral squamous cell carcinoma: a prospective study of prognosis, complications and quality of life. Journal of Craniofacial Surgery2014;42(8):1885-90. [DOI: 10.1016/j.jcms.2014.07.007]">Guo 2014</a> assessed University of Washington Quality of Life Questionnaire (UW‐QOL) scores for all disease‐free survivors at one year after treatment (<a href="./references#CD006205-bbs2-0070" title="DeleyiannisFW , WeymullerEA , ColtreraMD . Quality of life of disease-free survivors of advanced (stage III or IV) oropharyngeal cancer. Head and Neck1997;19(6):466-73.">Deleyiannis 1997</a>); scores from nine disease‐specific domains appeared to show that supraomohyoid neck dissection was superior to modified radical neck dissection in the domains of pain relief (78.8% versus 75.2%; P = 0.013) and shoulder function (81.1% versus 68.1%; P &lt; 0.001), but not in any of the other domains (very low‐certainty evidence). </p> </section> <section id="CD006205-sec-0097"> <h6 class="title">Direct and indirect costs to patients and health services</h6> <p><a href="./references#CD006205-bbs2-0006" title="GuoCB , FengZ , ZhangJG , PengX , CaiZG , MaoC , et al. Supraomohyoid neck dissection and modified radical neck dissection for clinically node-negative oral squamous cell carcinoma: a prospective study of prognosis, complications and quality of life. Journal of Craniofacial Surgery2014;42(8):1885-90. [DOI: 10.1016/j.jcms.2014.07.007]">Guo 2014</a> did not report costs. </p> </section> <section id="CD006205-sec-0098"> <h6 class="title">Participant satisfaction</h6> <p><a href="./references#CD006205-bbs2-0006" title="GuoCB , FengZ , ZhangJG , PengX , CaiZG , MaoC , et al. Supraomohyoid neck dissection and modified radical neck dissection for clinically node-negative oral squamous cell carcinoma: a prospective study of prognosis, complications and quality of life. Journal of Craniofacial Surgery2014;42(8):1885-90. [DOI: 10.1016/j.jcms.2014.07.007]">Guo 2014</a> did not report participant satisfaction. </p> </section> </section> </section> <section id="CD006205-sec-0099"> <h4 class="title">Comparison 5: sentinel node biopsy versus elective neck dissection</h4> <p>See <a href="./full#CD006205-tbl-0005">summary of findings Table 5</a>. </p> <p>One large multicentre trial evaluated sentinel node biopsy versus elective neck dissection in people with unclear nodal status (<a href="./references#CD006205-bbs2-0005" title="GarrelR , PerriardF , FavierV , RichardF , Pierre DauresJ , De BoutrayM . Equivalence randomized trial comparing treatment based on sentinel node biopsy versus neck dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States2020;38(Suppl 15):6501. GarrelR , PoissonnetG , Moyà PlanaA , FakhryN , DolivetG , LallemantB , et al. Equivalence randomized trial to compare treatment on the basis of sentinel node biopsy versus neck node dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology2020;38(34):4010-18. [DOI: 10.1200/JCO.20.01661]NCT02855723. Randomized, open-label economic and medical study on the lymph node management of squamous cell carcinoma of the oral cavity and oropharynx tumor Stage 1 or 2, nodes 0 (T1-T2 N0) operable (SentiMERORL). clinicaltrials.gov/ct2/show/NCT02855723 (first received 4 August 2016). ">Garrel 2020</a>). In the biopsy group, the participants with a positive biopsy received a neck dissection. </p> <section id="CD006205-sec-0100"> <h5 class="title">Primary outcomes</h5> <section id="CD006205-sec-0101"> <h6 class="title">Overall survival (or total mortality)</h6> <p><a href="./references#CD006205-bbs2-0005" title="GarrelR , PerriardF , FavierV , RichardF , Pierre DauresJ , De BoutrayM . Equivalence randomized trial comparing treatment based on sentinel node biopsy versus neck dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States2020;38(Suppl 15):6501. GarrelR , PoissonnetG , Moyà PlanaA , FakhryN , DolivetG , LallemantB , et al. Equivalence randomized trial to compare treatment on the basis of sentinel node biopsy versus neck node dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology2020;38(34):4010-18. [DOI: 10.1200/JCO.20.01661]NCT02855723. Randomized, open-label economic and medical study on the lymph node management of squamous cell carcinoma of the oral cavity and oropharynx tumor Stage 1 or 2, nodes 0 (T1-T2 N0) operable (SentiMERORL). clinicaltrials.gov/ct2/show/NCT02855723 (first received 4 August 2016). ">Garrel 2020</a> provided very low‐certainty evidence of little or no difference between sentinel node biopsy and elective neck dissection in total mortality at two years (HR 0.95, 95% 0.89 to 1.02; P = 0.15; 279 participants; <a href="./references#CD006205-fig-0012" title="">Analysis 3.1</a>), and low‐certainty evidence of little or no difference at five years (HR 1.00, 95% CI 0.90 to 1.11; P = 1.00; 279 participants; <a href="./references#CD006205-fig-0012" title="">Analysis 3.1</a>). </p> </section> <section id="CD006205-sec-0102"> <h6 class="title">Disease‐free survival (or new disease, progression, and mortality)</h6> <p><a href="./references#CD006205-bbs2-0005" title="GarrelR , PerriardF , FavierV , RichardF , Pierre DauresJ , De BoutrayM . Equivalence randomized trial comparing treatment based on sentinel node biopsy versus neck dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States2020;38(Suppl 15):6501. GarrelR , PoissonnetG , Moyà PlanaA , FakhryN , DolivetG , LallemantB , et al. Equivalence randomized trial to compare treatment on the basis of sentinel node biopsy versus neck node dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology2020;38(34):4010-18. [DOI: 10.1200/JCO.20.01661]NCT02855723. Randomized, open-label economic and medical study on the lymph node management of squamous cell carcinoma of the oral cavity and oropharynx tumor Stage 1 or 2, nodes 0 (T1-T2 N0) operable (SentiMERORL). clinicaltrials.gov/ct2/show/NCT02855723 (first received 4 August 2016). ">Garrel 2020</a> provided very low‐certainty evidence of little or no difference between sentinel node biopsy and elective neck dissection in new disease, progression, and mortality at two years (HR 0.97, 95% 0.92 to 1.03; P = 0.32; 279 participants; <a href="./references#CD006205-fig-0013" title="">Analysis 3.2</a>), and low‐certainty evidence of little or no difference at five years (HR 0.98, 95% CI 0.90 to 1.07; P = 0.66; 279 participants; <a href="./references#CD006205-fig-0013" title="">Analysis 3.2</a>). </p> </section> <section id="CD006205-sec-0103"> <h6 class="title">Locoregional recurrence</h6> <p><a href="./references#CD006205-bbs2-0005" title="GarrelR , PerriardF , FavierV , RichardF , Pierre DauresJ , De BoutrayM . Equivalence randomized trial comparing treatment based on sentinel node biopsy versus neck dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States2020;38(Suppl 15):6501. GarrelR , PoissonnetG , Moyà PlanaA , FakhryN , DolivetG , LallemantB , et al. Equivalence randomized trial to compare treatment on the basis of sentinel node biopsy versus neck node dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology2020;38(34):4010-18. [DOI: 10.1200/JCO.20.01661]NCT02855723. Randomized, open-label economic and medical study on the lymph node management of squamous cell carcinoma of the oral cavity and oropharynx tumor Stage 1 or 2, nodes 0 (T1-T2 N0) operable (SentiMERORL). clinicaltrials.gov/ct2/show/NCT02855723 (first received 4 August 2016). ">Garrel 2020</a> provided very low‐certainty evidence of little or no difference between sentinel node biopsy and elective neck dissection in locoregional recurrence at two years (HR 0.98, 95% 0.88 to 1.09; P = 0.72; 279 participants; <a href="./references#CD006205-fig-0014" title="">Analysis 3.3</a>), and low‐certainty evidence of little or no difference at five years (HR 1.04, 95% CI 0.91 to 1.19; P = 0.58; 279 participants; <a href="./references#CD006205-fig-0014" title="">Analysis 3.3</a>). </p> </section> <section id="CD006205-sec-0104"> <h6 class="title">Recurrence</h6> <p><a href="./references#CD006205-bbs2-0005" title="GarrelR , PerriardF , FavierV , RichardF , Pierre DauresJ , De BoutrayM . Equivalence randomized trial comparing treatment based on sentinel node biopsy versus neck dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States2020;38(Suppl 15):6501. GarrelR , PoissonnetG , Moyà PlanaA , FakhryN , DolivetG , LallemantB , et al. Equivalence randomized trial to compare treatment on the basis of sentinel node biopsy versus neck node dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology2020;38(34):4010-18. [DOI: 10.1200/JCO.20.01661]NCT02855723. Randomized, open-label economic and medical study on the lymph node management of squamous cell carcinoma of the oral cavity and oropharynx tumor Stage 1 or 2, nodes 0 (T1-T2 N0) operable (SentiMERORL). clinicaltrials.gov/ct2/show/NCT02855723 (first received 4 August 2016). ">Garrel 2020</a> reported recurrence, but the participants had variable follow‐up times, so we were unable to use the data. </p> </section> </section> <section id="CD006205-sec-0105"> <h5 class="title">Secondary outcomes</h5> <section id="CD006205-sec-0106"> <h6 class="title">Adverse events associated with treatment</h6> <p><a href="./references#CD006205-bbs2-0005" title="GarrelR , PerriardF , FavierV , RichardF , Pierre DauresJ , De BoutrayM . Equivalence randomized trial comparing treatment based on sentinel node biopsy versus neck dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States2020;38(Suppl 15):6501. GarrelR , PoissonnetG , Moyà PlanaA , FakhryN , DolivetG , LallemantB , et al. Equivalence randomized trial to compare treatment on the basis of sentinel node biopsy versus neck node dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology2020;38(34):4010-18. [DOI: 10.1200/JCO.20.01661]NCT02855723. Randomized, open-label economic and medical study on the lymph node management of squamous cell carcinoma of the oral cavity and oropharynx tumor Stage 1 or 2, nodes 0 (T1-T2 N0) operable (SentiMERORL). clinicaltrials.gov/ct2/show/NCT02855723 (first received 4 August 2016). ">Garrel 2020</a> did not report adverse events. </p> </section> <section id="CD006205-sec-0107"> <h6 class="title">Quality of life</h6> <p><a href="./references#CD006205-bbs2-0005" title="GarrelR , PerriardF , FavierV , RichardF , Pierre DauresJ , De BoutrayM . Equivalence randomized trial comparing treatment based on sentinel node biopsy versus neck dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States2020;38(Suppl 15):6501. GarrelR , PoissonnetG , Moyà PlanaA , FakhryN , DolivetG , LallemantB , et al. Equivalence randomized trial to compare treatment on the basis of sentinel node biopsy versus neck node dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology2020;38(34):4010-18. [DOI: 10.1200/JCO.20.01661]NCT02855723. Randomized, open-label economic and medical study on the lymph node management of squamous cell carcinoma of the oral cavity and oropharynx tumor Stage 1 or 2, nodes 0 (T1-T2 N0) operable (SentiMERORL). clinicaltrials.gov/ct2/show/NCT02855723 (first received 4 August 2016). ">Garrel 2020</a> reported neck‐shoulder functional morbidity, assessed by a self‐report neck and shoulder impairment questionnaire and arm abduction test. Up to 12 months after surgery, the scores of some items on the neck‐shoulder questionnaire favoured the sentinel biopsy (limited in ability to do your work or leisure activities, limited in ability to reach objects above your head); however, there were no statistically significant differences at 24 months (data not presented). The arm abduction test showed significant benefit for the sentinel biopsy participants at two, four, and six months; however, this benefit was not apparent at 12 and 18 months. </p> </section> <section id="CD006205-sec-0108"> <h6 class="title">Direct and indirect costs to patients and health services</h6> <p><a href="./references#CD006205-bbs2-0005" title="GarrelR , PerriardF , FavierV , RichardF , Pierre DauresJ , De BoutrayM . Equivalence randomized trial comparing treatment based on sentinel node biopsy versus neck dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States2020;38(Suppl 15):6501. GarrelR , PoissonnetG , Moyà PlanaA , FakhryN , DolivetG , LallemantB , et al. Equivalence randomized trial to compare treatment on the basis of sentinel node biopsy versus neck node dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology2020;38(34):4010-18. [DOI: 10.1200/JCO.20.01661]NCT02855723. Randomized, open-label economic and medical study on the lymph node management of squamous cell carcinoma of the oral cavity and oropharynx tumor Stage 1 or 2, nodes 0 (T1-T2 N0) operable (SentiMERORL). clinicaltrials.gov/ct2/show/NCT02855723 (first received 4 August 2016). ">Garrel 2020</a> did not report costs. </p> </section> <section id="CD006205-sec-0109"> <h6 class="title">Participant satisfaction</h6> <p><a href="./references#CD006205-bbs2-0005" title="GarrelR , PerriardF , FavierV , RichardF , Pierre DauresJ , De BoutrayM . Equivalence randomized trial comparing treatment based on sentinel node biopsy versus neck dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States2020;38(Suppl 15):6501. GarrelR , PoissonnetG , Moyà PlanaA , FakhryN , DolivetG , LallemantB , et al. Equivalence randomized trial to compare treatment on the basis of sentinel node biopsy versus neck node dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology2020;38(34):4010-18. [DOI: 10.1200/JCO.20.01661]NCT02855723. Randomized, open-label economic and medical study on the lymph node management of squamous cell carcinoma of the oral cavity and oropharynx tumor Stage 1 or 2, nodes 0 (T1-T2 N0) operable (SentiMERORL). clinicaltrials.gov/ct2/show/NCT02855723 (first received 4 August 2016). ">Garrel 2020</a> did not report participant satisfaction. </p> </section> </section> </section> <section id="CD006205-sec-0110"> <h4 class="title">Comparison 6: PET‐CT following chemoradiotherapy versus planned neck dissection before or after chemoradiotherapy </h4> <p>See <a href="./full#CD006205-tbl-0006">summary of findings Table 6</a>. </p> <p><a href="./references#CD006205-bbs2-0010" title='ISRCTN13735240. A multicentre randomised phase III trial comparing positron emission tomography–computed tomography guided watch and wait policy versus planned NECK dissection for the management of locally advanced (N2/N3) nodal metastases in patients with head and neck squamous cancer. www.isrctn.com/ISRCTN13735240 (first received 21 May 2007). MehannaH , McConkeyCC , RahmanJK , Wong W-L, SmithAF , NuttingC , et al. PET-NECK a multicentre randomised phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer. Health Technology Assessment2017;21:17. [DOI: 10.3310/hta21170]MehannaH , Wong W-L, McConkeyCC , RahmanJK , RobinsonM , HartleyAG , et al. PET-CT surveillance versus neck dissection in advanced head and neck cancer. New England Journal of Medicine2016;374(15):1444-54. [DOI: 10.1056/NEJMoa1514493]MehannaH . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 31 January 2023. '>Mehanna 2017</a> evaluated PET‐CT‐guided surveillance (with neck dissection only if no response or incomplete response to chemoradiotherapy) versus planned neck dissection (either before or after chemoradiotherapy) in 564 people with nodal disease (stage N2 or N3). </p> <section id="CD006205-sec-0111"> <h5 class="title">Primary outcomes</h5> <section id="CD006205-sec-0112"> <h6 class="title">Overall survival (or total mortality)</h6> <p>There was moderate‐certainty evidence of little or no difference between PET‐CT following chemoradiotherapy and planned neck dissection before or after chemoradiotherapy in terms of their effect on total mortality (HR 0.92, 95% CI 0.65 to 1.31; P = 0.66, 564 participants; <a href="./references#CD006205-fig-0015" title="">Analysis 4.1</a>). </p> </section> <section id="CD006205-sec-0113"> <h6 class="title">Disease‐free survival (or new disease, progression, and mortality)</h6> <p><a href="./references#CD006205-bbs2-0010" title='ISRCTN13735240. A multicentre randomised phase III trial comparing positron emission tomography–computed tomography guided watch and wait policy versus planned NECK dissection for the management of locally advanced (N2/N3) nodal metastases in patients with head and neck squamous cancer. www.isrctn.com/ISRCTN13735240 (first received 21 May 2007). MehannaH , McConkeyCC , RahmanJK , Wong W-L, SmithAF , NuttingC , et al. PET-NECK a multicentre randomised phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer. Health Technology Assessment2017;21:17. [DOI: 10.3310/hta21170]MehannaH , Wong W-L, McConkeyCC , RahmanJK , RobinsonM , HartleyAG , et al. PET-CT surveillance versus neck dissection in advanced head and neck cancer. New England Journal of Medicine2016;374(15):1444-54. [DOI: 10.1056/NEJMoa1514493]MehannaH . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 31 January 2023. '>Mehanna 2017</a> provided limited data that we were unable to analyse. The study report stated "Disease‐specific mortality and mortality from other causes did not differ significantly between the two groups (P = 0.80 and 0.41, respectively, according to Gray's test for differences)." </p> </section> <section id="CD006205-sec-0114"> <h6 class="title">Locoregional recurrence</h6> <p>We calculated HRs from the two‐year locoregional recurrence rates provided in <a href="./references#CD006205-bbs2-0010" title='ISRCTN13735240. A multicentre randomised phase III trial comparing positron emission tomography–computed tomography guided watch and wait policy versus planned NECK dissection for the management of locally advanced (N2/N3) nodal metastases in patients with head and neck squamous cancer. www.isrctn.com/ISRCTN13735240 (first received 21 May 2007). MehannaH , McConkeyCC , RahmanJK , Wong W-L, SmithAF , NuttingC , et al. PET-NECK a multicentre randomised phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer. Health Technology Assessment2017;21:17. [DOI: 10.3310/hta21170]MehannaH , Wong W-L, McConkeyCC , RahmanJK , RobinsonM , HartleyAG , et al. PET-CT surveillance versus neck dissection in advanced head and neck cancer. New England Journal of Medicine2016;374(15):1444-54. [DOI: 10.1056/NEJMoa1514493]MehannaH . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 31 January 2023. '>Mehanna 2017</a>. There was moderate‐certainty evidence of little or no difference between PET‐CT following chemoradiotherapy and planned neck dissection before or after chemoradiotherapy in terms of their effect on locoregional recurrence (HR 1.00, 95% CI 0.94 to 1.06; P = 1.00; 564 participants; <a href="./references#CD006205-fig-0016" title="">Analysis 4.2</a>). </p> </section> <section id="CD006205-sec-0115"> <h6 class="title">Recurrence</h6> <p><a href="./references#CD006205-bbs2-0010" title='ISRCTN13735240. A multicentre randomised phase III trial comparing positron emission tomography–computed tomography guided watch and wait policy versus planned NECK dissection for the management of locally advanced (N2/N3) nodal metastases in patients with head and neck squamous cancer. www.isrctn.com/ISRCTN13735240 (first received 21 May 2007). MehannaH , McConkeyCC , RahmanJK , Wong W-L, SmithAF , NuttingC , et al. PET-NECK a multicentre randomised phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer. Health Technology Assessment2017;21:17. [DOI: 10.3310/hta21170]MehannaH , Wong W-L, McConkeyCC , RahmanJK , RobinsonM , HartleyAG , et al. PET-CT surveillance versus neck dissection in advanced head and neck cancer. New England Journal of Medicine2016;374(15):1444-54. [DOI: 10.1056/NEJMoa1514493]MehannaH . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 31 January 2023. '>Mehanna 2017</a> provided limited data that we were unable to analyse. The study report stated "Documented recurrence in the nodes only (without concurrent disease in the primary site) occurred in 1 patient in the planned‐surgery group and in 3 patients in the surveillance group. Distant metastases were identified in 23 patients in the planned‐surgery group and in 21 patients in the surveillance group." </p> </section> </section> <section id="CD006205-sec-0116"> <h5 class="title">Secondary outcomes</h5> <section id="CD006205-sec-0117"> <h6 class="title">Adverse events associated with treatment</h6> <p>There were 22 surgical complications after neck dissection in the surveillance group compared with 83 in the planned‐surgery group. </p> </section> <section id="CD006205-sec-0118"> <h6 class="title">Quality of life</h6> <p><a href="./references#CD006205-bbs2-0010" title='ISRCTN13735240. A multicentre randomised phase III trial comparing positron emission tomography–computed tomography guided watch and wait policy versus planned NECK dissection for the management of locally advanced (N2/N3) nodal metastases in patients with head and neck squamous cancer. www.isrctn.com/ISRCTN13735240 (first received 21 May 2007). MehannaH , McConkeyCC , RahmanJK , Wong W-L, SmithAF , NuttingC , et al. PET-NECK a multicentre randomised phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer. Health Technology Assessment2017;21:17. [DOI: 10.3310/hta21170]MehannaH , Wong W-L, McConkeyCC , RahmanJK , RobinsonM , HartleyAG , et al. PET-CT surveillance versus neck dissection in advanced head and neck cancer. New England Journal of Medicine2016;374(15):1444-54. [DOI: 10.1056/NEJMoa1514493]MehannaH . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 31 January 2023. '>Mehanna 2017</a> assessed quality of life using the European Organisation for Research and Treatment of Cancer 30‐item Quality of Life Questionnaire (EORTC QLQ‐C30). There was a small difference in mean change in global health status scores in favour of the PET‐CT group at six months after randomisation relative to the planned surgery group (difference in mean change 4.94; P = 0.09). This difference narrowed at 12 months (difference in mean change 3.03; P = 0.09) and was no longer apparent at 24 months (difference in mean change –0.81; P = 0.85). </p> </section> <section id="CD006205-sec-0119"> <h6 class="title">Direct and indirect costs to patients and health services</h6> <p><a href="./references#CD006205-bbs2-0010" title='ISRCTN13735240. A multicentre randomised phase III trial comparing positron emission tomography–computed tomography guided watch and wait policy versus planned NECK dissection for the management of locally advanced (N2/N3) nodal metastases in patients with head and neck squamous cancer. www.isrctn.com/ISRCTN13735240 (first received 21 May 2007). MehannaH , McConkeyCC , RahmanJK , Wong W-L, SmithAF , NuttingC , et al. PET-NECK a multicentre randomised phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer. Health Technology Assessment2017;21:17. [DOI: 10.3310/hta21170]MehannaH , Wong W-L, McConkeyCC , RahmanJK , RobinsonM , HartleyAG , et al. PET-CT surveillance versus neck dissection in advanced head and neck cancer. New England Journal of Medicine2016;374(15):1444-54. [DOI: 10.1056/NEJMoa1514493]MehannaH . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 31 January 2023. '>Mehanna 2017</a> undertook an economic evaluation consisting of two components: a within‐trial analysis and a decision analytic model. The primary analysis was conducted from a UK National Health Service (NHS) secondary care perspective (i.e. including NHS hospital costs). Compared with planned neck dissection, PET‐CT surveillance produced an incremental net health benefit of 0.16 quality‐of‐life years (QALYs; 95% CI 0.03 to 0.28) over the trial period, and 0.21 QALYs (95% CI 0.41 to 0.85) over the modelled lifetime horizon. </p> </section> <section id="CD006205-sec-0120"> <h6 class="title">Participant satisfaction</h6> <p><a href="./references#CD006205-bbs2-0010" title='ISRCTN13735240. A multicentre randomised phase III trial comparing positron emission tomography–computed tomography guided watch and wait policy versus planned NECK dissection for the management of locally advanced (N2/N3) nodal metastases in patients with head and neck squamous cancer. www.isrctn.com/ISRCTN13735240 (first received 21 May 2007). MehannaH , McConkeyCC , RahmanJK , Wong W-L, SmithAF , NuttingC , et al. PET-NECK a multicentre randomised phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer. Health Technology Assessment2017;21:17. [DOI: 10.3310/hta21170]MehannaH , Wong W-L, McConkeyCC , RahmanJK , RobinsonM , HartleyAG , et al. PET-CT surveillance versus neck dissection in advanced head and neck cancer. New England Journal of Medicine2016;374(15):1444-54. [DOI: 10.1056/NEJMoa1514493]MehannaH . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 31 January 2023. '>Mehanna 2017</a> did not report participant satisfaction. </p> </section> </section> </section> <section id="CD006205-sec-0121"> <h4 class="title">Comparison 7: surgery plus radiotherapy versus radiotherapy alone</h4> <p>See <a href="./full#CD006205-tbl-0007">summary of findings Table 7</a>. </p> <p>One trial evaluated surgery plus postoperative radiotherapy versus radiotherapy alone (<a href="./references#CD006205-bbs2-0014" title="Dr Robertson. Personal communication2006. RobertsonAG , SoutarDS , PaulJ , WebsterM , LeonardAG , MooreKP , et al. Early closure of a randomized trial: surgery and postoperative radiotherapy versus radiotherapy in the management of intra-oral tumours. Clinical Oncology (Royal College of Radiologists (Great Britain))1998;10(3):155-60. ">Robertson 1998</a>). Participants in the surgery group had wide local excision of the primary tumour together with either a radical neck dissection or a more selective neck dissection at the discretion of the surgeon. The investigators intended to recruit 175 people with oral cavity or oropharyngeal cancer (neck nodes clinically staged as N0 to N2) to each arm of the trial, but after recruiting 35 participants, the trial was stopped due to the high death rate in the radiotherapy alone arm. </p> <section id="CD006205-sec-0122"> <h5 class="title">Primary outcomes</h5> <section id="CD006205-sec-0123"> <h6 class="title">Overall survival (or total mortality)</h6> <p><a href="./references#CD006205-bbs2-0014" title="Dr Robertson. Personal communication2006. RobertsonAG , SoutarDS , PaulJ , WebsterM , LeonardAG , MooreKP , et al. Early closure of a randomized trial: surgery and postoperative radiotherapy versus radiotherapy in the management of intra-oral tumours. Clinical Oncology (Royal College of Radiologists (Great Britain))1998;10(3):155-60. ">Robertson 1998</a> provided data from an interim analysis of 35 participants after 23 months. The evidence for total mortality favoured the surgery group (HR 0.24, 95% CI 0.10 to 0.59; P = 0.002; 35 participants; very low‐certainty evidence; <a href="./references#CD006205-fig-0017" title="">Analysis 5.1</a>). This estimate should be interpreted with extreme caution for several reasons. First, the authors stated that "the difference in survival is likely to be inflated" due to the small number of participants in the analysis. Second, only 41% of participants in the radiotherapy only arm received their radiotherapy as planned due to problems with faulty machines, and there were several other protocol violations in the trial. Finally, in the surgery plus radiotherapy arm, 50% of participants received radiotherapy as planned, but 12% received neither surgery to the mandible nor neck dissection. </p> </section> <section id="CD006205-sec-0124"> <h6 class="title">Disease‐free survival (or new disease, progression, and mortality)</h6> <p><a href="./references#CD006205-bbs2-0014" title="Dr Robertson. Personal communication2006. RobertsonAG , SoutarDS , PaulJ , WebsterM , LeonardAG , MooreKP , et al. Early closure of a randomized trial: surgery and postoperative radiotherapy versus radiotherapy in the management of intra-oral tumours. Clinical Oncology (Royal College of Radiologists (Great Britain))1998;10(3):155-60. ">Robertson 1998</a> did not report disease‐free survival. </p> </section> <section id="CD006205-sec-0125"> <h6 class="title">Locoregional recurrence</h6> <p><a href="./references#CD006205-bbs2-0014" title="Dr Robertson. Personal communication2006. RobertsonAG , SoutarDS , PaulJ , WebsterM , LeonardAG , MooreKP , et al. Early closure of a randomized trial: surgery and postoperative radiotherapy versus radiotherapy in the management of intra-oral tumours. Clinical Oncology (Royal College of Radiologists (Great Britain))1998;10(3):155-60. ">Robertson 1998</a> did not report locoregional recurrence. </p> </section> <section id="CD006205-sec-0126"> <h6 class="title">Recurrence</h6> <p><a href="./references#CD006205-bbs2-0014" title="Dr Robertson. Personal communication2006. RobertsonAG , SoutarDS , PaulJ , WebsterM , LeonardAG , MooreKP , et al. Early closure of a randomized trial: surgery and postoperative radiotherapy versus radiotherapy in the management of intra-oral tumours. Clinical Oncology (Royal College of Radiologists (Great Britain))1998;10(3):155-60. ">Robertson 1998</a> did not report recurrence. </p> </section> </section> <section id="CD006205-sec-0127"> <h5 class="title">Secondary outcomes</h5> <section id="CD006205-sec-0128"> <h6 class="title">Adverse events associated with treatment</h6> <p><a href="./references#CD006205-bbs2-0014" title="Dr Robertson. Personal communication2006. RobertsonAG , SoutarDS , PaulJ , WebsterM , LeonardAG , MooreKP , et al. Early closure of a randomized trial: surgery and postoperative radiotherapy versus radiotherapy in the management of intra-oral tumours. Clinical Oncology (Royal College of Radiologists (Great Britain))1998;10(3):155-60. ">Robertson 1998</a> reported the following severe acute adverse events in both groups: subcutaneous fibrosis, telangiectasia (1 cm² to 4 cm²), and moderate‐to‐severe oedema, xerostomia, trismus, and dysphagia. Subcutaneous fibrosis was more prevalent in the surgery plus radiotherapy group (P = 0.042), but the prevalence of other adverse events appeared to be similar in both groups (very low‐certainty evidence). </p> </section> <section id="CD006205-sec-0129"> <h6 class="title">Quality of life</h6> <p><a href="./references#CD006205-bbs2-0014" title="Dr Robertson. Personal communication2006. RobertsonAG , SoutarDS , PaulJ , WebsterM , LeonardAG , MooreKP , et al. Early closure of a randomized trial: surgery and postoperative radiotherapy versus radiotherapy in the management of intra-oral tumours. Clinical Oncology (Royal College of Radiologists (Great Britain))1998;10(3):155-60. ">Robertson 1998</a> did not report quality of life. </p> </section> <section id="CD006205-sec-0130"> <h6 class="title">Direct and indirect costs to patients and health services</h6> <p><a href="./references#CD006205-bbs2-0014" title="Dr Robertson. Personal communication2006. RobertsonAG , SoutarDS , PaulJ , WebsterM , LeonardAG , MooreKP , et al. Early closure of a randomized trial: surgery and postoperative radiotherapy versus radiotherapy in the management of intra-oral tumours. Clinical Oncology (Royal College of Radiologists (Great Britain))1998;10(3):155-60. ">Robertson 1998</a> did not report costs. </p> </section> <section id="CD006205-sec-0131"> <h6 class="title">Participant satisfaction</h6> <p><a href="./references#CD006205-bbs2-0014" title="Dr Robertson. Personal communication2006. RobertsonAG , SoutarDS , PaulJ , WebsterM , LeonardAG , MooreKP , et al. Early closure of a randomized trial: surgery and postoperative radiotherapy versus radiotherapy in the management of intra-oral tumours. Clinical Oncology (Royal College of Radiologists (Great Britain))1998;10(3):155-60. ">Robertson 1998</a> did not report participant satisfaction. </p> </section> </section> </section> <section id="CD006205-sec-0132"> <h4 class="title">Comparison 8: surgery versus radiotherapy alone</h4> <p>See <a href="./full#CD006205-tbl-0008">summary of findings Table 8</a>. </p> <p>One trial compared transoral robotic surgery (TORS) with radiotherapy in people with oropharyngeal cancer and nodal status of N0 to N2 (<a href="./references#CD006205-bbs2-0011" title="FabianA , KrugD . Radiotherapy versus transoral robotic surgery for primary treatment of oropharyngeal squamous cell carcinoma: randomisation decides. Strahlentherapie und Onkologie2019;196(2):202-4. NCT01590355. A phase II randomized trial for early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs trans-oral robotic surgery (ORATOR). clinicaltrials.gov/ct2/show/NCT01590355 (first received 2 May 2012). NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. Lancet Oncology2019;20(10):1349-59. [DOI: 10.1016/S1470-2045(19)30410-3] [PMID: 31416685]NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Randomized trial of radiotherapy versus transoral robotic surgery for oropharyngeal squamous cell carcinoma: long-term results of the ORATOR trial. Journal of Clinical Oncology2022;40(8):866-75. [DOI: 10.1200/JCO.21.01961]NicholsAC , YooJ , HammondJA , FungK , WinquistE , ReadN , et al. Early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs. trans-oral robotic surgery (ORATOR) – study protocol for a randomized phase II trial. BMC Cancer2013;13:133. [DOI: 10.1186/1471-2407-13-133]PalmaDA , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus trans-oral robotic surgery for oropharyngeal squamous cell carcinoma: results of a randomized trial. Radiotherapy and Oncology2019;139(Supp 1):S39-40. ">Nichols 2019</a>). Concurrent chemotherapy was recommended for participants in the radiotherapy group with node‐positive disease. Participants in the TORS group underwent selective neck dissections at the time of surgery or within two weeks. </p> <section id="CD006205-sec-0133"> <h5 class="title">Primary outcomes</h5> <section id="CD006205-sec-0134"> <h6 class="title">Overall survival (or total mortality)</h6> <p><a href="./references#CD006205-bbs2-0011" title="FabianA , KrugD . Radiotherapy versus transoral robotic surgery for primary treatment of oropharyngeal squamous cell carcinoma: randomisation decides. Strahlentherapie und Onkologie2019;196(2):202-4. NCT01590355. A phase II randomized trial for early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs trans-oral robotic surgery (ORATOR). clinicaltrials.gov/ct2/show/NCT01590355 (first received 2 May 2012). NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. Lancet Oncology2019;20(10):1349-59. [DOI: 10.1016/S1470-2045(19)30410-3] [PMID: 31416685]NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Randomized trial of radiotherapy versus transoral robotic surgery for oropharyngeal squamous cell carcinoma: long-term results of the ORATOR trial. Journal of Clinical Oncology2022;40(8):866-75. [DOI: 10.1200/JCO.21.01961]NicholsAC , YooJ , HammondJA , FungK , WinquistE , ReadN , et al. Early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs. trans-oral robotic surgery (ORATOR) – study protocol for a randomized phase II trial. BMC Cancer2013;13:133. [DOI: 10.1186/1471-2407-13-133]PalmaDA , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus trans-oral robotic surgery for oropharyngeal squamous cell carcinoma: results of a randomized trial. Radiotherapy and Oncology2019;139(Supp 1):S39-40. ">Nichols 2019</a> provided low‐certainty evidence of little or no difference between TORS and radiotherapy in terms of their effect on total mortality (HR 0.83, 95% CI 0.09 to 7.46; P = 0.87; 68 participants; <a href="./references#CD006205-fig-0018" title="">Analysis 6.1</a>). </p> </section> <section id="CD006205-sec-0135"> <h6 class="title">Disease‐free survival (or new disease, progression, and mortality)</h6> <p><a href="./references#CD006205-bbs2-0011" title="FabianA , KrugD . Radiotherapy versus transoral robotic surgery for primary treatment of oropharyngeal squamous cell carcinoma: randomisation decides. Strahlentherapie und Onkologie2019;196(2):202-4. NCT01590355. A phase II randomized trial for early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs trans-oral robotic surgery (ORATOR). clinicaltrials.gov/ct2/show/NCT01590355 (first received 2 May 2012). NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. Lancet Oncology2019;20(10):1349-59. [DOI: 10.1016/S1470-2045(19)30410-3] [PMID: 31416685]NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Randomized trial of radiotherapy versus transoral robotic surgery for oropharyngeal squamous cell carcinoma: long-term results of the ORATOR trial. Journal of Clinical Oncology2022;40(8):866-75. [DOI: 10.1200/JCO.21.01961]NicholsAC , YooJ , HammondJA , FungK , WinquistE , ReadN , et al. Early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs. trans-oral robotic surgery (ORATOR) – study protocol for a randomized phase II trial. BMC Cancer2013;13:133. [DOI: 10.1186/1471-2407-13-133]PalmaDA , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus trans-oral robotic surgery for oropharyngeal squamous cell carcinoma: results of a randomized trial. Radiotherapy and Oncology2019;139(Supp 1):S39-40. ">Nichols 2019</a> provided low‐certainty evidence of little or no difference between TORS and radiotherapy in terms of their effect on new disease, progression, and mortality (HR 1.07, 95% CI 0.27 to 4.22; P = 0.92; 68 participants; <a href="./references#CD006205-fig-0019" title="">Analysis 6.2</a>). </p> </section> <section id="CD006205-sec-0136"> <h6 class="title">Locoregional recurrence</h6> <p><a href="./references#CD006205-bbs2-0011" title="FabianA , KrugD . Radiotherapy versus transoral robotic surgery for primary treatment of oropharyngeal squamous cell carcinoma: randomisation decides. Strahlentherapie und Onkologie2019;196(2):202-4. NCT01590355. A phase II randomized trial for early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs trans-oral robotic surgery (ORATOR). clinicaltrials.gov/ct2/show/NCT01590355 (first received 2 May 2012). NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. Lancet Oncology2019;20(10):1349-59. [DOI: 10.1016/S1470-2045(19)30410-3] [PMID: 31416685]NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Randomized trial of radiotherapy versus transoral robotic surgery for oropharyngeal squamous cell carcinoma: long-term results of the ORATOR trial. Journal of Clinical Oncology2022;40(8):866-75. [DOI: 10.1200/JCO.21.01961]NicholsAC , YooJ , HammondJA , FungK , WinquistE , ReadN , et al. Early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs. trans-oral robotic surgery (ORATOR) – study protocol for a randomized phase II trial. BMC Cancer2013;13:133. [DOI: 10.1186/1471-2407-13-133]PalmaDA , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus trans-oral robotic surgery for oropharyngeal squamous cell carcinoma: results of a randomized trial. Radiotherapy and Oncology2019;139(Supp 1):S39-40. ">Nichols 2019</a> reported locoregional recurrence, but the participants had variable follow‐up times, so we were unable to use the data. </p> </section> <section id="CD006205-sec-0137"> <h6 class="title">Recurrence</h6> <p><a href="./references#CD006205-bbs2-0011" title="FabianA , KrugD . Radiotherapy versus transoral robotic surgery for primary treatment of oropharyngeal squamous cell carcinoma: randomisation decides. Strahlentherapie und Onkologie2019;196(2):202-4. NCT01590355. A phase II randomized trial for early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs trans-oral robotic surgery (ORATOR). clinicaltrials.gov/ct2/show/NCT01590355 (first received 2 May 2012). NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. Lancet Oncology2019;20(10):1349-59. [DOI: 10.1016/S1470-2045(19)30410-3] [PMID: 31416685]NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Randomized trial of radiotherapy versus transoral robotic surgery for oropharyngeal squamous cell carcinoma: long-term results of the ORATOR trial. Journal of Clinical Oncology2022;40(8):866-75. [DOI: 10.1200/JCO.21.01961]NicholsAC , YooJ , HammondJA , FungK , WinquistE , ReadN , et al. Early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs. trans-oral robotic surgery (ORATOR) – study protocol for a randomized phase II trial. BMC Cancer2013;13:133. [DOI: 10.1186/1471-2407-13-133]PalmaDA , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus trans-oral robotic surgery for oropharyngeal squamous cell carcinoma: results of a randomized trial. Radiotherapy and Oncology2019;139(Supp 1):S39-40. ">Nichols 2019</a> reported recurrence, but the participants had variable follow‐up times, so we were unable to use the data. </p> </section> </section> <section id="CD006205-sec-0138"> <h5 class="title">Secondary outcomes</h5> <section id="CD006205-sec-0139"> <h6 class="title">Adverse events associated with treatment</h6> <p><a href="./references#CD006205-bbs2-0011" title="FabianA , KrugD . Radiotherapy versus transoral robotic surgery for primary treatment of oropharyngeal squamous cell carcinoma: randomisation decides. Strahlentherapie und Onkologie2019;196(2):202-4. NCT01590355. A phase II randomized trial for early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs trans-oral robotic surgery (ORATOR). clinicaltrials.gov/ct2/show/NCT01590355 (first received 2 May 2012). NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. Lancet Oncology2019;20(10):1349-59. [DOI: 10.1016/S1470-2045(19)30410-3] [PMID: 31416685]NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Randomized trial of radiotherapy versus transoral robotic surgery for oropharyngeal squamous cell carcinoma: long-term results of the ORATOR trial. Journal of Clinical Oncology2022;40(8):866-75. [DOI: 10.1200/JCO.21.01961]NicholsAC , YooJ , HammondJA , FungK , WinquistE , ReadN , et al. Early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs. trans-oral robotic surgery (ORATOR) – study protocol for a randomized phase II trial. BMC Cancer2013;13:133. [DOI: 10.1186/1471-2407-13-133]PalmaDA , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus trans-oral robotic surgery for oropharyngeal squamous cell carcinoma: results of a randomized trial. Radiotherapy and Oncology2019;139(Supp 1):S39-40. ">Nichols 2019</a> provided some detailed information on over 60 adverse events in the text. The incidence of treatment‐related grade 2 or higher adverse events was similar: 31/34 participants in the radiotherapy group compared with 33/34 participants in the TORS group (RR 0.94, 95% CI 0.83 to 1.06). Participants in the radiotherapy group had more hearing loss, neutropenia, constipation, and tinnitus; whereas oral bleeding and trismus were more common in the TORS plus neck dissection group. There were too many outcomes measured to draw any sensible conclusions (very low‐certainty evidence). </p> </section> <section id="CD006205-sec-0140"> <h6 class="title">Quality of life</h6> <p><a href="./references#CD006205-bbs2-0011" title="FabianA , KrugD . Radiotherapy versus transoral robotic surgery for primary treatment of oropharyngeal squamous cell carcinoma: randomisation decides. Strahlentherapie und Onkologie2019;196(2):202-4. NCT01590355. A phase II randomized trial for early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs trans-oral robotic surgery (ORATOR). clinicaltrials.gov/ct2/show/NCT01590355 (first received 2 May 2012). NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. Lancet Oncology2019;20(10):1349-59. [DOI: 10.1016/S1470-2045(19)30410-3] [PMID: 31416685]NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Randomized trial of radiotherapy versus transoral robotic surgery for oropharyngeal squamous cell carcinoma: long-term results of the ORATOR trial. Journal of Clinical Oncology2022;40(8):866-75. [DOI: 10.1200/JCO.21.01961]NicholsAC , YooJ , HammondJA , FungK , WinquistE , ReadN , et al. Early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs. trans-oral robotic surgery (ORATOR) – study protocol for a randomized phase II trial. BMC Cancer2013;13:133. [DOI: 10.1186/1471-2407-13-133]PalmaDA , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus trans-oral robotic surgery for oropharyngeal squamous cell carcinoma: results of a randomized trial. Radiotherapy and Oncology2019;139(Supp 1):S39-40. ">Nichols 2019</a> did not report quality of life. </p> </section> <section id="CD006205-sec-0141"> <h6 class="title">Direct and indirect costs to patients and health services</h6> <p><a href="./references#CD006205-bbs2-0011" title="FabianA , KrugD . Radiotherapy versus transoral robotic surgery for primary treatment of oropharyngeal squamous cell carcinoma: randomisation decides. Strahlentherapie und Onkologie2019;196(2):202-4. NCT01590355. A phase II randomized trial for early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs trans-oral robotic surgery (ORATOR). clinicaltrials.gov/ct2/show/NCT01590355 (first received 2 May 2012). NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. Lancet Oncology2019;20(10):1349-59. [DOI: 10.1016/S1470-2045(19)30410-3] [PMID: 31416685]NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Randomized trial of radiotherapy versus transoral robotic surgery for oropharyngeal squamous cell carcinoma: long-term results of the ORATOR trial. Journal of Clinical Oncology2022;40(8):866-75. [DOI: 10.1200/JCO.21.01961]NicholsAC , YooJ , HammondJA , FungK , WinquistE , ReadN , et al. Early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs. trans-oral robotic surgery (ORATOR) – study protocol for a randomized phase II trial. BMC Cancer2013;13:133. [DOI: 10.1186/1471-2407-13-133]PalmaDA , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus trans-oral robotic surgery for oropharyngeal squamous cell carcinoma: results of a randomized trial. Radiotherapy and Oncology2019;139(Supp 1):S39-40. ">Nichols 2019</a> did not report costs. </p> </section> <section id="CD006205-sec-0142"> <h6 class="title">Participant satisfaction</h6> <p><a href="./references#CD006205-bbs2-0011" title="FabianA , KrugD . Radiotherapy versus transoral robotic surgery for primary treatment of oropharyngeal squamous cell carcinoma: randomisation decides. Strahlentherapie und Onkologie2019;196(2):202-4. NCT01590355. A phase II randomized trial for early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs trans-oral robotic surgery (ORATOR). clinicaltrials.gov/ct2/show/NCT01590355 (first received 2 May 2012). NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. Lancet Oncology2019;20(10):1349-59. [DOI: 10.1016/S1470-2045(19)30410-3] [PMID: 31416685]NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Randomized trial of radiotherapy versus transoral robotic surgery for oropharyngeal squamous cell carcinoma: long-term results of the ORATOR trial. Journal of Clinical Oncology2022;40(8):866-75. [DOI: 10.1200/JCO.21.01961]NicholsAC , YooJ , HammondJA , FungK , WinquistE , ReadN , et al. Early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs. trans-oral robotic surgery (ORATOR) – study protocol for a randomized phase II trial. BMC Cancer2013;13:133. [DOI: 10.1186/1471-2407-13-133]PalmaDA , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus trans-oral robotic surgery for oropharyngeal squamous cell carcinoma: results of a randomized trial. Radiotherapy and Oncology2019;139(Supp 1):S39-40. ">Nichols 2019</a> did not report participant satisfaction. </p> </section> </section> </section> <section id="CD006205-sec-0143"> <h4 class="title">Comparison 9: surgery plus adjuvant radiotherapy versus chemotherapy</h4> <p>See <a href="./full#CD006205-tbl-0009">summary of findings Table 9</a>. </p> <p>One trial evaluated neck dissection surgery plus adjuvant radiotherapy versus chemotherapy in 119 participants with histologically confirmed resectable stage III/IV head and neck SCC (excluding nasopharynx and salivary gland SCC), with and without nodal disease (<a href="./references#CD006205-bbs2-0008" title="IyerNG , TanDS , TanVK , WangW , HwangJ , Tan N-C, et al. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. Cancer2015;121(10):1599-607. SooKC , TanEH , WeeJ , LimD , TaiBC , Khoo ML et al. Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison. British Journal of Cancer2005;8(93):279-86. [DOI: 10.1038/sj.bjc.6602696] [PMCID: PMC2361563] [PMID: 16012523]">Iyer 2015</a>). The median follow‐up for surviving participants was 13 years. As 48% of participants had oral cavity and oropharyngeal cancer, we were only able to use data from the oral cavity cancer subgroup (32 participants) and the oropharyngeal cancer subgroup (25 participants). The text stated "there were no differences noted between the treatment arms with regard to cancers of the oropharynx, larynx, and hypopharynx"; however, it is unclear which outcomes this statement relates to, and the study provided no other information on the oropharynx subgroup. </p> <section id="CD006205-sec-0144"> <h5 class="title">Primary outcomes</h5> <section id="CD006205-sec-0145"> <h6 class="title">Overall survival (or total mortality)</h6> <p><a href="./references#CD006205-bbs2-0008" title="IyerNG , TanDS , TanVK , WangW , HwangJ , Tan N-C, et al. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. Cancer2015;121(10):1599-607. SooKC , TanEH , WeeJ , LimD , TaiBC , Khoo ML et al. Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison. British Journal of Cancer2005;8(93):279-86. [DOI: 10.1038/sj.bjc.6602696] [PMCID: PMC2361563] [PMID: 16012523]">Iyer 2015</a> did not report overall survival data for the oral cavity cancer subgroup; however, the text stated "For the oral cavity, survival was significantly better in patients who underwent surgery and RT compared with the CRT group". </p> </section> <section id="CD006205-sec-0146"> <h6 class="title">Disease‐free survival (or new disease, progression, and mortality)</h6> <p><a href="./references#CD006205-bbs2-0008" title="IyerNG , TanDS , TanVK , WangW , HwangJ , Tan N-C, et al. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. Cancer2015;121(10):1599-607. SooKC , TanEH , WeeJ , LimD , TaiBC , Khoo ML et al. Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison. British Journal of Cancer2005;8(93):279-86. [DOI: 10.1038/sj.bjc.6602696] [PMCID: PMC2361563] [PMID: 16012523]">Iyer 2015</a> did not report disease free survival. </p> </section> <section id="CD006205-sec-0147"> <h6 class="title">Locoregional recurrence</h6> <p><a href="./references#CD006205-bbs2-0008" title="IyerNG , TanDS , TanVK , WangW , HwangJ , Tan N-C, et al. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. Cancer2015;121(10):1599-607. SooKC , TanEH , WeeJ , LimD , TaiBC , Khoo ML et al. Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison. British Journal of Cancer2005;8(93):279-86. [DOI: 10.1038/sj.bjc.6602696] [PMCID: PMC2361563] [PMID: 16012523]">Iyer 2015</a> reported that locoregional recurrence‐free survival in the oral cavity cancer subgroup was not statistically significant between the groups (P = 0.355), but there were no useable data (very low‐certainty evidence). </p> </section> <section id="CD006205-sec-0148"> <h6 class="title">Recurrence</h6> <p><a href="./references#CD006205-bbs2-0008" title="IyerNG , TanDS , TanVK , WangW , HwangJ , Tan N-C, et al. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. Cancer2015;121(10):1599-607. SooKC , TanEH , WeeJ , LimD , TaiBC , Khoo ML et al. Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison. British Journal of Cancer2005;8(93):279-86. [DOI: 10.1038/sj.bjc.6602696] [PMCID: PMC2361563] [PMID: 16012523]">Iyer 2015</a> did not report recurrence for the oral cavity cancer subgroup. </p> </section> </section> <section id="CD006205-sec-0149"> <h5 class="title">Secondary outcomes</h5> <section id="CD006205-sec-0150"> <h6 class="title">Adverse events associated with treatment</h6> <p><a href="./references#CD006205-bbs2-0008" title="IyerNG , TanDS , TanVK , WangW , HwangJ , Tan N-C, et al. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. Cancer2015;121(10):1599-607. SooKC , TanEH , WeeJ , LimD , TaiBC , Khoo ML et al. Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison. British Journal of Cancer2005;8(93):279-86. [DOI: 10.1038/sj.bjc.6602696] [PMCID: PMC2361563] [PMID: 16012523]">Iyer 2015</a> did not report adverse events. </p> </section> <section id="CD006205-sec-0151"> <h6 class="title">Quality of life</h6> <p><a href="./references#CD006205-bbs2-0008" title="IyerNG , TanDS , TanVK , WangW , HwangJ , Tan N-C, et al. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. Cancer2015;121(10):1599-607. SooKC , TanEH , WeeJ , LimD , TaiBC , Khoo ML et al. Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison. British Journal of Cancer2005;8(93):279-86. [DOI: 10.1038/sj.bjc.6602696] [PMCID: PMC2361563] [PMID: 16012523]">Iyer 2015</a> did not report quality of life. </p> </section> <section id="CD006205-sec-0152"> <h6 class="title">Direct and indirect costs to patients and health services</h6> <p><a href="./references#CD006205-bbs2-0008" title="IyerNG , TanDS , TanVK , WangW , HwangJ , Tan N-C, et al. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. Cancer2015;121(10):1599-607. SooKC , TanEH , WeeJ , LimD , TaiBC , Khoo ML et al. Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison. British Journal of Cancer2005;8(93):279-86. [DOI: 10.1038/sj.bjc.6602696] [PMCID: PMC2361563] [PMID: 16012523]">Iyer 2015</a> did not report costs. </p> </section> <section id="CD006205-sec-0153"> <h6 class="title">Participant satisfaction</h6> <p><a href="./references#CD006205-bbs2-0008" title="IyerNG , TanDS , TanVK , WangW , HwangJ , Tan N-C, et al. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. Cancer2015;121(10):1599-607. SooKC , TanEH , WeeJ , LimD , TaiBC , Khoo ML et al. Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison. British Journal of Cancer2005;8(93):279-86. [DOI: 10.1038/sj.bjc.6602696] [PMCID: PMC2361563] [PMID: 16012523]">Iyer 2015</a> did not report participant satisfaction. </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD006205-sec-0154" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD006205-sec-0154"></div> <section id="CD006205-sec-0155"> <h3 class="title" id="CD006205-sec-0155">Summary of main results</h3> <p>We undertook this systematic review to evaluate whether treatment with surgery improves outcomes for people with oral cavity and oropharyngeal cancers, and to determine which type of surgery is most effective for treating people with oral cavity and oropharyngeal cancers. We included 15 RCTs with a combined total of 2820 randomised participants. Approximately 2074 of these participants had oral cavity cancers. Most trials were at high or unclear risk of bias overall. </p> <p>No trials compared different surgical approaches to the removal of the primary tumour. Five trials evaluated the timing of neck dissection surgery in the course of treatment, and five trials evaluated the extent of neck dissection. </p> <p>Five trials evaluated elective neck dissection versus therapeutic (delayed) neck dissection (<a href="./full#CD006205-tbl-0001">summary of findings Table 1</a>). All participants had oral cavity cancers, specifically tongue or floor of mouth tumours, and clinically negative neck nodes. All the evidence was graded as moderate‐certainty. Elective neck dissection compared with therapeutic neck dissection probably improves overall survival, disease‐free survival, locoregional recurrence, and recurrence; but is probably associated with more adverse events (although these were generally of lower grade in the included trials). The results for this comparison may reflect the likely improvements in background standards of care associated with oral cancer surgery and the increasing use of adjuvant chemoradiation after surgery in the newer trials (<a href="./references#CD006205-bbs2-0003" title="D'CruzA . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment&quot; [personal communication]. Email to: H Worthington 6 February 2023. D'CruzAK , VaishR , KapreN , DandekarM , GuptaS , HawaldarR , et al. Elective versus therapeutic neck dissection in node-negative oral cancer. New England Journal of Medicine2015;373(6):521-9. [DOI: 10.1056/NEJMoa1506007]NCT00193765. Elective vs therapeutic neck dissection in treatment of early node negative squamous carcinoma of oral cavity. www.clinicaltrials.gov/ct2/show/NCT00193765 (first received 19 September 2005). ">D'Cruz 2015</a>; <a href="./references#CD006205-bbs2-0007" title="HutchisonIL , RidoutF , CheungSM , ShahN , HardeeP , SurwaldC , et al. Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort. British Journal of Cancer2019;121(10):827-36. [DOI: 0.1038/s41416-019-0587-2] [PMID: 31611612]ISRCTN65018995. The role of selective neck dissection in patients with early oral squamous cell carcinoma (1-3cm primary size) and no clinical evidence of lymph node metastases in the neck (N0). www.isrctn.com/ISRCTN65018995 (first received 23 April 2010). NCT00571883. Neck surgery in treating patients with early-stage oral cancer. clinicaltrials.gov/ct2/show/NCT00571883 (first received 12 December 2007). ">Hutchison 2019</a>). When we combined only these two recent trials, the pooled HR for total mortality was 0.66 (95% CI 0.49 to 0.89; P = 0.006), and the pooled HR for new disease, progression, and mortality was 0.53 (95% CI 0.37 to 0.77; P &lt; 0.001); both results clearly favour elective neck dissection. </p> <p>Two trials compared elective radical (comprehensive) neck dissection with a selective neck dissection in people with oral cavity cancers (<a href="./full#CD006205-tbl-0002">summary of findings Table 2</a>). One trial included only participants with clinically negative neck nodes and the other included those with movable positive neck nodes as well. There may be no difference between the interventions in terms of overall survival, disease‐free survival, and recurrence, but the evidence is very uncertain. </p> <p>Two trials evaluated superselective neck dissection versus selective neck dissection but provided no usable data (<a href="./full#CD006205-tbl-0003">summary of findings Table 3</a>). </p> <p>One trial evaluated supraomohyoid neck dissection versus modified radical neck dissection (<a href="./full#CD006205-tbl-0004">summary of findings Table 4</a>). We were unable to use the data for the primary outcomes. The evidence was very uncertain for adverse events, with more complications, pain, and poorer shoulder function in the modified radical neck dissection group. </p> <p>One large multicentre trial evaluated sentinel node biopsy versus elective neck dissection (<a href="./full#CD006205-tbl-0005">summary of findings Table 5</a>). There may be no difference between the interventions in overall survival, disease‐free survival, and locoregional recurrence. The study did not fully report recurrence data and stated "no adverse events were judged to be related to the interventions". </p> <p>One trial evaluated PET‐CT (with neck dissection only if no/incomplete response to chemoradiotherapy identified) versus planned neck dissection before or after chemoradiotherapy (<a href="./full#CD006205-tbl-0006">summary of findings Table 6</a>). There is probably no difference in overall survival and locoregional recurrence between the interventions. The trial did not provide usable data for the other outcomes. </p> <p>One trial evaluated surgery plus postoperative radiotherapy versus radiotherapy alone (<a href="./full#CD006205-tbl-0007">summary of findings Table 7</a>). It was stopped early due to an unacceptably high death rate in the radiotherapy alone group. Surgery plus radiotherapy compared with radiotherapy alone may improve overall survival, but the evidence is very uncertain. Subcutaneous fibrosis was more prevalent in the surgery plus radiotherapy group, and both groups had similar prevalences of other adverse events, but the evidence was very uncertain. The trial did not report other outcomes of interest. </p> <p>One small trial evaluated surgery versus radiotherapy in people with oropharyngeal cancer (<a href="./full#CD006205-tbl-0008">summary of findings Table 8</a>). There may be no difference between the interventions in overall survival or disease‐free survival. The trial did not report locoregional recurrence or recurrence. Over 60 adverse events were described, but there were too many outcomes measured to draw any reliable conclusions. </p> <p>One trial compared surgery plus adjunctive radiotherapy versus chemoradiotherapy (<a href="./full#CD006205-tbl-0009">summary of findings Table 9</a>). The study reported that survival was significantly better in participants who underwent surgery and radiotherapy compared with the chemoradiotherapy group, but there were no useable data for this outcome (or for any other outcomes). </p> </section> <section id="CD006205-sec-0156"> <h3 class="title" id="CD006205-sec-0156">Overall completeness and applicability of evidence</h3> <p>This review included only studies that directly compared different surgical treatment modalities against one another, or compared surgery to a different treatment regimen such as radiotherapy, chemotherapy, or immunotherapy. </p> <p>For trials to be included, they had to have more than 50% participants with oral cavity or oropharyngeal cancer, or provide separate data for participants with oral cavity or oropharyngeal cancer. In this version of the review, 2074 of 2820 participants had oral cavity cancers, most commonly in the tongue or floor of mouth. Participant numbers ranged from 20 to 596 in the 15 included trials, and people were recruited between 1966 and 2020. This update includes two new large multicentre clinical trials published since 2017. An important factor to consider when interpreting results is whether the trials are single‐centre or multicentre; multicentre trials may reflect a wider range of surgical experience and provide more generalisable findings. </p> <p>For the five trials in the primary comparison that compared elective neck dissection with therapeutic (delayed) neck dissection, the reporting was generally good. Four of these trials reported overall survival and locoregional control, and five reported disease‐free survival. Two of these trials provided information on adverse events. Only two other studies (included in the other eight comparisons) reported harms or adverse events of treatment, but neither presented outcomes per person (<a href="./references#CD006205-bbs2-0001" title="Brazilian Head and Neck Cancer Study Group. Results of a prospective trial on elective modified radical classical versus supraomohyoid neck dissection in the management of oral squamous carcinoma. American Journal of Surgery1998;176(5):422-7. ">BHNCSG 1998</a>; <a href="./references#CD006205-bbs2-0014" title="Dr Robertson. Personal communication2006. RobertsonAG , SoutarDS , PaulJ , WebsterM , LeonardAG , MooreKP , et al. Early closure of a randomized trial: surgery and postoperative radiotherapy versus radiotherapy in the management of intra-oral tumours. Clinical Oncology (Royal College of Radiologists (Great Britain))1998;10(3):155-60. ">Robertson 1998</a>). Incorporation of quality of life outcomes into randomised trials is essential if the true benefits and harms of different types of surgery are to be evaluated. It is noteworthy that while some trials included in this review reported participant dropouts due to refusal to undergo the allocated surgical treatment, there was no information on the quality of life of these people compared with those who stayed in the trials. </p> <p>Only one of the included studies, published in 2019, focused purely on people with oropharyngeal cancer. Since the late 2000s, the percentage of people with oropharyngeal cancer who test positive for HPV has increased steadily. It is now recognised that HPV status is an important factor in the prognosis of people with oropharyngeal cancer (<a href="./references#CD006205-bbs2-0051" title="AdelsteinDJ , RidgeJA , GillisonML , ChaturvediAK , D'SouzaG , GravittPE , et al. Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting; 2008 Nov 9-10; Washington (DC). Head &amp; Neck2009;31(11):1393-422.">Adelstein 2009</a>; <a href="./references#CD006205-bbs2-0062" title="BrizelDM , LydiattW , ColevasAD . Controversies in the locoregional management of head and neck cancer. Journal of National Comprehensive Cancer Network2011;9(6):653-62.">Brizel 2011</a>). If future updates of this review include sufficient data, we will undertake a subgroup analysis for the surgical management of HPV‐related oropharyngeal cancer and the surgical management of non‐HPV related oropharyngeal cancer. In addition, robotic surgery is now being used for oropharyngeal cancer. We anticipate further trials of this technique, and will consider restructuring the review to reflect newly emerging comparisons. It may be appropriate to split the review in the future to cover oral cavity cancer and oropharyngeal cancer separately. </p> </section> <section id="CD006205-sec-0157"> <h3 class="title" id="CD006205-sec-0157">Quality of the evidence</h3> <p>The overall certainty of the evidence included in this systematic review was moderate for the first comparison (elective neck dissection versus therapeutic neck dissection) and for some outcomes in two other comparisons (supraomohyoid neck dissection versus modified radical neck dissection; PET‐CT following chemoradiotherapy versus planned neck dissection before or after chemoradiotherapy). The evidence for the other comparisons was low‐ or very low‐certainty. Trials at low risk of selection bias, attrition bias, reporting bias, and other bias were judged at overall low risk of bias for objective outcomes such as total mortality. Only three of the included studies met these criteria. No trials reported blinding of participants or outcome assessors. We recognise that blinding is difficult to maintain in trials of surgery, and it may not be possible (or ethical) to blind trial participants. The clinicians treating participants likely performed many of the outcome assessments. </p> <p>Participants were recruited over five decades (1966 to 2020). Surgical and non‐surgical treatments for oral cavity and oropharyngeal cancers have advanced substantially since the 2000s. Further objective assessments of current surgical treatments for these cancers are needed to inform both patients and clinicians about the benefits and risks of different treatments. </p> </section> <section id="CD006205-sec-0158"> <h3 class="title" id="CD006205-sec-0158">Potential biases in the review process</h3> <p>To minimise risk of bias related to study selection, we used a comprehensive search strategy with no language restrictions, and we clearly specified inclusion criteria for the review in line with the other reviews in this series (<a href="./references#CD006205-bbs2-0065" title="ChanKK , Glenny A-M, WeldonJC , FurnessS , WorthingtonHV , WakefordH . Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy. Cochrane Database of Systematic Reviews2015, Issue 12. Art. No: CD010341. [DOI: 10.1002/14651858.CD010341.pub2]">Chan 2015</a>; <a href="./references#CD006205-bbs2-0081" title="GlennyAM , FurnessS , WorthingtonHV , ConwayDI , OliverR , ClarksonJE , et al. Interventions for the treatment of oral cavity and oropharyngeal cancer: radiotherapy. Cochrane Database of Systematic Reviews2010, Issue 12. Art. No: CD006387. [DOI: 10.1002/14651858.CD006387.pub2]">Glenny 2010</a>; <a href="./references#CD006205-bbs2-0102" title="ParmarA , MacluskeyM , Mc GoldrickN , ConwayDI , Glenny A-M, ClarksonJE , et al. Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy. Cochrane Database of Systematic Reviews2021, Issue 12. Art. No: CD006386. [DOI: 10.1002/14651858.CD006386.pub4]">Parmar 2021</a>). </p> <p><a href="#CD006205-fig-0003">Figure 3</a> shows the review authors' judgements about each risk of bias item presented as percentages across all included studies. We applied the low risk of bias judgement for objective outcomes (based on overall survival) to all 15 studies, although not all studies evaluated overall survival. This represents a source of bias in the review process. </p> </section> <section id="CD006205-sec-0159"> <h3 class="title" id="CD006205-sec-0159">Agreements and disagreements with other studies or reviews</h3> <p>One of the newly included studies reported a meta‐analysis of overall survival, disease‐free survival, and locoregional control for the primary comparison of elective neck dissection versus therapeutic neck dissection (<a href="./references#CD006205-bbs2-0007" title="HutchisonIL , RidoutF , CheungSM , ShahN , HardeeP , SurwaldC , et al. Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort. British Journal of Cancer2019;121(10):827-36. [DOI: 0.1038/s41416-019-0587-2] [PMID: 31611612]ISRCTN65018995. The role of selective neck dissection in patients with early oral squamous cell carcinoma (1-3cm primary size) and no clinical evidence of lymph node metastases in the neck (N0). www.isrctn.com/ISRCTN65018995 (first received 23 April 2010). NCT00571883. Neck surgery in treating patients with early-stage oral cancer. clinicaltrials.gov/ct2/show/NCT00571883 (first received 12 December 2007). ">Hutchison 2019</a> (SEND)). The findings favour elective neck dissection, in line with this review. </p> <p>We found two reviews that evaluated treatment of neck dissection in the surgical treatment of oral cavity cancer (<a href="./references#CD006205-bbs2-0077" title="FasunlaAJ , GreeneBH , TimmesfeldN , WiegandS , WernerJA , SesterhennAM . A meta-analysis of the randomized controlled trials on elective neck dissection versus therapeutic neck dissection in oral cavity cancers with clinically node-negative neck. Oral Oncology2011;47(5):320-4.">Fasunla 2011</a>; <a href="./references#CD006205-bbs2-0091" title="KowalskiLP , SanabriaA . Elective neck dissection in oral carcinoma: a critical review of the evidence. Acta Otorhinolaryngologica Italica2007;27(3):113-7.">Kowalski 2007</a>). <a href="./references#CD006205-bbs2-0091" title="KowalskiLP , SanabriaA . Elective neck dissection in oral carcinoma: a critical review of the evidence. Acta Otorhinolaryngologica Italica2007;27(3):113-7.">Kowalski 2007</a> investigated dichotomous outcomes (percentages in each group) in three RCTs (<a href="./references#CD006205-bbs2-0004" title="FakihAR , RaoRS , BorgesAM , PatelAR . Elective versus therapeutic neck dissection in early carcinoma of the oral tongue. American Journal of Surgery1989;158(4):309-13. FakihAR , RaoRS , PatelAR . Prophylactic neck dissection in squamous cell carcinoma of oral tongue: a prospective randomized study. Seminars in Surgical Oncology1989;5(5):327-30. ">Fakih 1989</a>; <a href="./references#CD006205-bbs2-0009" title="Dr Kilgerman. Personal communcation2006. KligermanJ , LimaRA , SoaresJR , PradoL , DiasFL , FreitasEQ , et al. Supraomohyoid neck dissection in the treatment of T1/T2 squamous cell carcinoma of oral cavity. American Journal of Surgery1994;168(5):391-4. ">Kligerman 1994</a>; <a href="./references#CD006205-bbs2-0037" title="VandenbrouckC , Sancho-GarnierH , ChassagneD , SaravaneD , CachinY , MicheauC . Elective versus therapeutic radical neck dissection in epidermoid carcinoma of the oral cavity: results of a randomized clinical trial. Cancer1980;46(2):386-90. ">Vandenbrouck 1980</a>). This previous review included no meta‐analysis and only noted the summary outcome estimates, without examining their variance. The conclusions were based on "vote‐counting" and "suggest that elective neck dissection offers advantages in terms of overall, cancer specific and disease‐free survival". <a href="./references#CD006205-bbs2-0077" title="FasunlaAJ , GreeneBH , TimmesfeldN , WiegandS , WernerJA , SesterhennAM . A meta-analysis of the randomized controlled trials on elective neck dissection versus therapeutic neck dissection in oral cavity cancers with clinically node-negative neck. Oral Oncology2011;47(5):320-4.">Fasunla 2011</a> reviewed the same RCTs plus one other (<a href="./references#CD006205-bbs2-0015" title="YuenAP , HoCM , ChowTL , TangLC , CheungWY , NgRW , et al. Prospective randomized study of selective neck dissection versus observation for N0 neck of early tongue carcinoma. Head &amp; Neck2009;31(6):765-72. ">Yuen 2009</a>), and reported the dichotomous outcome of disease‐specific death after approximately three years of follow‐up. The RR of disease‐specific death favoured elective neck dissection (RR 0.57, 95% CI 0.36 to 0.89). </p> <p>We chose to evaluate overall survival/total mortality because we believe it is the most important outcome for patients, and we used HRs where possible, as they have the advantage of incorporating all available information, including data from participants who did not complete the trial. We look forward to adding data from ongoing trials to the next update of this review, especially trials on oropharyngeal SCC induced by HPV </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD006205-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/urn:x-wiley:14651858:media:CD006205:CD006205-FIG-01" target="_blank"><b></b></a></p> </div><img alt="PRISMA diagram showing study selection process." data-id="CD006205-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_n/nCD006205-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_t/tCD006205-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA diagram showing study selection process.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/full#CD006205-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_n/nCD006205-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006205-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/urn:x-wiley:14651858:media:CD006205:CD006205-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD006205-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_n/nCD006205-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_t/tCD006205-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/full#CD006205-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_n/nCD006205-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006205-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/urn:x-wiley:14651858:media:CD006205:CD006205-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD006205-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_n/nCD006205-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_t/tCD006205-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/full#CD006205-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_n/nCD006205-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006205-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/urn:x-wiley:14651858:media:CD006205:CD006205-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Elective neck dissection (ND) versus therapeutic (delayed) ND, Outcome 1: Total mortality" data-id="CD006205-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_n/nCD006205-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_t/tCD006205-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Elective neck dissection (ND) versus therapeutic (delayed) ND, Outcome 1: Total mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/references#CD006205-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_n/nCD006205-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006205-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/urn:x-wiley:14651858:media:CD006205:CD006205-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Elective neck dissection (ND) versus therapeutic (delayed) ND, Outcome 2: New disease, progression, and mortality" data-id="CD006205-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_n/nCD006205-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_t/tCD006205-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Elective neck dissection (ND) versus therapeutic (delayed) ND, Outcome 2: New disease, progression, and mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/references#CD006205-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_n/nCD006205-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006205-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/urn:x-wiley:14651858:media:CD006205:CD006205-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Elective neck dissection (ND) versus therapeutic (delayed) ND, Outcome 3: Locoregional recurrence" data-id="CD006205-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_n/nCD006205-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_t/tCD006205-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Elective neck dissection (ND) versus therapeutic (delayed) ND, Outcome 3: Locoregional recurrence </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/references#CD006205-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_n/nCD006205-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006205-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/urn:x-wiley:14651858:media:CD006205:CD006205-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Elective neck dissection (ND) versus therapeutic (delayed) ND, Outcome 4: Recurrence" data-id="CD006205-fig-0007" src="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_n/nCD006205-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_t/tCD006205-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Elective neck dissection (ND) versus therapeutic (delayed) ND, Outcome 4: Recurrence </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/references#CD006205-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_n/nCD006205-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006205-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/urn:x-wiley:14651858:media:CD006205:CD006205-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Elective neck dissection (ND) versus therapeutic (delayed) ND, Outcome 5: Total adverse events" data-id="CD006205-fig-0008" src="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_n/nCD006205-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_t/tCD006205-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Elective neck dissection (ND) versus therapeutic (delayed) ND, Outcome 5: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/references#CD006205-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_n/nCD006205-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006205-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/urn:x-wiley:14651858:media:CD006205:CD006205-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Elective radical neck dissection (ND) versus elective selective ND, Outcome 1: Total mortality" data-id="CD006205-fig-0009" src="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_n/nCD006205-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_t/tCD006205-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Elective radical neck dissection (ND) versus elective selective ND, Outcome 1: Total mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/references#CD006205-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_n/nCD006205-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006205-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/urn:x-wiley:14651858:media:CD006205:CD006205-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Elective radical neck dissection (ND) versus elective selective ND, Outcome 2: New disease, progression, and mortality" data-id="CD006205-fig-0010" src="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_n/nCD006205-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_t/tCD006205-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Elective radical neck dissection (ND) versus elective selective ND, Outcome 2: New disease, progression, and mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/references#CD006205-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_n/nCD006205-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006205-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/urn:x-wiley:14651858:media:CD006205:CD006205-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Elective radical neck dissection (ND) versus elective selective ND, Outcome 3: Recurrence" data-id="CD006205-fig-0011" src="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_n/nCD006205-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_t/tCD006205-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Elective radical neck dissection (ND) versus elective selective ND, Outcome 3: Recurrence </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/references#CD006205-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_n/nCD006205-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006205-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/urn:x-wiley:14651858:media:CD006205:CD006205-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sentinel node biopsy versus elective neck dissection (ND), Outcome 1: Total mortality" data-id="CD006205-fig-0012" src="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_n/nCD006205-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_t/tCD006205-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Sentinel node biopsy versus elective neck dissection (ND), Outcome 1: Total mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/references#CD006205-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_n/nCD006205-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006205-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/urn:x-wiley:14651858:media:CD006205:CD006205-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sentinel node biopsy versus elective neck dissection (ND), Outcome 2: New disease, progression, and mortality" data-id="CD006205-fig-0013" src="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_n/nCD006205-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_t/tCD006205-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Sentinel node biopsy versus elective neck dissection (ND), Outcome 2: New disease, progression, and mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/references#CD006205-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_n/nCD006205-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006205-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/urn:x-wiley:14651858:media:CD006205:CD006205-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sentinel node biopsy versus elective neck dissection (ND), Outcome 3: Locoregional recurrence" data-id="CD006205-fig-0014" src="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_n/nCD006205-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_t/tCD006205-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Sentinel node biopsy versus elective neck dissection (ND), Outcome 3: Locoregional recurrence </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/references#CD006205-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_n/nCD006205-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006205-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/urn:x-wiley:14651858:media:CD006205:CD006205-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: PET‐CT following chemoradiotherapy versus planned neck dissection (ND) before or after chemoradiotherapy, Outcome 1: Total mortality" data-id="CD006205-fig-0015" src="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_n/nCD006205-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_t/tCD006205-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: PET‐CT following chemoradiotherapy versus planned neck dissection (ND) before or after chemoradiotherapy, Outcome 1: Total mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/references#CD006205-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_n/nCD006205-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006205-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/urn:x-wiley:14651858:media:CD006205:CD006205-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: PET‐CT following chemoradiotherapy versus planned neck dissection (ND) before or after chemoradiotherapy, Outcome 2: Locoregional recurrence" data-id="CD006205-fig-0016" src="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_n/nCD006205-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_t/tCD006205-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: PET‐CT following chemoradiotherapy versus planned neck dissection (ND) before or after chemoradiotherapy, Outcome 2: Locoregional recurrence </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/references#CD006205-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_n/nCD006205-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006205-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/urn:x-wiley:14651858:media:CD006205:CD006205-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Surgery plus radiotherapy (RT) versus RT alone, Outcome 1: Total mortality" data-id="CD006205-fig-0017" src="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_n/nCD006205-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_t/tCD006205-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Surgery plus radiotherapy (RT) versus RT alone, Outcome 1: Total mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/references#CD006205-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_n/nCD006205-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006205-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/urn:x-wiley:14651858:media:CD006205:CD006205-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Surgery versus radiotherapy (RT) alone, Outcome 1: Mortality" data-id="CD006205-fig-0018" src="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_n/nCD006205-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_t/tCD006205-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Surgery versus radiotherapy (RT) alone, Outcome 1: Mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/references#CD006205-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_n/nCD006205-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006205-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/urn:x-wiley:14651858:media:CD006205:CD006205-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Surgery versus radiotherapy (RT) alone, Outcome 2: New disease, progression, and mortality" data-id="CD006205-fig-0019" src="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_n/nCD006205-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_t/tCD006205-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Surgery versus radiotherapy (RT) alone, Outcome 2: New disease, progression, and mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/references#CD006205-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/media/CDSR/CD006205/image_n/nCD006205-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD006205-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Elective neck dissection versus therapeutic (delayed) neck dissection</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Elective neck dissection versus therapeutic (delayed) neck dissection</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> adults with oral cancer </p> <p><b>Setting:</b> inpatient </p> <p><b>Intervention:</b> elective ND </p> <p><b>Comparison:</b> therapeutic (delayed) ND </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk (therapeutic ND)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk (elective ND)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> </p> <p>Follow‐up: 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>350<sup>a</sup> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>241 per 1000</p> <p>(194 to 301)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.64</b> </p> <p>(0.50 to 0.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>883</p> <p>(4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>We calculated mortality in place of overall survival.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>250<sup>b</sup> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>168 per 1000 (134 to 212)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>New disease, progression, and mortality</b> </p> <p>Follow‐up: 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>550<sup>a</sup> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>361 per 1000</p> <p>(302 to 428)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.56</b> </p> <p>(0.45 to 0.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>954</p> <p>(5 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>We calculated new disease, progression, and mortality in place of disease‐free survival.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>450<sup>b</sup> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>285 per 1000</p> <p>(236 to 342)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Locoregional recurrence</b> </p> <p>Follow‐up: 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300<sup>b</sup> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>187 per 1000</p> <p>(142 to 243)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.58</b> </p> <p>(0.43 to 0.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>458</p> <p>(4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Recurrence</b> </p> <p>Follow‐up: 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>600<sup>a</sup> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>348 per 1000</p> <p>(288 to 420)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.58</b> (0.48 to 0.70) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>633</p> <p>(3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events associated with treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.31</b> </p> <p>(1.11 to 1.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>746</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk not calculated as event rate (in the therapeutic groups) in 1 study was 3.6% compared with 60.5% in the other study. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>ND:</b> neck dissection; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Based on data from <a href="./references#CD006205-bbs2-0003" title="D'CruzA . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment&quot; [personal communication]. Email to: H Worthington 6 February 2023. D'CruzAK , VaishR , KapreN , DandekarM , GuptaS , HawaldarR , et al. Elective versus therapeutic neck dissection in node-negative oral cancer. New England Journal of Medicine2015;373(6):521-9. [DOI: 10.1056/NEJMoa1506007]NCT00193765. Elective vs therapeutic neck dissection in treatment of early node negative squamous carcinoma of oral cavity. www.clinicaltrials.gov/ct2/show/NCT00193765 (first received 19 September 2005). ">D'Cruz 2015</a> (lower‐middle income country).<br/><sup>b</sup> Based on data from <a href="./references#CD006205-bbs2-0007" title="HutchisonIL , RidoutF , CheungSM , ShahN , HardeeP , SurwaldC , et al. Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort. British Journal of Cancer2019;121(10):827-36. [DOI: 0.1038/s41416-019-0587-2] [PMID: 31611612]ISRCTN65018995. The role of selective neck dissection in patients with early oral squamous cell carcinoma (1-3cm primary size) and no clinical evidence of lymph node metastases in the neck (N0). www.isrctn.com/ISRCTN65018995 (first received 23 April 2010). NCT00571883. Neck surgery in treating patients with early-stage oral cancer. clinicaltrials.gov/ct2/show/NCT00571883 (first received 12 December 2007). ">Hutchison 2019</a> (high‐income country).<br/><sup>c</sup> Downgraded once due to risk of bias.<br/><sup>d</sup> Downgraded once for risk of bias as only 2/5 trials provided data on adverse events (selective reporting of subjective outcomes). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Elective neck dissection versus therapeutic (delayed) neck dissection</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/full#CD006205-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006205-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Elective radical neck dissection versus elective selective neck dissection</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Elective radical neck dissection versus elective selective neck dissection</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> adults with oral cancer </p> <p><b>Setting:</b> inpatient </p> <p><b>Intervention:</b> elective radical ND </p> <p><b>Comparison:</b> elective selective ND </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk (elective selective ND)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk (elective radical ND)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>252<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 trials reported HR for mortality but used different surgical procedures, so we could not pool data. Neither trial indicated any difference in mortality between the 2 interventions. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>New disease, progression, and mortality</b> </p> <p>Follow‐up: 5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300<sup>b</sup> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>184 per 1000<br/>(142 to 243) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.57</b> </p> <p>(0.29 to 1.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>These data were calculated from the reported HR for disease‐free survival.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Locoregional recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Recurrence</b> </p> <p>Follow‐up: 5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>250<sup>d</sup> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>303 per 1000<br/>(158 to 583) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.21</b> </p> <p>(0.63 to 2.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events associated with treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p>1 trial reported the following adverse events: flap necrosis, wound infection, fistula, vascular rupture, haematoma, seroma, and chyle fistula. There were no complications in 45 participants (59%) in the modified radical neck dissection group and no complications in 54 participants (75%) in the elective neck dissection group. There were 2 postoperative deaths in the modified radical neck dissection group and 1 postoperative death in the elective neck dissection group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>ND:</b> neck dissection; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded twice for very serious inconsistency and once for unclear/high risk of bias.<br/><sup>b</sup> Based on data from <a href="./references#CD006205-bbs2-0003" title="D'CruzA . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment&quot; [personal communication]. Email to: H Worthington 6 February 2023. D'CruzAK , VaishR , KapreN , DandekarM , GuptaS , HawaldarR , et al. Elective versus therapeutic neck dissection in node-negative oral cancer. New England Journal of Medicine2015;373(6):521-9. [DOI: 10.1056/NEJMoa1506007]NCT00193765. Elective vs therapeutic neck dissection in treatment of early node negative squamous carcinoma of oral cavity. www.clinicaltrials.gov/ct2/show/NCT00193765 (first received 19 September 2005). ">D'Cruz 2015</a> and <a href="./references#CD006205-bbs2-0007" title="HutchisonIL , RidoutF , CheungSM , ShahN , HardeeP , SurwaldC , et al. Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort. British Journal of Cancer2019;121(10):827-36. [DOI: 0.1038/s41416-019-0587-2] [PMID: 31611612]ISRCTN65018995. The role of selective neck dissection in patients with early oral squamous cell carcinoma (1-3cm primary size) and no clinical evidence of lymph node metastases in the neck (N0). www.isrctn.com/ISRCTN65018995 (first received 23 April 2010). NCT00571883. Neck surgery in treating patients with early-stage oral cancer. clinicaltrials.gov/ct2/show/NCT00571883 (first received 12 December 2007). ">Hutchison 2019</a>.<br/><sup>c</sup> Downgraded twice for very serious imprecision and once for high risk of bias.<br/><sup>d</sup> Based on data from <a href="./references#CD006205-bbs2-0001" title="Brazilian Head and Neck Cancer Study Group. Results of a prospective trial on elective modified radical classical versus supraomohyoid neck dissection in the management of oral squamous carcinoma. American Journal of Surgery1998;176(5):422-7. ">BHNCSG 1998</a>.<br/><sup>e</sup> Downgraded twice for very serious imprecision and once for unclear risk of bias.<br/><sup>f</sup> Downgraded twice for very serious risk of bias. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Elective radical neck dissection versus elective selective neck dissection</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/full#CD006205-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006205-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Superselective neck dissection versus selective neck dissection</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> adults with oral or oropharyngeal cancer </p> <p><b>Setting:</b> inpatient </p> <p><b>Intervention:</b> superselective ND </p> <p><b>Comparison:</b> selective ND </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk (selective ND)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk (superselective ND)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>New disease, progression, and mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One study reported no clear difference between the interventions, but we were unable to use the data. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Locoregional recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data not presented in a useable way and inconsistent. 1 study reported no evidence of a difference. The other study reported lower recurrence in the superselective ND group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome not reported in a usable way in either study.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events associated with treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>No adverse events reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>ND:</b> neck dissection; <b>RCT:</b> randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded twice for very serious imprecision and once for unclear risk of bias. We were unable to use the data presented.<br/><sup>b</sup> Downgraded twice for very serious imprecision and once for high risk of bias for subjective outcomes. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Superselective neck dissection versus selective neck dissection</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/full#CD006205-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006205-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Supraomohyoid neck dissection versus modified radical neck dissection</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Supraomohyoid neck dissection versus modified radical neck dissection</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> adults with oral or oropharyngeal cancer </p> <p><b>Setting:</b> inpatient </p> <p><b>Intervention:</b> supraomohyoid ND </p> <p><b>Comparison:</b> modified radical ND </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk (modified radical ND)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk (supraomohyoid ND)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>New disease, progression, and mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Locoregional recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events associated with treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Significant difference in complication rates, with lower rates for the supraomohyoid procedure. </p> <p>UW‐QOL scores for all disease‐free survivors were assessed at 1 year after treatment. Scores from 9 disease‐specific domains appeared to show that supraomohyoid ND was superior to modified radical ND in the domains of pain relief (78.8% vs 75.2%, P = 0.013) and shoulder function (81.1% vs 68.1%, P &lt; 0.001), but not in any other domain. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>332</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>ND:</b> neck dissection; <b>RCT:</b> randomised controlled trial; <b>UW‐QOL:</b> University of Washington Quality of Life Questionnaire. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded twice for very serious imprecision and once for high risk of bias for subjective outcomes. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Supraomohyoid neck dissection versus modified radical neck dissection</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/full#CD006205-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006205-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Sentinel node biopsy versus elective neck dissection</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Sentinel node biopsy versus elective neck dissection</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> adults with oral or oropharyngeal cancer </p> <p><b>Setting:</b> inpatient </p> <p><b>Intervention:</b> sentinel node biopsy </p> <p><b>Comparison:</b> elective ND </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk (elective ND)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk (sentinel node biopsy)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total mortality</b> </p> <p>Follow‐up: 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200<sup>a</sup> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1000</p> <p>(182 to 219)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 1.00</b> </p> <p>(0.90 to 1.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>279</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We calculated total mortality in place of overall survival.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>New disease, progression, and mortality</b> </p> <p>Follow‐up: 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300<sup>a</sup> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>295 per 1000</p> <p>(275 to 317)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.98</b> </p> <p>(0.90 to 1.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>279</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We calculated new disease, progression, and mortality in place of disease‐free survival.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Locoregional recurrence</b> </p> <p>Follow‐up: 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200<sup>c</sup> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>207 per 1000</p> <p>(184 to 233)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 1.04</b> </p> <p>(0.91 to 1.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>279</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>279</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"[...] the number of patients with recurrences in both arms was almost identical."</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events associated with treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>No adverse events were reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Verylow</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>ND:</b> neck dissection; <b>RCT:</b> randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Based on data from <a href="./references#CD006205-bbs2-0003" title="D'CruzA . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment&quot; [personal communication]. Email to: H Worthington 6 February 2023. D'CruzAK , VaishR , KapreN , DandekarM , GuptaS , HawaldarR , et al. Elective versus therapeutic neck dissection in node-negative oral cancer. New England Journal of Medicine2015;373(6):521-9. [DOI: 10.1056/NEJMoa1506007]NCT00193765. Elective vs therapeutic neck dissection in treatment of early node negative squamous carcinoma of oral cavity. www.clinicaltrials.gov/ct2/show/NCT00193765 (first received 19 September 2005). ">D'Cruz 2015</a> and <a href="./references#CD006205-bbs2-0007" title="HutchisonIL , RidoutF , CheungSM , ShahN , HardeeP , SurwaldC , et al. Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort. British Journal of Cancer2019;121(10):827-36. [DOI: 0.1038/s41416-019-0587-2] [PMID: 31611612]ISRCTN65018995. The role of selective neck dissection in patients with early oral squamous cell carcinoma (1-3cm primary size) and no clinical evidence of lymph node metastases in the neck (N0). www.isrctn.com/ISRCTN65018995 (first received 23 April 2010). NCT00571883. Neck surgery in treating patients with early-stage oral cancer. clinicaltrials.gov/ct2/show/NCT00571883 (first received 12 December 2007). ">Hutchison 2019</a> for elective neck dissection.<br/><sup>b</sup> Downgraded once for imprecision and once for unclear risk of bias.<br/><sup>c</sup> Based on data from <a href="./references#CD006205-bbs2-0007" title="HutchisonIL , RidoutF , CheungSM , ShahN , HardeeP , SurwaldC , et al. Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort. British Journal of Cancer2019;121(10):827-36. [DOI: 0.1038/s41416-019-0587-2] [PMID: 31611612]ISRCTN65018995. The role of selective neck dissection in patients with early oral squamous cell carcinoma (1-3cm primary size) and no clinical evidence of lymph node metastases in the neck (N0). www.isrctn.com/ISRCTN65018995 (first received 23 April 2010). NCT00571883. Neck surgery in treating patients with early-stage oral cancer. clinicaltrials.gov/ct2/show/NCT00571883 (first received 12 December 2007). ">Hutchison 2019</a> for elective neck dissection.<br/><sup>d</sup> Downgraded twice for very serious imprecision and once for high risk of bias for subjective outcomes. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Sentinel node biopsy versus elective neck dissection</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/full#CD006205-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006205-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">PET‐CT following chemoradiotherapy versus planned neck dissection before or after chemoradiotherapy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>PET‐CT following chemoradiotherapy versus planned neck dissection before or after chemoradiotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> adults with oral or oropharyngeal cancer </p> <p><b>Setting:</b> inpatient </p> <p><b>Intervention:</b> PET‐CT following chemoradiotherapy </p> <p><b>Comparison:</b> planned ND before or after chemoradiotherapy </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk (planned ND)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk (PET‐CT)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total mortality</b> </p> <p>Follow‐up: 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200<sup>a</sup> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>186 per 1000<br/>(135 to 253) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.92</b> </p> <p>(0.65 to 1.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>564<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>These data were calculated from the reported HR for overall survival.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>New disease, progression, and mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome not reported in a usable way.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Locoregional recurrence</b> </p> <p>Follow‐up: 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200<sup>c</sup> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1000 (189 to 211)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 1.00</b> (0.94 to 1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>564<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome not reported in a usable way.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events associated with treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>22 surgical complications in PET‐CT group compared with 83 in planned surgery group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>ND:</b> neck dissection; <b>PET‐CT:</b> positron emission tomography–computed tomography; <b>RCT:</b> randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Based on data from <a href="./references#CD006205-bbs2-0003" title="D'CruzA . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment&quot; [personal communication]. Email to: H Worthington 6 February 2023. D'CruzAK , VaishR , KapreN , DandekarM , GuptaS , HawaldarR , et al. Elective versus therapeutic neck dissection in node-negative oral cancer. New England Journal of Medicine2015;373(6):521-9. [DOI: 10.1056/NEJMoa1506007]NCT00193765. Elective vs therapeutic neck dissection in treatment of early node negative squamous carcinoma of oral cavity. www.clinicaltrials.gov/ct2/show/NCT00193765 (first received 19 September 2005). ">D'Cruz 2015</a> and <a href="./references#CD006205-bbs2-0007" title="HutchisonIL , RidoutF , CheungSM , ShahN , HardeeP , SurwaldC , et al. Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort. British Journal of Cancer2019;121(10):827-36. [DOI: 0.1038/s41416-019-0587-2] [PMID: 31611612]ISRCTN65018995. The role of selective neck dissection in patients with early oral squamous cell carcinoma (1-3cm primary size) and no clinical evidence of lymph node metastases in the neck (N0). www.isrctn.com/ISRCTN65018995 (first received 23 April 2010). NCT00571883. Neck surgery in treating patients with early-stage oral cancer. clinicaltrials.gov/ct2/show/NCT00571883 (first received 12 December 2007). ">Hutchison 2019</a> for elective ND.<br/><sup>b</sup> Downgraded once due to imprecision.<br/><sup>c</sup> Based on data from <a href="./references#CD006205-bbs2-0007" title="HutchisonIL , RidoutF , CheungSM , ShahN , HardeeP , SurwaldC , et al. Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort. British Journal of Cancer2019;121(10):827-36. [DOI: 0.1038/s41416-019-0587-2] [PMID: 31611612]ISRCTN65018995. The role of selective neck dissection in patients with early oral squamous cell carcinoma (1-3cm primary size) and no clinical evidence of lymph node metastases in the neck (N0). www.isrctn.com/ISRCTN65018995 (first received 23 April 2010). NCT00571883. Neck surgery in treating patients with early-stage oral cancer. clinicaltrials.gov/ct2/show/NCT00571883 (first received 12 December 2007). ">Hutchison 2019</a> for elective ND.<br/><sup>d</sup> Downgraded twice for very serious imprecision and once for high risk of bias for subjective outcomes. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">PET‐CT following chemoradiotherapy versus planned neck dissection before or after chemoradiotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/full#CD006205-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006205-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Surgery plus radiotherapy versus radiotherapy alone</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Surgery plus radiotherapy versus radiotherapy alone</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> adults with oral or oropharyngeal cancer </p> <p><b>Setting:</b> inpatient </p> <p><b>Intervention:</b> surgery + radiotherapy </p> <p><b>Comparison:</b> radiotherapy alone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk (radiotherapy alone)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk (surgery + radiotherapy)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total mortality</b> </p> <p>Follow‐up: 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500<sup>a</sup> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>153 per 1000<br/>(67 to 336) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.24</b> </p> <p>(0.10 to 0.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>These data were calculated from the reported HR for overall survival.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>New disease, progression, and mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Locoregional recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events associated with treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Both groups reported the following severe acute adverse effects: subcutaneous fibrosis; telangiectasia (1–4 cm²); and moderate‐to‐severe oedema, xerostomia, trismus, and dysphagia. Subcutaneous fibrosis was more prevalent in the surgery + radiotherapy group (P = 0.042), but the prevalence of other adverse effects appeared to be similar in both groups. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low<sup>c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HR</b> : hazard ratio; <b>RCT:</b> randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Based on data presented by <a href="./references#CD006205-bbs2-0118" title="WarnakulasuriyaS . Global epidemiology of oral and oropharyngeal cancer. Oral Oncology2009;45(4-5):309-16.">Warnakulasuriya 2009</a><sup>.</sup><br/><sup>b</sup> Downgraded twice for very serious imprecision and once for high risk of bias.<br/><sup>c</sup> Downgraded twice for very serious imprecision and once for high risk of bias for subjective outcomes. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Surgery plus radiotherapy versus radiotherapy alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/full#CD006205-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006205-tbl-0008"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Surgery versus radiotherapy alone</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Surgery versus radiotherapy alone</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> adults with oropharyngeal cancer </p> <p><b>Setting:</b> inpatient </p> <p><b>Intervention:</b> surgery </p> <p><b>Comparison:</b> radiotherapy alone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk (radiotherapy alone)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk (surgery)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total mortality</b> </p> <p>Follow‐up: 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500<sup>a</sup> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>437 per 1000<br/>(60 to 994) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.83</b> </p> <p>(0.09 to 7.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We calculated mortality in place of overall survival.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>New disease, progression, and mortality</b> </p> <p>Follow‐up: 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>600<sup>c</sup> per 1000 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>625 per 1000<br/>(219 to 979) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 1.07</b> </p> <p>(0.27 to 4.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We calculated new disease, progression, and mortality in place of disease‐free survival.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Locoregional recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events associated with treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Both groups reported the following severe acute adverse effects: subcutaneous fibrosis, telangiectasia (1–4 cm²), and moderate‐to‐severe oedema, xerostomia, trismus, and dysphagia. Subcutaneous fibrosis was more prevalent in the surgery + radiotherapy group (P = 0.042), but the prevalence of other adverse effects appeared to be similar in both groups. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HR</b> : hazard ratio; <b>RCT:</b> randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Based on data presented by <a href="./references#CD006205-bbs2-0118" title="WarnakulasuriyaS . Global epidemiology of oral and oropharyngeal cancer. Oral Oncology2009;45(4-5):309-16.">Warnakulasuriya 2009</a>.<br/><sup>b</sup> Downgraded twice for very serious imprecision.<br/><sup>c</sup> For illustrative purposes only.<br/><sup>d</sup> Downgraded twice for very serious imprecision and once for high risk of bias for subjective outcomes. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Surgery versus radiotherapy alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/full#CD006205-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006205-tbl-0009"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Surgery plus adjuvant radiotherapy versus chemotherapy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Surgery plus adjuvant radiotherapy versus chemotherapy</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> adults with oral or oropharyngeal cancer </p> <p><b>Setting:</b> inpatient </p> <p><b>Intervention:</b> surgery + adjuvant radiotherapy </p> <p><b>Comparison:</b> chemotherapy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk (chemotherapy)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk (surgery + adjuvant radiotherapy)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study reported that survival was significantly better in participants who underwent surgery and RT compared with the CRT group, but there were no useable data. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>New disease, progression, and mortality</b> </p> <p>Follow‐up: 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>—</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Locoregional recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported difference between groups not "statistically significant" (P = 0.355), but there were no useable data. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported for the oral cancer subgroup.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events associated with treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported for any participants.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>RCT:</b> randomised controlled trial. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup> Estimated from chemotherapy arm of <a href="./references#CD006205-bbs2-0008" title="IyerNG , TanDS , TanVK , WangW , HwangJ , Tan N-C, et al. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. Cancer2015;121(10):1599-607. SooKC , TanEH , WeeJ , LimD , TaiBC , Khoo ML et al. Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison. British Journal of Cancer2005;8(93):279-86. [DOI: 10.1038/sj.bjc.6602696] [PMCID: PMC2361563] [PMID: 16012523]">Iyer 2015</a>.<br/><sup>b</sup> Downgraded twice for very serious imprecision and once for high risk of bias. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Surgery plus adjuvant radiotherapy versus chemotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/full#CD006205-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006205-tbl-0010"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Stage of cancer</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Cancer types</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>TNM stage</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Nodal status</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006205-bbs2-0001" title="Brazilian Head and Neck Cancer Study Group. Results of a prospective trial on elective modified radical classical versus supraomohyoid neck dissection in the management of oral squamous carcinoma. American Journal of Surgery1998;176(5):422-7. ">BHNCSG 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral cavity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T2–T4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative neck</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006205-bbs2-0002" title='BierJ , HowaldtHP , PitzH , 4th German-Austrian-Swiss Study Group therapy study. Prospective, randomized, clinical study of squamous cell cancer of the mouth: "Radical neck dissection versus conservative neck dissection". Fortschritte der Kiefer- und Gesichts-Chirurgie1992;37:108-10. BierJ , SchlumsD , MetelmannH , HowaldtHP , PitzH . A comparison of radical and conservative neck dissection. International Journal of Oral &amp; Maxillofacial Surgery1993;22(2):102-7. BierJ . Radical neck dissection versus conservative neck dissection for squamous cell carcinoma of the oral cavity. Recent Results in Cancer Research1994;134:57-62. '>Bier 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral cavity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative or positive neck, range unspecified</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006205-bbs2-0003" title="D'CruzA . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment&quot; [personal communication]. Email to: H Worthington 6 February 2023. D'CruzAK , VaishR , KapreN , DandekarM , GuptaS , HawaldarR , et al. Elective versus therapeutic neck dissection in node-negative oral cancer. New England Journal of Medicine2015;373(6):521-9. [DOI: 10.1056/NEJMoa1506007]NCT00193765. Elective vs therapeutic neck dissection in treatment of early node negative squamous carcinoma of oral cavity. www.clinicaltrials.gov/ct2/show/NCT00193765 (first received 19 September 2005). ">D'Cruz 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral cavity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T1–T2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative neck</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006205-bbs2-0004" title="FakihAR , RaoRS , BorgesAM , PatelAR . Elective versus therapeutic neck dissection in early carcinoma of the oral tongue. American Journal of Surgery1989;158(4):309-13. FakihAR , RaoRS , PatelAR . Prophylactic neck dissection in squamous cell carcinoma of oral tongue: a prospective randomized study. Seminars in Surgical Oncology1989;5(5):327-30. ">Fakih 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral cavity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T1–T2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative neck</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006205-bbs2-0005" title="GarrelR , PerriardF , FavierV , RichardF , Pierre DauresJ , De BoutrayM . Equivalence randomized trial comparing treatment based on sentinel node biopsy versus neck dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States2020;38(Suppl 15):6501. GarrelR , PoissonnetG , Moyà PlanaA , FakhryN , DolivetG , LallemantB , et al. Equivalence randomized trial to compare treatment on the basis of sentinel node biopsy versus neck node dissection in operable T1-T2N0 oral and oropharyngeal cancer. Journal of Clinical Oncology2020;38(34):4010-18. [DOI: 10.1200/JCO.20.01661]NCT02855723. Randomized, open-label economic and medical study on the lymph node management of squamous cell carcinoma of the oral cavity and oropharynx tumor Stage 1 or 2, nodes 0 (T1-T2 N0) operable (SentiMERORL). clinicaltrials.gov/ct2/show/NCT02855723 (first received 4 August 2016). ">Garrel 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral cavity/oropharyngeal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T1–T2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative neck</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006205-bbs2-0006" title="GuoCB , FengZ , ZhangJG , PengX , CaiZG , MaoC , et al. Supraomohyoid neck dissection and modified radical neck dissection for clinically node-negative oral squamous cell carcinoma: a prospective study of prognosis, complications and quality of life. Journal of Craniofacial Surgery2014;42(8):1885-90. [DOI: 10.1016/j.jcms.2014.07.007]">Guo 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral cavity/oropharyngeal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T1–T4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N0‐2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006205-bbs2-0007" title="HutchisonIL , RidoutF , CheungSM , ShahN , HardeeP , SurwaldC , et al. Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort. British Journal of Cancer2019;121(10):827-36. [DOI: 0.1038/s41416-019-0587-2] [PMID: 31611612]ISRCTN65018995. The role of selective neck dissection in patients with early oral squamous cell carcinoma (1-3cm primary size) and no clinical evidence of lymph node metastases in the neck (N0). www.isrctn.com/ISRCTN65018995 (first received 23 April 2010). NCT00571883. Neck surgery in treating patients with early-stage oral cancer. clinicaltrials.gov/ct2/show/NCT00571883 (first received 12 December 2007). ">Hutchison 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral cavity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T1–T2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative neck</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006205-bbs2-0008" title="IyerNG , TanDS , TanVK , WangW , HwangJ , Tan N-C, et al. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. Cancer2015;121(10):1599-607. SooKC , TanEH , WeeJ , LimD , TaiBC , Khoo ML et al. Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison. British Journal of Cancer2005;8(93):279-86. [DOI: 10.1038/sj.bjc.6602696] [PMCID: PMC2361563] [PMID: 16012523]">Iyer 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral cavity (other cancer types included in the study but only data for oral cavity cancer included in the review) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T1–T4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N0‐3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006205-bbs2-0009" title="Dr Kilgerman. Personal communcation2006. KligermanJ , LimaRA , SoaresJR , PradoL , DiasFL , FreitasEQ , et al. Supraomohyoid neck dissection in the treatment of T1/T2 squamous cell carcinoma of oral cavity. American Journal of Surgery1994;168(5):391-4. ">Kligerman 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral cavity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T1–T2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative neck</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006205-bbs2-0010" title='ISRCTN13735240. A multicentre randomised phase III trial comparing positron emission tomography–computed tomography guided watch and wait policy versus planned NECK dissection for the management of locally advanced (N2/N3) nodal metastases in patients with head and neck squamous cancer. www.isrctn.com/ISRCTN13735240 (first received 21 May 2007). MehannaH , McConkeyCC , RahmanJK , Wong W-L, SmithAF , NuttingC , et al. PET-NECK a multicentre randomised phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer. Health Technology Assessment2017;21:17. [DOI: 10.3310/hta21170]MehannaH , Wong W-L, McConkeyCC , RahmanJK , RobinsonM , HartleyAG , et al. PET-CT surveillance versus neck dissection in advanced head and neck cancer. New England Journal of Medicine2016;374(15):1444-54. [DOI: 10.1056/NEJMoa1514493]MehannaH . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 31 January 2023. '>Mehanna 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral cavity, tonsil, base of tongue, supraglottis and glottis or subglottis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T1–T4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N2‐3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006205-bbs2-0011" title="FabianA , KrugD . Radiotherapy versus transoral robotic surgery for primary treatment of oropharyngeal squamous cell carcinoma: randomisation decides. Strahlentherapie und Onkologie2019;196(2):202-4. NCT01590355. A phase II randomized trial for early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs trans-oral robotic surgery (ORATOR). clinicaltrials.gov/ct2/show/NCT01590355 (first received 2 May 2012). NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. Lancet Oncology2019;20(10):1349-59. [DOI: 10.1016/S1470-2045(19)30410-3] [PMID: 31416685]NicholsAC , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Randomized trial of radiotherapy versus transoral robotic surgery for oropharyngeal squamous cell carcinoma: long-term results of the ORATOR trial. Journal of Clinical Oncology2022;40(8):866-75. [DOI: 10.1200/JCO.21.01961]NicholsAC , YooJ , HammondJA , FungK , WinquistE , ReadN , et al. Early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs. trans-oral robotic surgery (ORATOR) – study protocol for a randomized phase II trial. BMC Cancer2013;13:133. [DOI: 10.1186/1471-2407-13-133]PalmaDA , TheurerJ , PrismanE , ReadN , BertheletE , TranE , et al. Radiotherapy versus trans-oral robotic surgery for oropharyngeal squamous cell carcinoma: results of a randomized trial. Radiotherapy and Oncology2019;139(Supp 1):S39-40. ">Nichols 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oropharyngeal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T1–T2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N0‐2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006205-bbs2-0012" title='NCT00847717. Trial of IIb preserving neck dissection. clinicaltrials.gov/ct2/show/NCT00847717 (first received 19 February 2009). PandeyM , KarthikeyanS , JoshiD , KumarM , ShuklaM . Results of a randomized controlled trial of level IIb preserving neck dissection in clinically node-negative squamous carcinoma of the oral cavity. World Journal of Surgical Oncology2018;16(1):219. [DOI: 10.1186/s12957-018-1518-z] [PMID: 30409212]PandeyM . Re: Cochrane review on “Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment" [personal communication]. Email to: H Worthington 2 February 2023. '>Pandey 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral cavity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T1–T4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative neck</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006205-bbs2-0013" title="RastogiS , SharmaA , ChoudhuryR , TripathiS , Al WayliH , AmrithrajA , et al. Is superselective neck dissection safer than supraomohyoid neck dissection for oral carcinoma patients with N0 neck in terms of shoulder morbidity and recurrence rate?Journal of Oral and Maxillofacial Surgery2018;76(3):647-55. [DOI: 10.1016/j.joms.2017.08.002]">Rastogi 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral cavity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T1–T3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative neck</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006205-bbs2-0014" title="Dr Robertson. Personal communication2006. RobertsonAG , SoutarDS , PaulJ , WebsterM , LeonardAG , MooreKP , et al. Early closure of a randomized trial: surgery and postoperative radiotherapy versus radiotherapy in the management of intra-oral tumours. Clinical Oncology (Royal College of Radiologists (Great Britain))1998;10(3):155-60. ">Robertson 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral cavity/oropharyngeal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T2–T4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N0‐2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006205-bbs2-0015" title="YuenAP , HoCM , ChowTL , TangLC , CheungWY , NgRW , et al. Prospective randomized study of selective neck dissection versus observation for N0 neck of early tongue carcinoma. Head &amp; Neck2009;31(6):765-72. ">Yuen 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral cavity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T1–T2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative neck</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>In the TNM cancer staging system, T defines tumour size and any spread of cancer into nearby tissue, N defines spread of cancer to nearby lymph nodes; and M defines metastasis. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Stage of cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/full#CD006205-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006205-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Elective neck dissection (ND) versus therapeutic (delayed) ND</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Total mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.50, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 New disease, progression, and mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.45, 0.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Locoregional recurrence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.43, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Recurrence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>633</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.48, 0.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>746</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [1.11, 1.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Elective neck dissection (ND) versus therapeutic (delayed) ND</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/references#CD006205-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006205-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Elective radical neck dissection (ND) versus elective selective ND</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Total mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 New disease, progression, and mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Recurrence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Elective radical neck dissection (ND) versus elective selective ND</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/references#CD006205-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006205-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Sentinel node biopsy versus elective neck dissection (ND)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Total mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 New disease, progression, and mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.2 5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Locoregional recurrence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Sentinel node biopsy versus elective neck dissection (ND)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/references#CD006205-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006205-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">PET‐CT following chemoradiotherapy versus planned neck dissection (ND) before or after chemoradiotherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Total mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.65, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Locoregional recurrence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.94, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">PET‐CT following chemoradiotherapy versus planned neck dissection (ND) before or after chemoradiotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/references#CD006205-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006205-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Surgery plus radiotherapy (RT) versus RT alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Total mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.10, 0.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Surgery plus radiotherapy (RT) versus RT alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/references#CD006205-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006205-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Surgery versus radiotherapy (RT) alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.09, 7.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 New disease, progression, and mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.27, 4.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Surgery versus radiotherapy (RT) alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006205.pub5/references#CD006205-tbl-0016">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD006205.pub5&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD006205-note-0014">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD006205-note-0024">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD006205-note-0020">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD006205-note-0022">Français</a> </li> <li class="section-language"> <a class="" href="hi#CD006205-note-0015">हिंदी</a> </li> <li class="section-language"> <a class="" href="id#CD006205-note-0021">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="ms#CD006205-note-0019">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD006205-note-0023">Polski</a> </li> <li class="section-language"> <a class="" href="pt#CD006205-note-0017">Português</a> </li> <li class="section-language"> <a class="" href="th#CD006205-note-0018">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD006205-note-0016">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006205\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006205\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006205\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006205\x2epub5"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006205\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006205\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006205\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006205\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006205\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006205\x2epub5"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006205\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006205\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006205\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006205\x2epub5"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006205\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006205\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006205\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006205\x2epub5"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=FKeXZrqu&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006205.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006205.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD006205.pub5/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD006205.pub5/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006205.pub5%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740727111463"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006205.pub5/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740727111467"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006205.pub5/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ea410df989365',t:'MTc0MDcyNzExMS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 